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1. Transplantation immunobiology
1.1. Transplantation and the immune system
The immune system allows individuals to mount defensive reactions against a
vast array of antigens. This system is a critical component of our defence against
infection, but immune responses are unfortunately also elicited by antigens not
associated with pathogens, like grafted tissue. Nevertheless, organ transplanta-
tion has become a successful therapeutic modality for end-stage renal, cardiac,
hepatic and pulmonary disease. Progress in transplantation medicine has been
realized in great part by the advent of potent immunosuppressive drugs during
the 1980’s1. Still, successful allotransplantation is characterized by a non-physio-
logical situation imposed upon an immune system that has evolved to function
in an entirely different context2. The patient receiving the transplanted tissue
has to use immunosuppressive drugs lifelong and as a consequence, will be at
risk of malignancy, infection, renal failure or other adverse effects. Therefore,
the “holy grail” in transplantation medicine remains to reach a state in which an
individual’s immune system accepts the grafted tissue as if it were its own3,4.
1.2. Allorecognition
Allorecognition occurs when the host immune system detects same-species,
non self antigens and this is the trigger for allograft rejection. The primary basis
for allograft rejection is the ability of T-cells to recognize polymorphic versions
of a variety of proteins, which are referred to as alloantigens. The most impor-
tant series of alloantigens are those encoded within the Major Histocompatibil-
ity Complex (MHC). The physiological role of MHC molecules is to present
peptide determinants to T-cells as part of normal immune responses, but they
were first discovered because of their dominant role as targets for rejection. A
very high proportion of T-cells (0.1%-10%) is able to directly bind and respond
to allogeneic molecules1,5. Allorecognition can occur by two distinct but not
mutually exclusive pathways: direct and indirect. The direct pathway results
from the recognition of foreign MHC molecules, intact, on the surface of
donor cells. Indirect allorecognition occurs when donor MHC molecules are
internalised, processed, and presented as peptides by host antigen presenting
cells- the manner in which the immune system normally “sees” antigen6,7.
general introduction
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Specificity for the response of T-cells to antigen is determined by the T-cell
receptor. This first TCR-MHC triggering step is generally referred to as signal 1.
Recognition of allogeneic MHC class-II molecules by the T-cell receptor pre-
sent on CD4+ T-cells results in activation and subsequent production of pro-
proliferative cytokines, e.g. IL-2, that are necessary to initiate allograft immuni-
ty. These cytokines act in an autocrine manner on the CD4+ T-cells and in a
paracrine way on the other cells, such as CD8+ T-cells, macrophages and B-
cells8,9. Activation of CD8+ T-cells by MHC class I molecules present on the
donor cells results in cytolysis of these cells. For a proper function, CD8+ T-cells
need help from CD4+ T-cells via cytokines and cell-to-cell interactions mediat-
ed via co-stimulatory pathways on antigen presenting cells (APC) or other T-
cells10,11.
Full T-cell activation requires a second ‘positive’ costimulatory signal, gener-
ally referred to as signal 2 (Fig. 1). This signal is provided by interaction with the
APC12. The first identified molecules responsible for costimulation were identi-
fied as T cell based CD28 interacting with B7 ligands (CD80 and CD86) on
APC13. Additionally, a molecule structurally related to CD28, called cytotoxic T
lymphocyte antigen-4 (CTLA-4) was found to also bind to the same B7 ligands.
These molecules belong to the CD28:B7-family14. Next, the CD154(CD40L):
CD40 interaction emerged as a second set of costimulatory molecules, belong-
ing to the tumor necrosis factor:tumor necrosis factor receptor (TNF:TNF-
receptor) family. CD40 is expressed on APC’s and CD154 is expressed after 
activation on CD4+ T-cells as well as on some CD8+ T-cells, NK cells and
eosinophils. It is the integration of positive and negative costimulatory signals
that will determine the outcome of the alloreactive T-cell response.
The CD28:B7-family has now been extended by novel family members,
ICOS:B7h and PD1:PDL-1/PDL-2, which have both positive and negative
roles in T-cell activation, respectively. The TNF:TNFR family has grown with
the receptor:ligand pairs 4-1BB:4-1BBL and CD134:CD134L (OX40:OX40L).
Their functions in immune responses including alloimmunity are under
intense investigation15.
1.3. Inhibition of allograft rejection
The important role of the CD40L and CD28 families in the activation of allore-
active T-cells is demonstrated by the observation that CD40 blockade using
anti-CD154 monoclonal antibody (mAb) has successfully been shown to pre-
vent acute rejection and promote long-term allograft acceptance in murine
10
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transplant models16,17. Also, blockade of CD80 and CD86 can prevent acute
allograft rejection and can, depending on the model or strain combination,
induce donor-specific tolerance in several murine transplant models18,19. Several
studies indicate that intact CTLA-4 signalling is required for the induction of
tolerance to alloantigen. CTLA-4 has a limiting effect on the alloreactive clone
size20. Also, a role of CTLA-4 on regulatory T-cell function has also been impli-
cated by some studies21,22 (discussed further below).
Calcineurin inhibitors like cyclosporin and tacrolimus (FK506) are used as
conventional immunosuppression to block transcription of the gene encoding
the pro-proliferative cytokine IL-2. This successfully reduces the expansion of
alloreactive effector cells and thereby prevents graft rejection. Unlike FK506
and CsA, rapamycin does not inhibit T-cell receptor (TCR)-induced cal-
cineurin activity. Rather, rapamycin inhibits the activation of the mammalian
target of rapamycin (mTOR), which is required for protein synthesis and cell-
cycle progression. Thus, CsA inhibits TCR-induced activation, whereas
rapamycin blocks signaling in response to growth factors23,24.
B7 Family
TNF Family
CD28 Family
TNF-R Family
APC
Signal
B7-1 or B7-2
(CD80 or CD 86)
B7-1 or B7-2
B7-1 or B7-2
MHC/Peptide
CD40
CD40
T Cell
Signal
CTLA-4 (CD152)
CD28
TCR/CD3 complex
CD40L (CD154)
CD27
Figure 1. Costimulatory molecules and their ligands.
Depicted are the costimulatory molecules and their ligands.These molecules belong to the
CD28:B7 and tumor necrosis factor : tumor necrosis factor receptor (TNF:TNFR) families 
and have either positive or inhibitory effects on signaling in T-cells. (Adapted from Rothstein
et al. Imm. Reviews 2003).
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1.4. Transplantation tolerance
Immunological tolerance is defined as a state in which (a) the immune system
does not mount a pathological response against a specific antigen, (b) there is no
requirement for exogenous immunosuppression, and (c) responses to other
antigens are maintained25,26. Two major pathways leading to tolerance are dis-
cerned, peripheral and central tolerance induction.
Central tolerance induction occurs in the thymus. In transplantation, cen-
tral tolerance to a solid organ allograft requires the presence of donor bone mar-
row derived cells in the thymus. This can be achieved by donor bone marrow
transplantation and myeloablative conditioning prior to organ transplantation.
T-cells that develop under these circumstances lack reactivity to donor antigens
due to clonal selection in the thymus27,28. However, a major obstacle of this
therapy is the high morbidity risk of the conditioning regimen required for
bone marrow engraftment and deletion of pre-existing alloreactive T-cells.
Peripheral tolerance as opposed to central tolerance occurs upon antigen
encounter in the peripheral immune compartments, including lymph nodes
and spleen. Several immune interventions have been shown to successfully
induce peripheral tolerance in animal models4,28-30. To establish transplantation
tolerance, alloreactive effector cells need to be eliminated, inactivated, or con-
verted to an immunosuppressive alloreactive T cell. Mechanisms involved are
deletion, anergy, immunoregulation, clonal exhaustion and ignorance of allore-
active T cells4,6. Deletion of alloreactive T-cells might be triggered under subop-
timal stimulation, such as costimulation blockade, or by depletion via the use of
depleting mAb like anti-CD3 or CAMPATH-1H31-35. T-cell anergy is defined as
the functional inactivation of alloreactive T-cells due to disturbed costimulation
and is often linked to immunoregulation36,37. Clonal exhaustion may occur as a
result of chronic administration of alloantigen under suboptimal conditions,
leading to deletion of alloantigen specific T-cells38. Ignorance may only play a
minor role in transplantation tolerance, if any, as it is unlikely that the immune
system is not triggered by the alloantigen presence. Of all the mechanisms
implicated in transplantation tolerance, immunoregulation crucially deter-
mines the difference between tolerance or immunity to alloantigen.
Immunoregulation is an active process where regulatory T-cells control the
response of alloreactive effector cells. Currently, much attention focuses on the
naturally occurring regulatory CD4+CD25+ T-cells.
12
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2. Regulatory T-cells
2.1. The self vs. non-self problem in adaptive immunity
A quantitative analysis of published experimental data indicates that a CD4+ T
cell restricted by a particular MHC Class II allele will recognize about one pep-
tide in every 104 presented by that allele39. Each MHC allele can potentially pre-
sent 1010 nonamer peptides. Given that, as noted above, a T cell has a 10-4 prob-
ability of recognizing one, it follows that a single T cell is able to recognize 106
different nonamers40. Clearly, these cells are highly cross-reactive and conse-
quently pose a problem in self non-self discrimination. However, a unique pro-
tective self-tolerance mechanism attributed to the thymus and peripheral com-
partments is the generation of antigen specific regulatory CD4+CD25+ T cells
(TREG). These cells are also referred to as “naturally occurring TREG”, designat-
ing them as a separate lineage39,41.
2.1.1. Naturally occurring TREG as a separate lineage in the thymus
In the thymus, the generated T cell repertoire will provide a set of receptors of
varying avidities for self-antigens, creating a continuous distribution (Fig. 2).
Clonal deletion will remove those cells recognizing self-antigens with receptors
of the highest avidity. It is hypothesized that a part of these potentially destruc-
tive effector T cells is converted into TREG. These cells are the T cells with recep-
tors that are on the high end of self avidity, but on the lower end of clonal dele-
tion by negative selection42,43. When activated by auto-antigen, the TREG exert
their suppressive capacity and limit autoreactivity by downregulating the
responses of T cells with receptors that recognize other auto-antigens in the
same tissue. Thymic TREG cells were shown to make a substantial contribution
to the peripheral TREG population. Thus, the distinct TREG act as a safeguard
for tolerance to self-antigen.
general introduction
13
Coenen_prfsch_def  20-03-2007  20:57  Pagina 13
Treg cell
+2
–2
Clonal 
deletion
Positive
selection
Ce
lls
 w
ith
 re
ce
pt
or
s
o
f a
vi
di
ty
 le
ss
 th
an
 X
 (lo
g %
)
Low                                                                                                   High
Avidity for sell antigens
Figure 2. Selection of the T cell repertoire as a consequence of TCR avidity for self 
antigens in the thymus.
Cells whose receptor have an avidity greater than that indicated by the vertical bar (middle)
undergo positive selection. Of those, cells with receptors of the highest avidities (striped area,
far right) undergo negative selection by clonal deletion. Natural TREG cells arise from the
group of cells whose avidities are near the lower end of the negative selection spectrum and
the higher end of the remaining positively selected cells. (Adapted from RH Schwartz, Nat.
Immunology 2005).
2.1.2. Peripheral generation of TREG
Thymic selection seems not to be the only mode by which TREG cells can be
generated. It has been demonstrated that presentation of peptides in “subim-
munogenic” conditions (low dose and/or lack of costimulation) can convert
naïve T cells into CD4+CD25+ TREG cells in the periphery. This conversion also
occurs in conditions in which the possibility of proliferation of pre-existing
CD4+CD25+ T-cells can be excluded44. Importantly, to achieve the conversion
it is pivotal for the antigen to be presented in “subimmunogenic” conditions45-
47. It is proposed that in the periphery T-cells become an effector T-cell when
the threshold for full activation is reached. However, if activation fails to reach
that threshold, the incomplete activation may drive the T-cell towards regulato-
ry function. TGF-β may contribute to this phenomenon by raising the level of
the full activation threshold48. On the other hand, it is also hypothesized that
full activation of CD4+CD25- cells may ultimately lead to conversion to a regu-
latory phenotype, thereby providing a negative feedback mechanism of conven-
tional immune responses49.
14
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2.2. Phenotype of TREG
The naturally occurring TREG cells found in the CD4+CD25+ T cell pool con-
stitute about 5-10% of mature CD4+CD8- thymocytes and about 10% of
peripheral CD4+ T cells50,51. These cells may also convert to CD4+CD25- T cells
with a regulatory phenotype49. Other cell surface markers, such as CD45RB,
CTLA-4, glucocorticoid-induced TNF receptor family-related receptor
(GITR), CD122, CD103, CD134, CD62L and CD27, can also be used to define
and isolate CD4+CD25+ TREG4,52. However, as with CD25, none of these mole-
cules alone represents a distinct marker for naturally occurring TREG as they are
also expressed on other T cells. The forkhead/winged helix transcription factor
Foxp3 was shown to be uniquely expressed by naturally occurring TREG, and is
thought to be an important component in controlling TREG differentiation53,54.
Nevertheless, recent findings indicate that this unique expression is only
restricted to mice, for human CD4+CD25- T cells may also express Foxp3 upon
activation52,55. It has been proposed that as a result of activation this Foxp3
upregulation directs human activated CD4+CD25- cells to a regulatory pheno-
type49,56. From this perspective, Foxp3 would still be a unique marker for T cells
with a regulatory phenotype.
2.3. Mechanisms of suppression
The exact mechanism by which CD4+CD25+ TREG cells exert their suppressive
effects remains enigmatic, but these cells have been found to suppress effector T
cell proliferation in vitro through a cell contact-dependent mechanism that is
largely cytokine independent57-59. A role for GITR and CTLA-4 on the surface
of TREG has been implicated, but it appears that blocking CTLA-4 on
CD4+CD25- effector cells rather than on the CD4+CD25+ cells interferes with
suppression by making the CD4+CD25- cells less susceptible (this thesis). Nev-
ertheless, a role for CTLA-4 on the CD4+CD25+ TREG is not excluded. Ligation
of CD80 and/or CD86 on effector T cells by CTLA-4 on the TREG was postu-
lated to cause “outside-in” signalling and to result in suppression of the effector
cell60. Ligation of CD80 and/or CD86 on dendritic cells by CTLA-4 on the
TREG results in the activation of indoleamine 2,3-dioxegenase (IDO). Reduced
amounts of free tryptophan as a consequence of the induction of IDO are asso-
ciated with decreased activation of T cells61. However, this APC dependent
mechanism is not essential, for suppression is also found in APC free culture
systems62.
In contrast to in vitro findings, blockade of both IL-10 and TGF-β has been
reported to abrogate TREG mediated unresponsiveness to alloantigen in vivo
general introduction
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implicating a role for these cytokines in CD4+CD25+ TREG function63-66. The
apparent discrepancy could be explained by a requirement for cell contact with
a third cell, such as an APC, or the de novo generation of regulatory T cells (dis-
cussed below) 67,68. Recent findings may also indicate a role for TGF-β at the
site of the effector cell, for TGF-β deficient T cells were resistant to suppression
by CD4+CD25+ T cells. Moreover, CD4+CD25+ TREG cells developed normally
in the absence of TGF-β, ruling out an essential role of this cytokine in
CD4+CD25+ TREG physiology69.
Direct cytotoxicity seems to be unlikely as a mechanism of action since it
appears that CD4+CD25+ TREG and suppressed CD4+CD25- T cells can co-
exist for long periods of time. Separation of CD4+CD25+ TREG and suppressed
CD4+CD25- T cells demonstrates an intact effector potential of the latter, for
isolated CD4+CD25- T cells can proliferate normally and produce IL-2 after
antigenic stimulation70.
2.4 Interrelationship of naturally occurring TREG and induced TREG
As outlined above, suppression by naturally occurring CD4+CD25+ TREG is
clearly not a result of effector T cell elimination but rather a result of active con-
trol of effector cell proliferation and effector function71. Additional de novo gen-
eration of TREG cells might be another fundamental mechanism for the induc-
tion and maintenance of peripheral tolerance. A different class of CD4+ TREG
has been described whose suppressive properties are in contrast to naturally
occurring CD4+CD25+ TREG cell contact independent and mediated through
suppressive cytokines like IL-10 and TGF-β72. Two main types of these cells
have been described as Tr1 and Th3 cells. Tr1 cells are defined by their ability to
produce IL-10 and low amounts of TGF-β, whereas Th3 cells produce preferen-
tially TGF-β73,74. Different types of induced TREG develop under the influence
of suppressive agents like IL-10, TGF-β, dexamethasone, vitamin D3, modulat-
ed DC, costimulation blockade or potentially other inhibitory mechanisms in
different models, but may also develop from naïve conventional CD4+25- T-
cells as a result of cell-contact dependent interaction with naturally occurring
CD4+CD25+ TREG36,75-79. It appears that CD4+CD25+ TREG expressing the
α4β7-integrin convert anergized CD4+25- T-cells into IL-10 producing Tr1 like
T-cells, whereas α4β1+ TREG induce TGF-β producing Th3 like T-cell80. The
suppressive properties of TREG in vivo are thus complex and based on diverse
mediators like IL-10 and TGF-β to exert systemic suppressive effects81,82.
16
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2.5. Alloantigen specific TREG in transplantation
Given the earlier mentioned crossreactivity of T cells and the diversity of TCRs
that are expressed by TREG it would seem highly probable that a proportion of
TREG cross-reacts with alloantigens expressed on transplanted organs and tis-
sues. However, the frequency of these cells must be low, for rejection is the
inevitable outcome after transplantation of an allograft4,50. Nevertheless,
alloantigen specific TREG activity can be detected in various allograft models. In
vivo, TREG cells specific for donor MHC can be detected after exposing an indi-
vidual to donor alloantigens before transplantation and in mice with long term
surviving allografts63,65. Regulatory T cells can be identified at the site of the tol-
erated allograft and CD4+CD25+ T cells were found to actively restrain effector
T cells, indicating that alloantigen specific TREG contribute to allograft toler-
ance63,83-86.
Allograft tolerance induced through “central” allograft tolerance rests on
deletional mechanisms in the thymus after bone marrow transplantation rather
than active regulation87,88. Theoretically, a role for the thymus in the generation
of CD4+CD25+ TREG specific for alloantigen cannot be discarded, for expres-
sion of peptide in thymic epithelial cells resulted in the generation of
CD4+CD25+ TREG to that specific peptide. Alloantigens might thus induce the
development of TREG cells by positive selection in the thymus. Nevertheless,
the thymus is not essential for the generation of alloantigen specific TREG.
Alloantigen specific TREG can also be generated in the periphery by thymec-
tomized recipients of allografts in vivo, resulting in peripheral tolerance.
Repeated antigen exposure in the periphery has been suggested to induce TREG
cells, so it can be hypothesized that naturally occurring TREG crossreactive to
alloantigen might clonally expand in this fashion89. In support of both the pro-
posed central and peripheral mechanism it was found that the persistent pres-
ence of the graft itself as a permanent source of alloantigen is pivotal for the
maintenance of tolerance in vivo90. Additionally, the earlier mentioned infec-
tious de novo generation of TREG cells by naturally occurring CD4+CD25+
TREG might further expand the pool of allospecific TREG cells. Alloantigen spe-
cific TREG may thus arise from direct development in the thymus or in the
periphery from crossreactive naturally occurring TREG and conversion of effec-
tor T cells into a regulatory phenotype (Fig. 3).
general introduction
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Figure 3. Origin of alloantigen-specific regulatory T cells.
Theoretically alloantigens might induce the development of TREG cells by positive selection in
the thymus, by clonal expansion in the periphery of naturally occurring TREG cells that cross-
react with alloantigens, or by conversion of naive or activated alloantigen-specific peripheral 
T cells to a regulatory phenotype. (Adapted from KJ Wood, Nat. Immunology 2003).
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3. Balancing regulatory and effector cells in
transplantation
3.1. Regulatory T-cells in transplantation tolerance
Accumulating evidence indicates that a balance between regulation by TREG
and deletion of effector T-cells is an effective strategy to control immune
responsiveness after organ transplantation91. The large number of alloreactive T-
cells requires an extensive deletion of effectors and a reduction of these graft
destructive cells will facilitate the emergence of immunoregulation by TREG
subsets. As a result it is increasingly proposed that clinical transplantation toler-
ance protocols that target alloreactive T-lymphocytes need to specifically spare
TREG to induce proper transplantation tolerance. Once induced, immunoregu-
latory mechanisms like linked suppression and infectious tolerance contribute
to the maintenance of an immunoregulatory network, which is also essential to
harness alloreactivity of recent thymic emigrants92. Linked suppression occurs
when a potentially alloreactive T-cell comes under the tolerizing influence of a
TREG as both cells recognize their respective alloantigens presented by the same
APC93,94. This leads to a re-education of the destructive allo-responsive T-cell
with the induction of a TREG phenotype. The re-educated aggressive cell can in
turn induce other naïve CD4+ T-cells to adopt a regulatory phenotype, hereby
propagating the tolerant state. These mechanisms have been implicated in tol-
erance achieved through numerous strategies including costimulation blockade
or treatment with immunosuppressive drugs95-97. For a proper clinical applica-
tion of TREG in the induction of transplantation tolerance it is thus of high sig-
nificance to accurately determine the effects of immunosuppression for the
reduction of the alloreactive clone size on the development and functional
activity of TREG.
3.2. Regulatory T-cells and immunosuppression
3.2.1. Conventional immunosuppression
CsA inhibits TCR-induced activation, whereas rapamycin blocks signaling in
response to growth factors23,24. Albeit efficient in preventing allograft rejection
by reducing effector T-cell expansion, it remains to be elucidated how these
general introduction
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immunosuppressive drugs may antagonize the induction of tolerance by affect-
ing the naturally occurring TREG population. Signalling by IL-2 is also required
for the function of CD4+CD25+ TREG and there has been concern about the
impact of these drugs on the development and function of CD4+CD25+ TREG
in transplantation tolerance4,98,99. Considering the different modes of action
mentioned above, calcineurin inhibitors like CsA and FK506 and rapamycin
may thus have differential effects on CD4+CD25+ regulatory T-cells. Indeed,
high doses of calcineurin inhibition administered at the time of tolerance
induction can prevent long term allograft survival and the development of
CD4+CD25+ TREG, whereas rapamycin was found to selectively expand
CD4+CD25+ TREG in vitro, to increase the CD4+CD25+ TREG to CD4+CD25-
T-cell ratio and to preserve CD4+CD25+ TREG dependent immunoregulation
in vivo95,100-104. However, timing of calcineurin inhibition may be an important
factor on its effect on transplantation tolerance, for a delayed CsA administra-
tion was to preserve the induction of anti-CD40 and anti-CD86 mediated
hyporesponsiveness in vitro and to induce a prolonged drug-free allograft sur-
vival in a rhesus monkey kidney-allograft model in combination with anti-
CD40 and anti-CD86 costimulation blockade105,106.
Nevertheless, in the thymus, signaling through the common γ-chain of
cytokine receptors is essential for naturally occurring CD4+CD25+ TREG devel-
opment. CD4+CD25+ TREG are generated from thymocytes that express
FoxP354,107. In the periphery, IL-2 signaling is required for sustaining the TREG
population at a size necessary to maintain immune homeostasis108,109. This rais-
es considerable concern about the impact of blocking IL-2 signaling by different
immunosuppressive agents on CD4+CD25+ TREG homeostasis and the mainte-
nance of tolerance to self-antigens or the induction of tolerance to alloantigens.
If signaling of the growth factor IL-2 is as crucial for the functional activity of
TREG as recently proposed, both types of agents might thus affect TREG func-
tion after activation98,99,110,111.
3.2.2. Costimulation blockade
In the expansion of the alloreactive effector T-cell pool, costimulation is
required for optimal survival, cytokine production and proliferation of effector
T-cells112-115. Conversely, blockade or absence of costimulatory pathways has
been shown to result in the prevention of allograft rejection and the induction
of tolerance16-18,110,116-119. Jenkins and Schwartz showed that absence of costimu-
lation led to T-cell non-responsiveness both in vitro and in vivo120. This non-
responsive state of the T-cells could be rescued by antigen specific TCR stimula-
20
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tion in the presence of exogenous IL-2, a phenomenon referered to as T-cell
anergy121. Correspondingly, blockade in vivo of the costimulatory pathways
CD80/CD86-CD28 and or CD40-CD40L by monoclonal antibodies proved
an attractive target for immunosuppressive therapy110,122,123.
It was found that the application of anti-CD40L induces infectious toler-
ance and enables the emergence of donorspecific CD4+CD25+ regulatory T-
cells30,93. It can be hypothesized that a regimen that blocks pro-mitotic signal-
ing but ensures antigen driven T-cell activation, like co-stimulation blockade,
may facilitate a functional dominance of regulatory T-cells by the synergizing
effects of selective reduction of alloreactive effector pool and activation of
alloantigen specific regulatory T-cells. In line with this, it was found that succes-
full application of anti-CD40L and anti-CD86 blockade depends on the pres-
ence of CD4+CD25+ regulatory T-cells124.
3.3. Expansion and preservation of regulatory T-cells
In vivo, the optimal exploitation of the suppressive capacity of TREG may be
accomplished either by the generation of new regulatory T cells or by a selective
reduction of harmful T-cells, both resulting in a shift of balance towards domi-
nance of regulatory mechanisms. As an appealing therapeutic, the balance of
TREG vs. effector cells may also be shifted by infusion of TREG after large scale
expansion ex-vivo. Already, expanded TREG have been used as a therapeutic in
models of autoimmune disease and expanded TREG have been used to treat ani-
mal models of Graft Versus Host Disease (GVHD)125-128. In these models it
appeared that antigen-specific TREG were more effective than polyclonal
expanded TREG. Importantly, the antigen specific TREG were able to reverse dia-
betes with new onset disease. With respect to human allograft tolerance a subset
that emerges after in vitro expansion with cytokines may be of particular inter-
est; antigen-specific CD27+ TREG were shown to have an increased suppressive
capacity and were able to suppress ongoing and memory allograft responses, in
contrast to their CD27- counterpart52. The physiological relevance of potent
CD27+ suppressive T-cells in vivo has been established by identification of these
cells in synovial fluid of juvenile arthritis patients129.
Thus, characterizing the conditions that promote the perserverence and the
suppressive capacity of potent TREG in vivo may thus have important clinical
implications for both in vivo and expansion-based ex-vivo therapeutic ap-
proaches for the induction of transplantation tolerance.
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4. Scope of this thesis
In the present thesis we explored the the role of CD4+CD25+ regulatory T-cells
in transplantation and the effects of different immunosuppressive regimens on
these cells. In experimental immunosuppression, costimulation blockade is a
promising approach. In Chapter 2 we found that the tolerizing effects of anti-
CD40L and anti-CD86 costimulation blockade rest on the induction of func-
tional dominance of naturally occurring CD4+CD25+ T-cells over alloreactive
effector cells. Subsequently, in Chapter 3 we elaborate on the importance of bal-
ancing alloreactive effectors and regulatory T-cells as observed in chapter 2 by
demonstrating that negative co-stimulatory signalling via CTLA-4 is pivotal for
the containment of alloreactive effectors rather than the activation of
CD4+CD25+ regulatory T-cells. CD4+CD25+ regulatory T-cells are thus identi-
fied as key players in the regulation of the alloreactive effector response.
The suppressive characteristics of CD4+CD25+ regulatory T-cells have made
these cells themselves attractive candidates for immunotherapy in transplanta-
tion. Therefore, we analysed in Chapter 4 to what extent donor-specific
CD4+CD25+ regulatory T-cells arise from the naturally occurring CD4+CD25+
regulatory T-cell pool during different ex-vivo expansion protocols and how this
population of cells may facilitate an enhanced contribution to containment of
alloreactive effector cells.
Subsequently, in Chapter 5 and Chapter 6 we analyzed to what extent cur-
rently applied immunosuppressive drugs may facilitate or hamper clinical
implementation of regulatory T-cell therapy and may differentially influence
the induction of transplantation tolerance by affecting naturally occurring
CD4+CD25+ regulatory T-cell homeostasis. In Chapter 5, we found that in
human cells - in contrast to CsA - rapamycin preserves a highly suppressive
CD27+CD25+CD4+ regulatory T-cell subset. In Chapter 6 we demonstrate in a
murine in vivo model that the use of rapamycin preserves CD4+CD25+ regula-
tory T-cell generation in the thymus and persistence in the periphery, whereas
the use of CsA results in a specific reduction of these cells in all immune com-
partments. Finally, Chapter 7 summarizes this thesis and provides general con-
clusions.
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Abstract
Clinical tolerance is the net result of regulatory and effector functions. Here we
show, that tolerance induction by costimulation blockade preferentially works
through CD4+CD25+ regulatory T-cell mediated suppression that is effectively
achieved by selective reduction of the effector T-cell load. Anti-CD86+anti-
CD40L mAb treatment during in vitro MLR typically results in the induction
of a suppressive polyclonal T-cell population. This induced suppressive capacity
was found to be dependent on the presence of CD4+CD25+ T cells at the start of
MLR. Using a CFSE based strategy, we show that within the polyclonal T-cell
population the suppressive effect was exerted by a non-dividing CD4+CD25high
T-cell subset. The cells exclusively originated from pre-existing CD4+CD25+
regulatory T cells and proved anergic and highly suppressive upon isolation.
They carried the CD45RBlow and CD62Lhigh phenotype and expressed GITR.
There was no indication of de novo induction of TREG by co-stimulation block-
ers. Instead, we observed both in vitro and in vivo, that costimulation blockade
shifted the ratio between alloreactive effectors and regulatory T-cells in favour of
the latter. We therefore conclude that costimulation blockade contributes to
functional dominance of regulatory T-cells by preventing expansion of alloreac-
tive effector T-cells. Tolerance inducing protocols should ideally facilitate this
phenomenon.
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Introduction
The development of tolerance in vivo has been described as a highly dynamic
process involving several mechanisms, including deletion of the alloreactive 
T cell pool and immunoregulation1. CD4+CD25+ regulatory T-cells can exert
potent regulatory activity, both in vivo and in vitro2,3. Several in vivo studies
underscore the importance of balancing CD4+CD25+ regulatory T-cells and
effector T-cells in establishing T-cell homeostasis4-6. In parallel, naturally occur-
ring CD4+CD25+ regulatory T-cells were shown to mediate dose dependent
suppression in vitro7. Thus, it is increasingly appreciated that enhancement of
in vivo regulatory T-cell function and consequently tolerance induction, may
well be accomplished by inducing a balance shift between effectors and regula-
tors, resulting in dominance of regulatory T-cell suppression8-11.
In the expansion of the alloreactive effector T-cell pool, costimulation is
required for optimal survival, cytokine production and proliferation of T-cells12-15.
Conversely, blockade or absence of costimulatory pathways has been shown to
result in the prevention of allograft rejection and the induction of tolerance16-18.
We reasoned that a regimen that blocks pro-mitotic signaling but ensures anti-
gen driven T-cell activation, like co-stimulation blockade, may facilitate a func-
tional dominance of regulatory T-cells by the synergizing effects of selective
reduction of alloreactive effector pool and activation of alloantigen specific reg-
ulatory T-cells. Previously, we and others showed that costimulation blockade
by anti-CD40L+antiCD86 mAb treatment during in vitro MLR resulted in the
induction of a suppressive polyclonal T-cell population, dependent on the pres-
ence of CD4+CD25+ T cells at the start of MLR19,20.
We here demonstrate that regulatory T-cells become functionally dominant
when a shift of balance between regulatory and effector T-cells is effectuated by
costimulation blockade. These findings further support the notion that toler-
ance inducing protocols should allow for selective enrichment of regulatory 
T-cells.
Materials and methods
Cell purification
Experiments were performed with completely MHC-mismatched combina-
tions of C57BL/6 (H-2b) or C3H (H-2k) stimulators and BALB/c (H-2d)
responders. All mice were purchased from Charles River Lab (Charles River,
Sulzfeld, Germany). Mice were used at 8 to 12 weeks of age and housed in a
specified pathogen free facility. BALB/c responder cells were purified from
costimulation blockade favors treg function 
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pooled peripheral lymph node and spleen cells. Cells were depleted of erythro-
cytes by osmotic shock in lysis buffer containing 0.15mM NH4Cl (Merck,
Darmstadt, Germany), 10.0 mM KHCO3 (Merck) and 0.1 mM Na2EDTA
(Sigma-Aldrich, Steinheim, Germany). Cells were enriched for T-cells by deple-
tion of MHC class II positive cells by coating with anti MHC class II magnetic
microbeads (Miltenyi, Bergisch Gladbach, Germany), followed by passage
through a LD microbead column (Miltenyi). Depletion of CD4+CD25+ T-cells
was carried out by magnetic cell separation. To this end, the T cell enriched
population was inoculated with saturating amounts of biotin-labeled anti-
CD25 antibody (7D4; BD Biosciences, San Diego, USA). Cells were subse-
quently incubated with anti-biotin microbeads and separated using MS
columns according to the manufacturer’s instructions. Depleted populations
contained <1% CD4+CD25+ T-cells. C57BL/6 or C3H stimulator cells were
enriched by culturing splenocytes in 9 cm petridishes (Allegiance, Zutphen,
The Netherlands) for two hours and further overnight culture of the adherent
cell fraction. After 18 to 24 hours the non-adherent cells were obtained by har-
vesting the supernatant and gently washing the petridish.
Mixed Lymphocyte Reaction
For primary MLR, responder cells were cultured with γ-irradiated (27.5 Gray)
stimulator cells at concentrations of 1*105 responder cells/mL to 2.5*104 stimula-
tor cells/mL in flat bottom 96-well plates (Costar, Corning, USA) containing
RPMI (Gibco, Paisley, UK) with 10% FCS (Invitrogen, Dieren, The Nether-
lands), 50 mM 2-ME (Biorad, Hercules, USA), 1 mM sodium pyruvate, gluta-
max and antibiotics (100 U/mL penicillin; 100 mg/mL streptomycin)(all from
Gibco) at 37º, 95% humidity and 5% CO2. In specified cases 1 mg/mL anti-
CD40L mAb (MR1, Pangenetics, Amsterdam, The Netherlands) and 1 mg/mL
anti-CD86 mAb (HB253, Pangenetics, Amsterdam, The Netherlands) were
added. It was established that matched isotype controls did not modify the pro-
liferation of responder cells. To analyze the cells for regulatory capacities, cells
were harvested at day 7 of culture and washed to remove antibodies and
cytokines and subsequently rested in 5% FCS culture medium (see above).
Flow-cytometric analysis (FCM) confirmed that the cells used for restimulation
or suppression assays were devoid of antibodies. At day 10 the cells were γ-irradi-
ated (27.5 Gray) and added to a newly setup primary MLR of freshly purified
responder and stimulator cells at the indicated ratios. Regulatory capacity of the
cells previously cultured in the presence of anti-CD40L and anti-CD86 was
assessed by comparison to a parallel experiment with untreated cells as a con-
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trol. For functional characterization of different cellular subpopulations accord-
ing to CFSE dilution and CD25 expression, cells were harvested at day 6 or 7 of
culture. The different subpopulations of cells were enriched by FACS (Coulter
Epics Elite, Beckman Coulter, Miami, USA) and subsequently restimulated at
indicated numbers by 2.5*104 stimulator cells with or without exogenous rIL-2
(BD Biosciences, Erembodegem, Belgium), or assessed for regulatory capacity
by addition to a newly setup primary MLR of freshly purified responder and
stimulator cells at the indicated ratios. Cell proliferation was monitored by triti-
ated thymidine incorporation. Wells were pulsed with tritiated thymidine (0.5
mCi) for 16-18 h before harvesting at the indicated time points. Tritiated thymi-
dine incorporation was analyzed by a gas scintillation counter and is expressed
as mean count per 5 minutes and SD of at least triplicate measurements. Counts
per 5 minutes by gas scintillation analysis resembles counts per 1 minute as mea-
sured by liquid scintillation analysis. For each experiment proliferation was
measured at multiple timepoints. Peak proliferation was generally at day 5-6 for
primary MLR and at day 2-3 for secondary MLR. Typical results are shown.
Flow cytometry
Cells were phenotypically analyzed by direct labelling or by an indirect two-step
labelling procedure. Cells were washed twice with phosphate-buffered saline
supplemented with 0.2% bovine serum albumin (BSA) (Sigma). In case of indi-
rect labeling, cells were labeled first with fluorochrome-conjugated or with
biotin conjugated specific antibodies; PE-conjugated anti-CD4 (L3T4); PE-
conjugated anti-CD8 (Ly-2); PE-conjugated anti-CD25 (3C7); biotinylated
anti-CD25 (7D4); PE-conjugated anti-CD45RB(16A); PE-conjugated anti-
CD62L (MEL-14) (all by BD Biosciences) and biotinylated anti-glucocorti-
coid-induced TNF receptor (GITR goat polyclonal Ab; R&D systems, Min-
neapolis, USA). In the case of biotinylated antibodies cells were labeled with
streptavidin conjugated PE (BD Biosciences) or PE-Cy5 (Beckman Coulter) .
All incubations were for 20 minutes room temperature and thereafter cells were
washed twice. The samples were run on a Coulter Epics XL, Beckman Coulter
and at least 100.000-150.000 live gate events were collected based on live lym-
phocyte gating, as indicated by 5 mg/mL propidium iodide staining. Isotype
matched antibodies were used to define marker settings. Data were analyzed
using Coulter Epics Expo 32.
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Discrimination of subpopulations through CFSE dilution and 
CD25 expression
The cell division rate of allo-MHC primed T cells was studied by labelling
responder T cells with Carboxyfluorescein Diacetate Succinimidyl Ester
(CFDA-SE, Molecular Probe, Eugene, OR). T-cells were labelled at 0.25-0.5
mM CFSE at 1*107 cells for 10 min. An equal volume of FCS was added, and
cells were washed with medium. Simultaneous labelling of CD25+ T cells, by
fluorochrome conjugated mAb against CD25 (see above) enables the study of
division kinetics of different T cell subsets by flowcytometry. Data, preferential-
ly 100.000-150.000 live gate events, were analyzed using Coulter Epics Expo 32.
Murine cardiac allograft transplantation
Experiments were performed with completely MHC-mismatched combina-
tions of C57BL/6 (H-2b) donors and BALB/c (H-2d) recipients. Mice were pur-
chased from Charles River Lab (Charles River, Sulzfeld, Germany). Mice were
used at 8 to 12 weeks of age and housed in a specified pathogen free facility. Car-
diac allografts were placed in an intra-abdominal location using the technique
described by Corry et al 21. Graft function was assessed every two days by palpa-
tion. Animals received three doses of MR1 at days 0,2 and 4 (0.25 mg each) by
intra-peritoneal injection and two doses of HB253 at day 0 (0.2 mg) and day 1
(0.1 mg) by intra-venous injection. The day of rejection was defined as the day
of cessation of palpable heartbeat.
Statistical analysis
Statistical Analysis was performed using the Statistical Product and Services
Solutions (SPSS) package, version 10.0. For comparisons between groups we
used Student’s t test, assuming unequal variances because of small sample sizes.
The effect of various amounts of cells added in cocultures was analyzed by
ANOVA. For post-hoc comparisons we used Dunnett’s procedure, in which the
condition without adding cells was treated as control. A P value of less than 0.05
was considered statistically significant.
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Results
Costimulation blockade of MLR results in the generation of a non-dividing
CD25high cell population with strong regulatory capacity
Addition of anti-CD40L and anti-CD86 mAb to a primary MLR resulted in an
inhibition of the allogeneic response of 65% at day 5 of culture (fig. 1A). CFSE
analysis revealed that both CD4 and CD8 cells were affected to a similar extent
(data not shown). Cells that were harvested from such a costimulation blocked
MLR and added to a newly setup primary MLR, displayed a dose-dependent
suppressive effect (fig. 1B). When these cells were subdivided according to
CFSE intensity and IL-2 a-chain receptor expression (CD25), we identified
three distinct subpopulations: (a) a non-dividing CD25high subset; (b) the
CFSE low-negative progeny of dividing cells and (c) a non-responding CD25neg
subset (fig. 1C). Upon isolation by FACS sorting, the non-dividing CD25high
population (a) was hyporesponsive to allogeneic rechallenge (fig. 1D). This
hyporesponsive state could be reversed by the addition of exogenous IL-2. Also,
these cells displayed potent regulatory capacity, for they profoundly suppressed
naive alloreactive T-cells in a newly performed MLR (fig. 1E). This suppressive
capacity was found to be dose dependent (Fig. 1F). Notably, this population was
not exclusive for costimulation blocked MLR, but was also observed in an
untreated control MLR, albeit at lower numbers (see below). The non-dividing
CD25neg population (c) was refractory to antigenic rechallenge, irrespective of
the presence of exogenous IL-2 (fig. 1D), and did not display any suppressive
effects (fig. 1E and 1F). The progeny of dividing cells (b) was highly alloreactive,
since these cells rapidly responded to antigenic rechallenge, which was further
enhanced by exogenous IL-2 (fig. 1D), and moreover failed to suppress a newly
performed MLR (fig. 1E).
We subsequently examined whether the non-dividing CD25high population
was as efficient in inhibiting immune responses to third party antigens as to the
cognate antigen. After allogeneic stimulation by C57BL/6 APC’s in primary
MLR, the non-dividing CD25high TREG cells were isolated and proved to sup-
press potently the response to both types of antigen (fig. 1G). This indicates that
at that time point the non-dividing CD25high TREG population has the capacity
to restrain a diverse range of T-cell clonotypes in a non-specific way.
Phenotypic characterization of the non-dividing CD25high cells by flow
cytometry revealed that they were CD4pos, CD62Lhigh and predominantly
CD45RBlow (Fig. 2). Furthermore, these cells expressed GITR, which has been
shown to be a functional property of regulatory T-cells22.
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 Figure 1. Upon allogeneic MLR the non-dividing CD25high population harbors strong
suppressive capacity.
A. Primary MLR of 1*105 responder BALB/c T-cells were cultured with 2.5*104 C57BL/6 
γ-irradiated (27.5 Gy) splenocytes in the absence or presence of anti-CD40L+anti-CD86 mAb
(open or closed symbols, respectively). Proliferation as measured by 3H-Thymidine incorpo-
ration is shown on the y-axis and expressed as mean cpm ± SEM. *: P<0.05 for difference
baetween groups.
B. Cells obtained from primary cultures in the absence or presence of anti-CD40L+anti-
CD86 mAb (open or closed symbols, respectively) were γ-irradiated and subsequently added
to a fresh MLR in a responder:suppressor ratio of 4:1 and 2:1. Proliferation of co-cultures was
measured at day 5 of culture. Proliferation as measured by 3H-Thymidine incorporation is
shown on the y-axis and expressed as mean cpm ± SEM. *: P<0.05 for difference between
groups.
C. FCM analysis of live lymphocytes at day 7 of a primary MLR treated with anti-CD86+anti-
CD40L mAb. Freshly isolated 1*105 CFSE labeled responder BALB/c T-cells were cultured
with 2.5*104 C57BL/6 γ-irradiated (27.5 Gy) splenocytes and subsequently labeled for CD25
expression.Three distinct subpopulations indicated in squares, emerged: (a). a non-dividing
CD25high subset (8.1%); (b). a subset of CFSE low-negative proliferating cells (25%); (c). and
a non-responding CD25neg subset (66.9%). Subpopulations were subsequently isolated at
day 7 by FACS sorting, washed to remove antibodies and cytokines, and functionally charac-
terized.
D. Cells from each subset were restimulated a 2:1 responder:stimulator ratio in the absence
or presence of 50U/ml exogenous murine rIL-2. Proliferation as measured by 3H-Thymidine
incorporation at day 3 of culture is shown on the x-axis and expressed as mean cpm ± SEM.
**: P<0.01 for difference between groups.
E. Cells from each subset were added to a newly set up MLR of 1*105 syngeneic T-cells
depleted for CD4+CD25+ cells and 2.5*104 γ-irradiated (27.5 Gy) C57BL/6 stimulators, at a
ratio of 5:1 responder:sorted cell. Proliferation as measured by 3H-Thymidine incorporation 
is shown on the y-axis and expressed as mean cpm ± SEM. Autologous responses were 
< 100 cpm. **: P<0.01 for difference between groups (a) and (b). ##: P<0.05 for difference
between groups (a) and (c).
F. Increasing numbers of cells were added to a newly set-up MLR of 1*105 syngeneic T-cells
depleted for CD4+CD25+ cells and 2.5*104 C57BL/6 γ-irradiated (27.5 Gy) stimulators.
Proliferation of co-cultures was measured by 3H-Thymidine incorporation at day 5 of culture.
The y-axis represents the mean cpm ± SEM. Autologous responses were < 100 cpm.
*: P<0.05; **: P<0.01 for difference with condition without suppressor cells.
G. The non-dividing CD25high cells obtained from primary MLR were added to a newly setup
MLR of either 2.5*104 γ-irradiated (27.5 Gy) C57BL/6 or C3H stimulators and 1*105 syngene-
ic Balb/c T-cells depleted for CD4+CD25+ cells. Proliferation as measured at day 6 of culture
by 3H-Thymidine incorporation is shown on the y-axis and expressed as mean cpm ± SEM.
Autologous responses were < 100 cpm. Results are shown from one typical experiment out
of four. *: P<0.05; **: P<0.01 for difference with condition without suppressor cells.
costimulation blockade favors treg function 
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Figure 2. Phenotypic characterization of the non-dividing CD25high population.
Freshly isolated 1*105 CFSE labeled responder BALB/c T-cells were cultured with 2.5*104
C57BL/6 γ-irradiated (27.5 Gy) splenocytes. At day 6 of culture FCM expression profiles were
determined of the non-dividing CD25high subset, the divided cells, and the non-dividing
CD25neg subset.The dotted line indicates the matched isotype control.The solid line indi-
cates expression of CD4, CD45RB, CD62L and GITR.
Taken together, after costimulation blocked allogeneic stimulation of T
cells, the non-dividing CD25high population uniquely harbors potent regulato-
ry capacity and carries the phenotype of regulatory T-cells. From here on the
non-dividing CD25high subset will be referred to as TREG and the progeny of
dividing, alloreactive cells as TALLO.
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Non-dividing CD25high cells, descendant from naturally occurring
CD4+CD25+ T-cells are required for the induction of suppressive capacity
by costimulation blockade
To establish the role of naturally occurring CD4+CD25+ regulatory T-cells in
the induction of suppressive capacity by costimulation blockade, we performed
the MLR with either total T cell populations or T cells depleted for naturally
occurring CD4+CD25+ regulatory T-cells (fig. 3A). T cells depleted for
CD4+CD25+ T cells showed an increased proliferative response compared to a
total responder population (± 71,000 cpm peak proliferation at day 6 vs. ±
35,000 cpm peak proliferation at day 5 of culture respectively). Both the total
and the CD4+CD25+ T cell depleted populations were inhibited in their prolif-
eration by the combination of anti-CD40L and anti-CD86 mAb (65% vs. 45%
inhibition respectively).
Subsequently, cells harvested after costimulation blocked MLR with both
types of responder populations (total T cells vs. CD4+CD25+ depleted) were
added to a new primary MLR (fig. 3B). As already shown, a total T cell popula-
tion treated with anti-CD40L and anti-CD86 mAb during primary culture
inhibited the new MLR in a dose dependent manner. Conversely, CD4+CD25+
depleted T cell cultures failed to display suppressive capacities after exposure to
costimulation blockade in primary culture.
Based on our finding that the suppressive effect of costimulation blocked T
cells resides in the non-dividing CD25high T cells, we next determined the rela-
tionship of this cellular subset to naturally occurring CD4+CD25+ regulatory T-
cells. Depletion of the latter cells prior to allogeneic MLR resulted in a sharp
reduction of the non-dividing CD25high population at day 7 of culture (fig. 3C).
This indicates that the naturally occurring CD4+CD25+ regulatory T-cell popu-
lation brings forth the non-dividing CD25high population. However, we ques-
tioned whether the non-dividing CD25high TREG solely are descended from the
naturally occurring CD4+CD25+ regulatory T-cell population during MLR or,
in addition, are de novo induced by naturally occurring CD4+CD25+ cells. To
answer this, we labeled a CD4+CD25+ T-cell depleted T-cell population with
CFSE. These cells were co-cultured with an unlabeled population of
CD4+CD25+ regulatory T-cells, in the presence of anti-CD40L and anti-CD86
mAb. As a negative control, a co-culture with an unlabeled CD4+CD25+ T-cell
depleted population was performed with anti-CD40L and anti-CD86 mAb.
After six days of culture the number of non-dividing CD25high cells did not
exceed the background observed after depletion (fig. 3D). This indicates that
CD4+CD25+ regulatory T-cells do not induce the de novo emergence of non-
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 Figure 3. Naturally occurring CD4+CD25+ regulatory T-cells are essential for the
induction of suppressive capacity by costimulation blockade.
A. Primary MLR was performed with whole T-cells (squares) or CD4+CD25+ T-cell depleted
responders (diamonds). For either condition, control (no mAb) and anti-CD40L+anti-CD86
mAb treated MLR was performed (open or closed symbols, respectively). *: P<0.05; **:
P<0.01 for difference between groups.
B. Cells obtained from primary cultures were γ-irradiated and subsequently added to a fresh
MLR in a responder:suppressor ratio of 4:1 and 2:1. Proliferation of co-cultures was mea-
sured at day 5 of culture.The y-axis represents the mean cpm ± SEM. *: P<0.05 for difference
between groups.
C. Primary MLR treated with anti-CD40L+anti-CD86 mAb was performed with CFSE labeled
whole T-cells or T-cells depleted for CD4+CD25+ cells and γ-irradiated stimulator spleen cells.
FCM analysis for CFSE intensity and CD25 expression of live lymphocytes was performed at
day 7 of primary MLR.
D. 1*105 T-cells depleted for CD4+CD25+ cells (CD25- ) or 1*105 purified CD4+CD25+ T-cells
(CD25+) were co-cultured with 1*105 syngeneic CFSE labeled T-cells depleted for
CD4+CD25+ cells (CD25- ) and 2.5*104 C57BL/6 γ-irradiated (27.5 Gy) stimulators in the
presence of anti-CD40L+anti-CD86mAb. At day 6 of culture FCM expression profiles were
determined for CFSE and CD25 expression.
dividing CD25high cells in this experimental setting. Apparently, the suppressive
capacity induced by co-stimulation blockade rests on the pre-existing pool of
naturally occurring CD4+CD25+ regulatory T-cells.
Costimulation blockade allows regulatory T-cells to become functionally
dominant over effector T-cells
We observed that the non-dividing CD25high cell population was not exclusive
for co-stimulation blocked MLR, since also in an untreated control MLR a sim-
ilar, but smaller, population emerged as shown by FCM analysis (6% vs. 3.9%
respectively, day 7 of culture fig. 4B). However, in contrast to the whole T cell
population obtained after costimulation blocked MLR, the whole T cell popu-
lation harvested after an untreated control MLR had no suppressive capacity
(fig. 1A). We therefore hypothesized that it is not the mere presence of the TREG
subset that dictates the functional properties of a T-cell population, but rather
the ratio between regulatory T-cells and effector cells. First, we established that
the TREG subset isolated from either control MLR or co-stimulation blocked
MLR had equal suppressive capacity. When used in equal numbers, the addi-
tion of isolated non-dividing CD25high cells obtained from either culture condi-
tion resulted in similar inhibition of a new primary MLR (Fig. 4A). Subse-
quently, we determined the size of the TREG population and TALLO population
during culture in the presence or the absence of costimulation blockade by anti-
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 Figure 4. Enrichment of the non-dividing CD25high regulatory T cell fraction during
costimulation blockade.
A. The non-dividing CD25high cells obtained from primary MLR in the absence (control) or
presence of anti-CD40L+anti-CD86 mAb (costimulation blockade) were added to a newly
setup MLR of 2.5*104 γ-irradiated (27.5 Gy) C57BL/6 and 1*105 syngeneic BALB/c T-cells
depleted for CD4+CD25+ cells. Proliferation as measured at day 6 of culture by 3H-Thymidine
incorporation is shown on the y-axis and expressed as mean cpm ± SEM. Autologous
responses were < 100 cpm. **: P<0.01 for difference with condition without suppressor cells.
B. Proportion of dividing (TALLO) and non-dividing (TREG) cells, expressed as percentage of
the cells within the live lymphocyte gate, at day 3, 5 and 7 of both control and anti-
CD40L+anti-CD86 mAb treated MLR.TALLO numbers were corrected for numbers of remain-
ing CFSE negative stimulator cells, as defined on day 3.
C. Ratio between the relative fractions of TREG in the presence or absence of costimulation
blockade, determined according to the following equation; (TREG/(TALLO+ TREG))anti-CD86+
anti-CD40LmAb / (TREG/(TALLO+ TREG))Control . Data from one representative experiment out of 5
are shown.
CD40L and anti-CD86 mAb (fig. 4B). Indeed, by relating the percentage of the
TREG fraction to the TALLO fraction we observed that the induction of overall
suppressive capacity of the T-cell population correlated with a shift in the ratio
between these fractions. After 7 days of culture, costimulation blockade resulted
in a 3.5 fold increase of this ratio as compared to the control condition (Fig. 4C).
Taken together, this demonstrates that the observed induction of suppressive
capacity in the T-cell population as a whole by costimulation blockade is corre-
lated to a shift in relative number of regulatory vs. effector T-cells.
Costimulation blockade in vivo also induces a shift in the balance between
regulatory and effector T-cells
The in vitro findings prompted us to investigate the possibility of regulatory T-
cell enrichment induced by anti-CD40L and anti-CD86 treatment in vivo. To
this end, we used a heterotopic heart transplant model in the mouse. Treatment
with anti-CD40L and anti-CD86 mAb after cardiac transplantation from
C57BL/6 donors to BALB/c recipients typically resulted in a prolongation of
graft survival from about 7 days in untreated controls to more than 21 days in
the mAb treated situation. To assess the cellular composition in spleen and
lymph nodes, both mAb treated and non-treated animals were sacrificed at day
5 after transplantation. Treatment with anti-CD40L and anti-CD86 mAb did
not result in an increase of the number of CD4+CD25+ T-cells in either spleen
or lymph nodes (data not shown). However, this may not be an accurate mea-
costimulation blockade favors treg function 
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 Figure 5. Costimulation blockade results in enrichment of the non-dividing CD25high
regulatory T cell fraction in vivo.
A. CD4+CD25+ cells were obtained from both anti-CD40L and anti-CD86 mAb treated and
non-treated BALB/c recipients at day 5 after cardiac transplantation with C57BL/6 donors.
Cells were added to a newly setup MLR of 2.5*104 γ-irradiated (27.5 Gy) C57BL/6 and 
1*105 syngeneic naive BALB/c T-cells. Proliferation as measured at day 6 of culture by 
3H-Thymidine incorporation is shown on the y-axis and expressed as mean cpm ± SEM.
Autologous responses were < 100 cpm. *: P<0.05 for difference between groups. #: P=0.067
for difference between groups.
B. MLR was performed with 2.5*104 γ-irradiated (27.5 Gy) C57BL/6 stimulator spleen cells
and 1*105 CFSE labeled T cells depleted for CD4+CD25+ cells, obtained from spleens of both
anti-CD40L and anti-CD86 mAb treated and non-treated BALB/c recipients at day 5 after 
cardiac transplantation with C57BL/6 donors. FCM analysis for CFSE intensity and CD25
expression of live lymphocytes was performed at day 6 
of MLR.
C. At day 5 after cardiac transplantation, splenocytes were isolated from both control and
anti-CD40L+anti-CD86 mAb treated BALB/c recipients of C57BL/6 donors. Cells were 
extensively washed to remove antibodies, CFSE labeled, and restimulated by γ-irradiated
(27.5 Gy) C57BL/6 stimulator spleen cells (1*105 resonders and 2.5*104 stimulators).
Proportions of CFSElow/negative dividing T-cells and non-dividing CD25high cells were calcu-
lated as percentage of the cells within the live lymphocyte 
gate at day 6 of antigenic rechallenge. Data from one representative experiment out 
of 3 are shown.
sure as CD4+CD25+ T-cells can reflect both activated alloreactive effector cells
as well as regulatory T-cells. So, we continued by isolating the CD4+CD25+ T-
cell fraction harvested from the spleen following transplantation, and estab-
lished that irrespective of the treatment with mAbs, the CD25+ cells did harbour
suppressive capacity (fig. 5A). Moreover, depletion of this CD4+CD25+ subset
prior to ex-vivo rechallenge of CFSE labelled cells resulted in the absence of the
characteristic non-dividing CD25high cell subset as previously defined in the in
vitro experiments (fig. 5B). So, in both cases regulatory T cells were present in
the spleen and they were contained in the non-dividing CD25high fraction.
Analogous to our in vitro experiments, we therefore compared the ratio
between the non-dividing CD25high cells and the CFSElow/negative dividing T-
cells after ex-vivo rechallenge of T cells obtained from anti-CD40L and anti-
CD86 mAb treated graft recipients or untreated controls. T-cells were harvested
from the spleen at day 5 following transplantation, CFSE labeled and subse-
quently rechallenged with stimulator splenocytes of the C57BL/6 cardiac allo-
graft type. It was observed that antigenic rechallenge of splenocytes harvested
from graft recipients following costimulation blockade results in an elevated
ratio of non-dividing CD25high cells vs. the CFSElow/negative dividing T-cells (fig.
costimulation blockade favors treg function 
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5C). This indicates that costimulation blockade also in vivo results in a shift of
balance between alloreactive effectors and a regulatory subset.
Discussion
It has previously been demonstrated that costimulation blockade during allo-
geneic T cell stimulation can result in the generation of a polyclonal T cell pop-
ulation with suppressive properties23,24. By simultaneously measuring the CFSE
dilution and CD25 expression within this population, we here demonstrate for
the first time that this suppressive capacity resides in a relatively small subset of
non-dividing CD25high cells. Conversely, the cells that underwent multiple cell
divisions according to loss of CFSE intensity belonged to the alloreactive effec-
tor pool since they responded vividly to an antigenic rechallenge and did not
display any regulatory potential.
After allogeneic MLR, the regulatory non-dividing CD25high cells carried
the CD45RBlow, CD62Lhigh phenotype and expressed GITR, which is akin to
other known subsets of regulatory T-cells1,22. Furthermore, we found that the
development of regulatory capacity mediated by these non-dividing CD25high
cells was dependent on the presence of naturally occurring CD4+CD25+ regula-
tory T-cells at the start of MLR. Since we did not observe de novo induction of
non-dividing CD25high cells, we conclude that in our experimental setting the
particular subset of non-dividing CD25high cells exclusively originates from the
population of naturally occurring CD4+CD25+ regulatory T-cells. However,
this does not preclude the in vivo occurrence of infectious tolerance or the skew-
ing of APC’s to a tolerizing phenotype, as has been demonstrated by others25,26.
Although the non-dividing CD25high cells could also be detected during
control MLR, their functional dominance, as reflected by the suppressive
capacity of the total T cell population harvested after MLR, only emerged after
costimulation blockade. Our data indicate that the absence of pro-mitotic sig-
nals due to impaired CD28:CD86 and CD40:CD40L signalling selectively
reduced the alloreactive effector T-cell pool size, while regulatory T-cell func-
tion was allowed by intact TCR engagement. Consequently, combined anti-
CD86 and anti-CD40L mAb treatment tipped the balance between effectors
and regulators, favoring dominance of immunoregulatory mechanisms exerted
by a relatively small number of activated CD4+CD25+ T-cells. This implicates
that anti-CD40L plus anti-CD86 mAb treatment does not compromise the
suppressive capacity of CD4+CD25+ regulatory T-cells, despite their dependen-
cy on costimulation for thymic generation and homeostasis27. This fits observa-
tions by Taylor et al. for single anti-CD40L mAb and by Shevach et al. for single
50
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anti-CD86 mAb treatment 20,28. Also in vivo, we observed that costimulation
blockade resulted in a shift of balance between alloreactive effectors and regula-
tory CD4+CD25+ T-cells. These findings are in agreement with other studies,
where CD4+CD25+ regulatory T-cells have specifically been implicated in the
induction and preservation of transplantation tolerance. In these studies, reduc-
tion of the alloreactive T-cell clone size was shown to be pivotal for the
immunoregulatory function of CD4+CD25+ T-cells10,11. In addition, it was
shown that in the absence of CD4+CD25+ regulatory T-cells, reduction of the
alloreactive T-cell pool may lead to immunological ignorance, but not to the
establishment of an immunoregulatory network 8. This supports the concept
that regulatory T cells, once facilitated by reduction of the alloreactive pool size,
can actively constrain an alloreactive effector T-cell response.
The regulatory T cell subset that was found during costimulation blocked
MLR, exerted suppressive effects on third-party antigen responses as well. Since
the antigen specificity of CD4+CD25+ regulatory T-cells resides in the activa-
tion of these cells rather than in the suppressor-effector function, bystander
suppression of the response to third party antigens by activated regulatory T
cells can be well imagined7. A somewhat longer resting period of these cells
might be necessary to reveal their antigen-specificity. Alternatively, it cannot be
ruled out that after a single round of stimulation the non-dividing CD25high T
cells still constitute a heterogeneous population also harboring regulatory T-
cells specific for the third-party antigens presented. In that case, activation of
these cells could have contributed to the observed non-specific suppression.
Nonspecific downregulation of T-cell responses to third-party antigens was also
observed in an alternative model of induction of suppressive function based on
anti-CD40L mAb24. The finding that the suppressive population in this model
retained a broad Vβ repertoire, which indicates a lack of antigenic skewing,
underscores the potential heterogeneity within the CD4+CD25+ regulatory T-
cell subset. On the other hand, repeated stimulation with cognate antigen and
cytokines in-vitro was shown to skew regulatory T-cells in an antigen-specific
way19,29. A similar phenomenon may in vivo lead to the emergence of donor-
specific tolerance after reduction of the alloreactive effector pool8. This would
resolve the apparent inconsistency of non-specific suppression in our in vitro
system and in vivo observations of donor-specific hyporesponsiveness after cos-
timulation blockade.
Our method to identify and isolate a subset of potent regulatory T-cells
within a polyclonal T-cell population is of great potential value for
immunotherapeutical applications. Based on CFSE-staining, we were able to
costimulation blockade favors treg function 
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isolate a potent regulatory T cell subset. Already, CFSE based depletion of
alloreactive effector cells proved promising in the prevention of GVHD in a
mouse model, providing proof of principle for therapeutical application of
CFSE based isolation strategies30. We here show that the CFSE based strategy
proves ideal not only for purposes of depleting subsets, but also for the selective
isolation of defined TREG subsets. The beneficial effects of these cells can subse-
quently be exploited by reinfusion in the transplant recipient after ex-vivo
expansion. Determining the proper culture conditions for the expansion of
these cells without loss of their regulatory function is essential in the develop-
ment of such a strategy19,31.
In summary, we put forward that costimulation blockade fosters the func-
tional dominance of regulatory T-cells and in this way can contribute to durable
transplantation tolerance. A CFSE based approach enabled us to identify vari-
ous subpopulations of T-cells with distinct functional characteristics. Isolation
thus achieved and subsequent ex-vivo expansion of a subset with strong regula-
tory capacity forms a promising tool for immunotherapy.
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Abstract
Blockade of costimulatory signals is a promising therapeutic target to prevent
allograft rejection. Here we sought to characterize to what extent CTLA-4
engagement contributes to the development of transplantation tolerance under
the cover of CD40/CD40L and CD28/CD86 blockade. In vitro, we found that
inhibition of the primary alloresponse and induction of alloantigen hypore-
sponsiveness by costimulation blockade was abrogated by anti-CTLA-4 mAb.
In addition, CD4+CD25+ regulatory T-cells (TREG) were confirmed to play a
critical role in the induction of hyporesponsiveness by anti-CD40L and anti-
CD86 mAb. Our data indicated that CTLA-4 engagement is not required for
activation or suppressor function of TREG. Instead, in the absence of either
CTLA-4 signaling or TREG, CD8+ T-cell division was enhanced, whereas the
inhibition of CD4+ T-cell division by costimulation blockade remained largely
unaffected. In vivo, the administration of additional anti-CTLA-4 mAb abro-
gated anti-CD40L and anti-CD86 mAb induced cardiac allograft survival. Cor-
respondingly, rejection was accompanied by enhanced allograft infiltration of
CD8+ cells. We conclude that CTLA-4 signaling and TREG independently
cooperate in the inhibition of CD8+ T-cell expansion under costimulation
blockade.
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Introduction
Elucidating the mechanisms underlying the regulation of T-cell responses is
crucial for the improvement of tolerogenic strategies in clinical transplantation.
Blockade of costimulatory signals is a promising therapeutic target, for block-
ade of the CD28/B7 and CD40/CD40L pathways results in profound T-cell
hyporesponsiveness and application of costimulation blockade in vivo results in
long-term allograft survival1-3.
An important regulatory mechanism in T-cell responses is the engagement
of the CD28 homologue cytotoxic T lymphocyte antigen-4 (CTLA-4)4,5.
CTLA-4 is up regulated upon T-cell activation, and subsequent binding of this
molecule to B7 molecules CD80 or CD86 results in down regulation of the T-
cell response. CTLA-4 signaling has been implicated in the acquirement of
transplantation tolerance, but exactly how CTLA-4 exerts its effect in this
process remains a matter of debate6,7. It is of note that CTLA-4 is constitutively
expressed on regulatory CD4+CD25+ T-cells (TREG), which are by now firmly
established as critical mediators of peripheral allograft tolerance8. Various stud-
ies suggest an association between the engagement of CTLA-4 on these cells
and their regulatory function9-12. However, there are also studies that support
the contrary13-15.
Recently, we demonstrated that combined blockade of the CD40L and the
CD86 pathways by anti-CD40L and anti-CD86 monoclonal antibody (mAb)
resulted in a reduction of the alloreactive clone size, allowing immunoregulato-
ry mechanisms mediated by CD4+CD25+ regulatory T-cells to emerge16. Here,
we sought to characterize to what extent CTLA-4 engagement may contribute
to the development of transplantation tolerance under the cover of
CD40/CD40L and CD28/86 blockade, either by activation of regulatory T-
cells, by containment of the alloreactive effector pool size, or a combination of
both. 
Materials and methods
Cell purification
BALB/c responder cells were purified from pooled peripheral lymph node and
spleen cells. Cells were depleted of erythrocytes by osmotic shock in lysis buffer
containing 0.15mM NH4Cl (Merck, Darmstadt, Germany), 10.0 mM KHCO3
(Merck) and 0.1 mM Na2EDTA (Sigma-Aldrich, Steinheim, Germany). T-cells
were enriched by depletion of MHC class II positive cells by coating with anti
MHC class II magnetic microbeads (Miltenyi, Bergisch Gladbach, Germany),
independence of ctla-4 and cd4+cd25+ treg function
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followed by passage through a LD microbead column (Miltenyi). Purification
of CD4+CD25+ T-cells was carried out by magnetic cell separation. To this end,
the T-cell enriched population was inoculated with saturating amounts of
biotin-labeled anti-CD25 antibody (7D4; BD Biosciences, San Diego, USA).
Cells were subsequently incubated with anti-biotin microbeads and separated
using MS columns according to the manufacturer’s instructions, yielding >90%
CD25+ positivity of the CD4 T-cell fraction. CD25+ T-cell depleted populations
typically contained <1% CD4+CD25+ T-cells. C57BL/6 or BALB/c stimulator
cells were enriched by culturing splenocytes in 9 cm petridishes (Allegiance,
Zutphen, The Netherlands) for two hours and further overnight culture of the
adherent cell fraction. After 18 to 24 hours the non-adherent cells were obtained
by harvesting the supernatant and gently washing the petridish.
Proliferation assay
For primary MLR, responder cells were cultured with γ-irradiated (27.5 Gray)
stimulator cells at a ratio of 1*105 responders to 2.5*104 stimulator cells in flat
bottom 96-well plates (Costar, Corning, USA) containing RPMI (Gibco , Pais-
ley, UK) with 10% FCS (Invitrogen, Dieren, The Netherlands), 50 mM 2-ME
(Biorad, Hercules, USA), 1 mM sodium pyruvate, glutamax and antibiotics
(100 U/mL penicillin; 100 mg/mL streptomycin)(all from Gibco) at 37º, 95%
humidity and 5% CO2. In specified cases 1 mg/mL anti-CD40L (MR1, ATCC#;
CRL-2580),1 mg/mL anti-CD80 (HB301, ATCC#; HB301) and 1 mg/mL anti-
CD86 (HB253, ATCC#; HB253) were added. Blocking anti-CTLA-4 antibod-
ies (4F10, ATCC#; UC10-4F10-11) were added in various concentrations as
described. All antibodies were from Bioceros BV, Utrecht, The Netherlands.
Isotype matched control antibodies rat IgG2a and hamster IgG (R35-95 and
A19-3 both from BD biosciences, San Diego, USA) were used in equal concen-
trations. F(Ab)’2 fragments of the anti-CTLA-4 antibody were generated with
the Immunopure F(Ab)’2 Preparation Kit (Pierce, Rockford, USA) and the
Spectra/Por Float-A-Lyzer (Breda, The Netherlands) using the instructions of
the manufacturer. To study antigenic rechallenge, cells were harvested at day 7
of culture and washed and subsequently rested in 5% FCS culture medium (see
above). At day 10 the cells were added to fresh stimulator cells at the indicated
ratios. For plate-immobilized anti-CD3 stimulation, anti-CD3e mAb (145-
2C11; hamster IgG; BD Pharmingen, San Diego, USA) 2.5 mg/ml was precoat-
ed on flat bottom 96-well plates by overnight incubation at 4ºC. Before these
anti-CD3 coated plates were used they were washed with sterile PBS. CD25+ T-
cell depleted T-cells were plated in anti-CD3 mAb coated plates at 5*104 cells per
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well. Cell proliferation was monitored by tritiated thymidine incorporation. To
this end the cells were pulsed with tritiated thymidine (0.5 mCi) during the last
16-18 h of the culture. Tritiated thymidine incorporation was analyzed by a gas
scintillation counter and is expressed as mean count per 5 minutes and SD of at
least triplicate measurements.
Flow cytometry
Cells were phenotypically analysed by three-colour fluorescence. Cells were
washed twice with phosphate-buffered saline supplemented with 0.2% bovine
serum albumin (BSA) (Sigma). The following antibodies were used: PE-conju-
gated anti-CD4 (L3T4); anti-CD8 (53-6.7) both from BD Biosciences (Erem-
bodegem, Belgium). All incubations were conducted for 20 minutes at room
temperature and thereafter the cells were washed twice. The samples were run
on a Coulter Epics XL, Beckman Coulter and at least 100.000-150.000 live gate
events were collected based on live lymphocyte gating, as indicated by 5 mg/mL
propidium iodide staining. Isotype matched antibodies were used to define
marker settings. Data were analyzed using Coulter Epics Expo 32.
Immunofluorescence
Two micrometer sections were cut from cardiac allograft tissue samples embed-
ded in Tissue-Tek O.C.T. (Sakura Finetek, Zoeterwoude, the Netherlands) and
mounted on glass microscope slides. Sections were fixed for 10 min. with 90%
aceton, rinsed in PBS and incubated with isotype control FITC-conjugated
IgG2a, κ (R35-95); isotype control PE-conjugated IgG2b, k (A95-1); FITC-con-
jugated anti-CD3 (17A2); FITC conjugated Ly-6G+ (RB6-8C5) or PE-conju-
gated anti-CD8 (53-6.7) (all from BD Biosciences Erembodegem, Belgium) in
2% BSA-PBS for 1 hour. Finally, the sections were rinsed in PBS, postfixed with
1% paraformaldehyde-PBS, rinsed in PBS and embedded in Vecta-Shield
mounting medium H-1000 (Vector Laboratories, Inc., Burlingame, CA, USA).
The slides were investigated by fluorescence microscopy (Zeiss Axioscop micro-
scope equipped with an epi-illuminator) and photographed with a digital cam-
era (Nikon Coolpix DXM 1200 Bunnik, the Netherlands). Intragraft infiltra-
tion was examined by calculating the average number of infiltrating cells of 5-10
section areas. To asses CD4+ T-cell infiltration, section areas were co-scored for
the presence of CD3+CD8- cells. To asses neutrophil and CD8+ T-cell infiltra-
tion, Ly-6G+ and CD8+ cells were scored.
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Discrimination of subpopulations through CFSE dilution
The cell division rate of alloreactive T-cells was studied by labelling responder T-
cells with Carboxyfluorescein Diacetate Succinimidyl Ester (CFDA-SE, Molec-
ular Probe, Eugene, OR). 1*107 T-cells were labelled with 0.25-0.5 mM CFSE
for 10 min. Subsequently, an equal volume of FCS was added, and the cells were
washed with medium. Simultaneous labelling of T-cells by fluorochrome conju-
gated mAb enables the study of division kinetics of different T-cell subsets by
flowcytometry. Data, preferentially 100.000-150.000 live gate events, were ana-
lyzed using Coulter Epics Expo 32.
Murine cardiac allograft transplantation
Experiments were performed with completely MHC-mismatched combina-
tions of C3H recipients (H-2k) and BALB/c (H-2d) donors. Mice were pur-
chased from Charles River Lab (Charles River, Sulzfeld, Germany). Mice were
used at 8 to 12 weeks of age and housed in a specified pathogen free facility. Car-
diac allografts were placed in an intra-abdominal location using the technique
described by Corry et al 17.Graft function was assessed every two days by palpa-
tion. In at least 5 mice per group animals received three doses of MR1 (ATCC#;
CRL-2580) at days 0, 2 and 4 (0.25 mg each) by intra-peritoneal injection and
two doses of HB253 (ATCC#; HB253) at day 0 (0.2 mg) and day 1 (0.1 mg) by
intra-venous injection. In specified cases animals received three doses of addi-
tional 4F10 (ATCC#; UC10-4F10-11) at days 0, 2 and 4 (0.1mg each) by intra-
peritoneal injection. The day of rejection was defined as the day of cessation of
palpable heartbeat. All mAb were obtained from Bioceros BV, Utrecht, The
Netherlands. Experiments performed were approved in accordance with the
institutional animal care and utilization committee approved criteria and proto-
cols.
Statistical analysis
Statistical Analysis was performed using the Statistical Product and Services
Solutions (SPSS) package version 10.0 and Graphpad Prism 3.0. For compar-
isons between groups we used Student’s t test, assuming unequal variances
because of small sample size. Graft survival curves were analysed by a log-rank
test. A P value of less than 0.05 was considered statistically significant.
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Results
CTLA-4 signaling is required for inhibition of the allogeneic response by
anti-CD40L and anti-CD86 mAb
Typically, the addition of anti-CD40L and anti-CD86 mAb to a primary MLR
leads to a substantial inhibition of the T-cell response. Since this approach
leaves the CTLA4-CD80 signaling pathway intact, we set out to assess whether
in this system CTLA-4 engagement is involved in the restraint of the allo-
reactive T-cell response. Also, we addressed the question whether blockade of
CD80 would result in similar effects. To this end, we first examined the effect of
CTLA-4 blockade by anti-CTLA-4 mAb in costimulation blocked primary
MLR cultures. Figure 1A shows that, whereas addition of anti-CD40L and anti-
CD86 mAb to a primary MLR resulted in 65% inhibition of the alloresponse at
the proliferative peak of culture, additional anti-CTLA-4 mAb abrogated this
inhibition. Blockade of CD80 in addition to anti-CD40L and anti-CD86 mAb
resulted in enhanced inhibition by CD40L and CD86 costimulation blockade
(Fig. 1A). Equivalent quantities of isotype control antibodies did not modify the
proliferation of the cultures (Fig 1A). Thus, blockade of CTLA-4 signaling but
not CD80 abrogates the inhibition of the alloresponse by CD40L and CD86
costimulation blockade. This effect was found to be dose dependent (Fig. 1B.).
The use of F(Ab)’2 fragments of the anti-CTLA-4 mAb yielded similar results as
using the whole antibody (data not shown).
CTLA-4 signaling and CD4+CD25+ regulatory T-cell function are both
essential for the induction of alloantigen hyporesponsiveness by anti-CD40L
and anti-CD86
In addition to inhibiting a primary MLR, costimulation blockade based strate-
gies are known to induce secondary hyporesponsiveness to alloantigen1,18. We
analyzed the importance of CTLA-4 signaling and regulatory T-cell function in
the induction of alloantigen hyporesponsiveness by our costimulation blockade
protocol. We first showed that whereas the addition of anti-CD40L and anti-
CD86 to a primary MLR resulted in the induction of hyporesponsiveness to
antigenic rechallenge, the co-administration of a dose of 5 mg/mL anti-CTLA-4
mAb to the primary MLR was already sufficient to compromise the develop-
ment of this hyporesponsive state (Fig 2A). The addition of isotype control anti-
bodies during the primary culture did not alter the secondary response (data
not shown). Second, induction of hyporesponsiveness to antigenic rechallenge
by anti-CD40L and anti-CD86 mAb was dependent on TREG18. Whereas
independence of ctla-4 and cd4+cd25+ treg function
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whole T-cell populations treated with anti-CD40L and anti-CD86 mAb dis-
played hyporesponsiveness to allogeneic restimulation, T-cells that were deplet-
ed for CD25+ cells at the start of primary culture (in the presence of anti-
CD40L and anti-CD86 mAb) responded vigorously to allogeneic restimulation
(Fig. 2B). Taken together, these data indicate that active signaling by CTLA-4
and regulatory T-cell function are both required to establish hyporesponsiveness
to alloantigens by anti-CD40L and anti-CD86 mAb.
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 Figure 1. In vitro efficacy of anti-CD40L and anti-CD86 costimulation blockade rests
on CTLA-4 engagement.
A. Primary MLR was set up with 1*105 responder BALB/c whole T-cells and 2.5*104 C57BL/6
γ-irradiated (27.5 Gy) splenocytes. Cells were cultured with anti-CD40L and anti-CD86 mAb
(1mg/ml each), with anti-CD40L, anti-CD86 mAb (1mg/ml each) and anti-CTLA-4 mAb
(5mg/ml) or with anti-CD40L+anti-CD86 mAb + anti-CD80 mAb (1mg/ml each). Matched iso-
type control antibodies were tested in equivalent quantities. Polyclonal hamster IgG was the
control antibody for anti-CD40L, anti-CD80 and anti-CTLA-4, and rat IgG2a was the control
antibody for anti-CD86. Proliferation in time (X-axis) as measured by 3H-thymidine incorpora-
tion is shown on the Y-axis . *P<0.05 for difference between groups.
B. 1*105 responder BALB/c T-cells were cultured with 2.5*104 C57BL/6 γ-irradiated (27.5 Gy)
splenocytes. Cells were cultured in the presence of anti-CD40L+anti-CD86 mAb with increas-
ing amounts of anti-CTLA-4 mAb.The amount of proliferation as measured by 3H-thymidine
incorporation is shown on the Y-axis. *P<0.05 for difference between groups.
CTLA-4 engagement is not required for the activation or the suppressor-
effector function of CD4+CD25+ T-cells
The observation that both CD4+CD25+ TREG and CTLA-4 signaling are essen-
tial for the induction of hyporesponsiveness to alloantigen was suggestive of a
role for CTLA-4 signaling in CD4+CD25+ TREG. CD4+CD25+ TREG constitu-
tively express CTLA-4, which we confirmed by showing that CD4+CD25+
TREG express CTLA-4 with increasing expression upon allogeneic stimulation
(data not shown). Thus, we investigated whether the stimulatory effect of the
anti-CTLA-4 antibody was due to an impaired TREG function. CD4+CD25+
TREG require activation via their TCR to become suppressive, but once activat-
ed, their suppressor effector function is completely nonspecific19. Therefore,
suppression can be viewed as a two-step phenomenon. We wished to distin-
guish whether CTLA-4 engagement might be implicated in either the stage of
induction of suppression or the suppressor-effector stage of TREG. Purified
CD4+CD25+ T-cells were pre-activated with allogeneic splenocytes during five
days in the presence or absence of anti-CTLA-4 mAb. Cells were harvested,
washed and subsequently added to a MLR consisting of CD25- responder T-
cells and fresh splenocytes of the original stimulator type. The presence of anti-
CTLA-4 mAb during the pre-culture did not compromise the suppression of
CD25- responder T-cell proliferation by the CD4+CD25+ T-cells, ruling out an
active role for CTLA-4 in the activation of CD4+CD25+ T-cells (Fig. 3A).
Subsequently, we analyzed a role for CTLA-4 in the suppressor-effector
function of CD4+CD25+ T-cells. Freshly purified CD4+CD25+ regulatory 
independence of ctla-4 and cd4+cd25+ treg function
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T-cells were added to a co-culture of purified CD25- T-cells and allogeneic
splenocytes in the absence or presence of anti-CTLA-4 mAb. The addition of
CTLA-4, even at very high dose, to the co-culture did not disrupt the dose-
dependent suppression displayed by the CD4+CD25+ regulatory T-cells (Fig.
3B). We excluded the possibility that the observed decrease in proliferation was
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 Figure 2. Efficacy of costimulation blockade depends on CD4+CD25+ T-cells.
A. Secondary responses were examined by antigenic restimulation of 5*104 responder
BALB/c whole T-cells by 2.5*104 C57BL/6 γ-irradiated (27.5 Gy) splenocytes. Cells were
obtained from primary MLR cultured with anti-CD40L+anti-CD86 mAb (1mg/ml each), 
with anti-CD40L+anti-CD86 (1mg/ml each) + anti-CTLA-4 mAb (5mg/ml), or with no mAb.
Proliferation as measured by 3H-Thymidine incorporation is shown on the Y-axis. A typical
example out of three independent experiments is shown. *P<0.01 for difference between
groups (a) and (b). #P<0.01 for difference between groups (b) and (c).
B. Secondary responses were examined by antigenic restimulation of 5*104 responder
BALB/c T-cells by 2.5*104 C57BL/6 γ-irradiated (27.5 Gy) splenocytes. Responder cells were
obtained from primary MLR in which the responder fraction consisted of either 1*105 BALB/c
responder whole T-cells or CD4+CD25+ T-cell depleted T-cells. In both cases primary MLR
was carried out under the cover of anti-CD40L+anti-CD86 mAb. Cells obtained from a regular
primary MLR with whole T-cells and without mAb were used as control. Proliferation in time
(X-axis) is shown on the Y-axis . A typical example out of three independent experiments is
shown. *P<0.05 for difference between groups (a) and (b). #P<0.01 for difference between
groups (b) and (c).
due to crowding, by showing that the addition of equal amounts of CD25-
effector T-cells did not result in inhibition.
We conclude that CTLA-4 engagement does not significantly contribute to
the activation nor the suppressor-effector function of CD4+CD25+ regulatory
T-cells.
Blockade of CTLA-4 signaling enhances CD25- effector proliferation in the
presence or absence of APC
Since CTLA-4 engagement did not appear to be directly involved in the sup-
pressor function of TREG, the question remained whether anti-CTLA-4 mAb
could interfere in the tolerance inducing effect of co-stimulation blockade by
acting on effector T-cells. We observed that especially the addition of high doses
of anti-CTLA-4 mAb augmented the proliferative response of purified CD25-
cells to allogeneic splenocytes (Fig. 4A). Similar results were obtained when
purified CD25- T-cells were stimulated with immobilized anti-CD3 mAb, a
strong TCR signal that led to the expression of CD80 and CD86 on the activat-
ed T-cells (data not shown). Also in this case, CTLA-4 blockade increased the
proliferative response of CD25- T-cells (Fig. 4B). In the absence of CD3 stimula-
tion the anti-CTLA-4 mAb had no effect (data not shown), indicating that T-
cell activation is a prerequisite for the anti-CTLA-4 mAb to be effective. Thus,
it appeared that anti-CTLA-4 mAb directly acts on activated T-cells.
independence of ctla-4 and cd4+cd25+ treg function
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CD4+CD25+ regulatory T-cells and CTLA-4 signaling cooperate in control-
ling CD8+ T-cell expansion during costimulation blockade
Summarizing the findings above, we have demonstrated a restraining effect of
CTLA-4 engagement on the proliferation of CD25- T-cells, while CD4+CD25+
TREG function was independent of CTLA-4 signaling. The counteracting
effects of anti-CTLA-4 mAb on costimulation blockade, as shown in Figure 1,
might thus well be explained by a lack of control of CD25- effector T-cell divi-
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 Figure 3. CTLA-4 signaling is not required for activation and suppressor-effector
function of CD4+CD25+ regulatory T-cells.
A. BALB/c CD4+CD25+ T-cells were pre-activated with 2.5*104 C57BL/6 γ-irradiated (27.5
Gy) splenocytes in the absence or presence of 5 mg/ml anti-CTLA-4 mAb. Cells were har-
vested at day 5 of MLR, extensively washed and co-cultured in increasing numbers with
CD25- T-cells and 2.5*104 C57BL/6 γ-irradiated (27.5 Gy) splenocytes to asses their regula-
tory capacity. Proliferation as measured by 3H-thymidine incorporation on day 6 is shown on
the Y-axis and expressed as mean cpm ± SEM.
B. 1*105 BALB/c CD25- T-cells were co-cultured with increasing numbers of freshly isolated
CD4+CD25+ T-cells and stimulated with 2.5*104 C57BL/6 γ-irradiated (27.5 Gy) splenocytes
in the presence of the indicated amounts of anti-CTLA-4 mAb . Proliferation as measured by
3H-thymidine incorporation on day 6 is shown on the Y-axis. A typical example out of three
independent experiments is shown.
sion, rather than a disturbed TREG function. Nevertheless, the question
remained whether CTLA-4 signaling and CD4+CD25+ TREG can have additive
effects during costimulation blockade. Therefore, we studied the separate as
well as combined effects of CTLA-4 and CD4+CD25+ TREG on CD4+ and
CD8+ responder T-cell division under the cover of anti-CD40L and anti-CD86
mAb. The responder T-cell populations that were analyzed either contained the
natural proportion of CD4+CD25+ TREG (the whole T-cell population), or were
depleted for this population. Anti-CTLA-4 mAb was added to the appropriate
cultures. CFSE analysis revealed that the degree of inhibition of CD4+ T-cell
proliferation already obtained by costimulation blockade as such remained
largely unaffected by the additional presence of CTLA-4 signaling or TREG, for
neither CTLA-4 blockade nor TREG depletion substantially increased CD4+ T-
cell division (Fig. 5). In contrast, inhibition of CD8+ T-cell division by costimu-
lation blockade was markedly compromised when either CTLA-4 engagement
was blocked or TREG were depleted. The CD8+ T-cell proliferation was even
further enhanced when blockade of CTLA-4 was combined with depletion of
CD4+CD25+ T-cells. These data demonstrate that CTLA-4 engagement and
CD4+CD25+ TREG have cooperative effects in facilitating the anti-CD40L and
anti-CD86 mAb mediated inhibition of CD8+ T-cell expansion.
Also in vivo, CTLA-4 signaling contributes to CD8+ T-cell containment
during costimulation blockade
Previously, we established that the CD40L and CD86 costimulation blockade
protocol facilitates CD4+CD25+ regulatory T-cell function in vivo 16. Here we
found that in vitro CTLA-4 signaling serves to further constrain CD8+ T-cell
independence of ctla-4 and cd4+cd25+ treg function
69
Coenen_prfsch_def  20-03-2007  20:58  Pagina 69
Anti-CD3 2.5 µg/ml
3 H
-in
co
rp
or
at
io
n 
(x
10
-3
)
0
10
20
30
1 2 3
0
20
40
60
80
1 25
Allogeneic APC
0 100 50
Anti-CTLA-4 (µg/ml) Anti-CTLA-4 (µg/ml)
A B
3 H
-in
co
rp
or
at
io
n 
(x
10
-3
)
* *
Figure 4. Blockade of CTLA-4 signaling enhances CD25- effector proliferation in the
presence or absence of APC.
A. 1*105 BALB/c CD25- T-cells were stimulated with 2.5*104 C57BL/6 γ-irradiated (27.5 Gy)
splenocytes in the presence of the indicated amounts of anti-CTLA-4 mAb. Proliferation as
measured by 3H-thymidine incorporation is shown on the Y-axis.
B. 5*104 BALB/c CD25- T-cells were stimulated with immobilized anti-CD3 mAb in the
absence or presence of anti-CTLA-4 mAb. Proliferation (Y-axis) is shown at day 4 of culture.
A typical example out of three independent experiments is shown. *P<0.05 for difference
between groups.
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expansion in the presence of regulatory T-cells during CD40L and CD86 cos-
timulation blockade, and appears not directly involved in the activation of reg-
ulatory T-cells. We questioned whether the same holds true in an in vivo model.
Therefore, BALB/c cardiac allografts were transplanted into C3H recipients
under the cover of anti-CD40L and anti-CD86 mAb, typically resulting in a
mean survival of >90 days. In correspondence to our in vitro observations, we
demonstrated that blockade of CTLA-4 signaling abrogated the ability of anti-
CD86 and anti-CD40L mAb to prevent allograft rejection. Co-administration
of anti-CTLA-4 mAb resulted in the rejection of 80% of the cardiac allografts
within 90 days after transplantation (Fig. 6A).
Correspondingly, rejected allografts of recipient mice treated with anti-
CD40L mAb, anti-CD86 mAb and anti-CTLA-4 mAb displayed enhanced
70
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Figure 5. During costimulation blockade CTLA-4 signaling and CD4+CD25+ regulatory
T-cell function have complementary effects on CD8+ effector expansion.
1*105 responder BALB/c T-cells of either whole T-cells (including Treg; indicated as
“CD4+CD25+ Present”) or CD25+ depleted T-cells (indicated as “CD4+CD25+depleted”) were
CFSE labeled and cultured with 2.5*104 C57BL/6 γ-irradiated (27.5 Gy) splenocytes with
anti-CD86+anti-CD40L mAb (1mg/ml each). Either condition of whole T-cells (including TREG)
or CD25+ depleted T-cells was examined in the presence of anti-CTLA-mAb (5 mg/ml;
indicated as “CTLA-4 engagement No”), or absence of anti-CTLA-4 mAb (indicated as
“CTLA-4 engagement Yes”). Histograms are shown of the dividing T-cells within the live 
gate in the CD4+ and CD8+ T-cell populations analyzed by flowcytometry at day 7 of culture.
A typical example out of three independent experiments is shown.
CD8+ cell infiltration as compared to rejected allografts of control recipient
mice (Fig. 6B). Cell counting indicated that CD8+ cell infiltration was signifi-
cantly higher in recipient mice treated with anti-CD40L mAb, anti-CD86 mAb
and anti-CTLA-4 mAb compared to untreated recipients, whereas Ly-6 G+
(neutrophil marker) and CD4+ cell infiltration were similar under both con-
ditions (Fig. 6C). Thus also in vivo, CTLA-4 signaling serves to constrain 
CD8+ T-cell expansion in the presence of CD40L and CD86 costimulation
blockade.
independence of ctla-4 and cd4+cd25+ treg function
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 Figure 6. In vivo anti-CTLA-4 mAb abrogates allograft acceptance by anti-CD40L
and anti-CD86 mAb
A. Graft survival of BALB/c cardiac allografts in C3H recipients. Recipients received either
anti-CD40L+anti-CD86 mAb, or anti-CD40L+anti-CD86 mAb with additional anti-CTLA-4
mAb, or no mAb (control). P<0.01 for differences between groups.
B. Immunofluorescence staining for CD8+ cell infiltration in rejected allografts of control recip-
ient mice and anti-CD40L mAb, anti-CD86 mAb and anti-CTLA-4 mAb treated mice (magnifi-
cation x 250). Grafts were harvested within one day after complete cessation of palpable
heartbeat. A typical example out of 4 independent experiments is shown.
C. The average number of infiltrating Ly-6G+, CD4+ and CD8+ cells per section area was
determined for rejected allografts of control recipient mice and anti-CD40L mAb, anti-CD86
mAb and anti-CTLA-4 mAb treated mice. A typical example out of 2 independent experiments
is shown. *P<0.01 for difference between groups.
Discussion
In the present study, we demonstrate that the efficacy of costimulation blockade
in the prevention of allograft rejection relies on mechanisms that are integral in
maintaining normal immune homeostasis20. The effects of costimulation
blockade were markedly impaired if CTLA-4 engagement was abrogated or if
CD4+CD25+ regulatory T-cells were depleted. These regulatory mechanisms
were found to act independently. CTLA-4 engagement was not required for
CD4+CD25+ regulatory T-cell action, while in the absence of CD4+CD25+ reg-
ulatory T-cells, blockade of CTLA-4 signaling resulted in enhanced effector cell
proliferation, predominantly by compromised inhibition of CD8+ T-cell expan-
sion. Moreover, these pathways acted in concert since intact CTLA-4 engage-
ment in the presence of CD4+CD25+ regulatory T-cells resulted in the highest
inhibition of CD8+ T-cell proliferation by costimulation blockade.
In our model, anti-CTLA-4 mAb compromised the inhibition of the in
vitro alloresponse by anti-CD40L and anti-CD86 mAb. Moreover, an intact
CTLA-4 pathway in the primary MLR was required to induce a hyporesponsive
phenotype. Notably, in vivo the prolongation of allograft survival by anti-
CD40L and anti-CD86 mAb was dependent on the integrity of the CTLA-4
pathway, in line with the importance of CTLA-4 signaling in attenuation of T-
cell responses21,22. Initially, we had three reasons to assume that these observa-
tions should be explained by interference of the anti-CTLA-4 mAb with the
activation or suppressive effect of regulatory T-cells. First, like others, we had
observed that the in vitro effects of costimulation blockade were dependent on
the presence of CD4+CD25+ T-cells18. Second, CD4+CD25+ T-cells were shown
independence of ctla-4 and cd4+cd25+ treg function
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to play an important role in experimental models of peripheral allograft toler-
ance12,23,24. Finally, CTLA-4 is constitutively expressed on regulatory
CD4+CD25+ T-cells, and several studies have postulated that engagement of
CTLA-4 on CD4+CD25+ T-cells indeed is essential for their regulatory func-
tion9,11. However, in cocultures with alloreactive CD25- cells, we were unable to
reverse the suppressive effect of purified CD4+CD25+ T-cells by CTLA-4 block-
ade. Because it has been suggested that lower concentrations of anti-CTLA-4
mAb may facilitate cross-linking of CTLA-4 instead of blocking engagement of
CTLA-4 with its ligands9, we also tested a high concentration of anti-CTLA-4
mAb (100 mg/ml). Even at this high dosage, anti-CTLA-4 mAb did not abro-
gate the suppression of CD4+CD25+ T-cells. These data indicated that
CD4+CD25+ T-cell function is not dependent on CTLA-4 engagement on
these cells.
Interestingly, high doses of anti-CTLA-4-mAb increased the proliferative
response of the CD25- effector cell population in both the presence and absence
of APC, indicating that the inhibition of T-cell proliferation by CTLA-4 signal-
ing was CD25- T-cell specific. Previous in vivo studies reporting a functional role
for CTLA-4 on regulatory T-cells may have been confounded by this effect of
CTLA-4 blockade on the CD25- T-cells11,12,25. Also in cocultures of CD25+ and
CD25- cells, the effects of anti-CTLA-4 are difficult to interpret since the anti-
body may theoretically affect the regulatory T-cells, the effector T-cells, or both
populations. This problem was circumvented in studies that used cocultures of
CTLA-4 deficient effector T-cells and CD4+CD25+ regulatory T-cells from
wild-type mice9,26. In these studies, addition of anti-CTLA-4 mAb abolished
the suppressive effect of regulatory T cells, which strongly indicates a functional
role for CTLA-4 on these cells. As an alternative approach to uncouple the
effects of anti-CTLA-4 on regulatory T-cells from those on effector T-cells, we
incubated regulatory T-cells with anti-CTLA-4 in a pre-activation culture,
before adding them to the coculture with CD25- cells in the absence of CTLA-
4. In agreement with findings of Thornton et al.13, we did not observe an effect
of anti-CTLA-4 in this situation. Several other recent studies support our con-
clusion that the main effect of anti-CTLA-4 is on the level of effector T-cells
rather than regulatory T cells6,14,21. In addition, CTLA-4 deficient CD4+CD25+
cells retain their suppressor function in vitro, which indicates that CTLA-4 is
not indispensable9,15,26. We cannot readily explain the diverging findings
obtained in the studies with CTLA-4 deficient effector cells. However, it is
known that these cells show strong signs of activation5, which may be accompa-
nied by upregulation of B7 molecules27. One can imagine that the interaction
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with CTLA-4 bearing regulatory T-cells and the effects of anti-CTLA-4 are dif-
ferent in this situation.
The stimulating effect of anti-CTLA-4 mAb on the proliferation of CD25-
T-cells was especially observed during blockade of CD40L and CD86. In this
situation, addition of anti-CTLA-4 mAb resulted in a marked increase in prolif-
eration, predominantly of CD8+ T-cells. In vivo, this was reflected by rejection
that was mediated by an enhanced infiltration of CD8+ cells in cardiac allografts
of recipients treated with anti-CD40L, anti-CD86 and anti-CTLA-4 mAb as
compared to untreated recipients. Current dogma holds that CD40-CD40L
interactions are required for the CD4+ T helper cell dependent stimulation of
naïve CD8+ T-cells28. Apparently, in the allogeneic response CTLA-4 engage-
ment is still essential to inhibit the proliferation of CD8+ T-cells despite the
absence of CD40L and CD86 signaling during costimulation blockade. How-
ever, it is of note that a CD4 help-independent pathway of alloreactive CD8+ T-
cell activation has been demonstrated29. This may allow CD8+ T-cell activation
in the absence of CD4+ T-cell help in the condition of anti-CD40L and anti-
CD86 costimulation blockade. Moreover, in contrast to CD4+ T-cells, CD8+ T-
cells were shown to be less dependent on CD28/CD40L interactions with
respect to cell cycle entry and initial expansion30. Since CTLA-4 is up-regulated
upon sufficient T-cell activation20, it appears that under the cover of costimula-
tion blockade with anti-CD40L and anti-CD86 mAb activated CD8+ T-cells
are more responsive to CTLA-4 blockade than the inhibited CD4+ T-cells.
The most obvious ligand for CTLA-4 during CD40L and CD86 blockade
would be CD80. Indeed, biophysical studies indicate that CD80 is predomi-
nantly inhibitory by preferential engagement of CTLA-4. Conversely, CD86
was found to be more costimulatory due to more effective interactions with
CD2831. However, CD80 does not exclusively interact with CTLA-4, it can also
bind to CD28. Since the peripheral homeostasis of regulatory T cells is con-
trolled by CD28 engagement32, the interaction between C80 and CD28 may be
essential for the survival and self-renewal homeostasis of regulatory T cells dur-
ing treatment with anti-CD86. An interaction between CD80 and CD28 on
effector T-cells is supported by our finding that addition of anti-CD80 to the
combination of anti-CD40L and anti-CD86 during a primary MLR further
decreased the proliferative response. Of note, it was recently demonstrated that
in particular in the presence of CD28 signaling the CTLA-4 pathway provides a
negative signal to alloreactive CD8+ cells33. Possibly, CTLA-4 signaling can
serve as a negative regulator in our protocol by virtue of the intact CD80:CD28
signaling. Yet, our data and results from other studies indicate that costimula-
independence of ctla-4 and cd4+cd25+ treg function
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tion blockade protocols that allow the negatively signaling CD80-CTLA-4
interaction are preferable for tolerance induction 34,35.
Previously, we established that costimulation blockade contributes to allo-
graft tolerance by inducing functional dominance of CD4+CD25+ regulatory T-
cells16. In line with others we here underscore the role of CTLA-4 signaling on
effector cells during costimulation blockade and not on regulatory T-cells13-15.
We extend these findings by the observation that the counteracting effect of
CTLA-4 blockade appears specifically due to an increase in CD8+ T-cell prolif-
eration, despite the presence of costimulation blockade by anti-CD40L and
anti-CD86 mAb. When CTLA-4 engagement is blocked in this protocol, CD8+
T-cell expansion overcomes CD4+CD25+ T-cell mediated suppression. We pro-
pose that CTLA-4 signaling and CD4+CD25+ regulatory T-cell function consti-
tute fully complementary immunoregulatory mechanisms and have additive
effects in the containment of the alloreactive effector pool. Correspondingly, in
a tumor vaccination model maximal tumor eradication by CD8+ effector T-cells
was achieved by combining CTLA-4 blockade and CD4+CD25+ T-cell deple-
tion36. Also, CD4+CD25+ TREG and CTLA-4 signaling were found to act coop-
eratively to maintain tolerance to self-antigen in a transgenic mouse model of
diabetes37.
Thus, CTLA-4 engagement limits the expansion of deleterious alloreactive
T-cells, which facilitates the ability of CD4+CD25+ T-cells to maintain the bal-
ance between regulatory versus effector cells. We thus propose that strategies
targeting costimulatory molecules without interfering in CTLA-4 signaling
might prove of added value in the induction of transplantation tolerance.
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Abstract
Current therapies in transplantation require continuous immunosuppression
and do not result in transplantation tolerance. It is increasingly appreciated that
CD4+CD25+ regulatory T-cell (TREG) activation is pivotal for the induction
and maintenance of peripheral tolerance. To optimally exploit TREG in allograft
tolerance, we investigated how to further harness their function.
In vitro, CD4+CD25+ T-cells were expanded by allogeneic bone-marrow
derived DC or polyclonal stimulation and were compared in suppressive capac-
ity and phenotype. In vivo, naive allogeneic CD4+CD25+ T-cells were analyzed
in wild type hosts for proliferative capacity and suppressive capacity upon prim-
ing by alloantigen. DC of donor origin were found to potently stimulate allore-
active TREG in vitro. This was accompanied by a substantial enhancement of the
suppressive capacity of the TREG population as a whole, likely due to a propor-
tional rise of alloreactive TREG as indicated by CFSE analysis. In vivo analysis of
infused naturally occurring allogeneic TREG revealed a robust proliferative
capacity for TREG upon stimulation. Moreover, allogeneic skin transplantation
resulted in enhanced capacity of the TREG population to suppress the response
towards donorantigens.
Combining, activation of alloreactive TREG is an intrinsic part of the regular
alloimmune response and this feature can be exploited for therapeutic purposes.
We propose that selectively favoring the effects of alloreactive TREG is a pivotal
element in inducing graft acceptance.
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Introduction
Approaches to inhibit organ transplant rejection have predominantly relied on
potent immunosuppression that blocks the development and function of
alloreactive effector T-cells (TEFF). Unfortunately, these current therapies
require continuous application and do not result in transplantation tolerance.
Moreover, lifelong administration of the different immunosuppressive drugs
has resulted in a range of unwanted side effects which can negatively affect the
outcome for the graft and the patient1.
Naturally occurring CD4+CD25+ regulatory T-cells (TREG) represent 5-10%
of CD4+ T-cells in the blood of mice and humans. TREG play a pivotal role in
the maintenance of self-tolerance and in the protection of autoimmune dis-
eases2. Also in transplantation, it is increasingly appreciated that the differ-
ence between rejection and tolerance is determined by the balance between
alloreactive TEFF and TREG3-6. Expansion of the TREG pool is therefore an
appealing approach in transplantation medicine to inhibit graft rejection7-9.
Whether it is crucial to selectively expand the proportion of TREG that are
donor specific is not quite clear. TREG isolated from naïve alloantigen-inexperi-
enced mice can inhibit rejection of MHC-mismatched allografts at high sup-
pressor to effector ratios, reflecting the inherent cross-reactivity of TREG to
alloantigen. Furthermore, TREG that are present after allo-antigen exposure in
the presence of a tolerizing regimen, have been shown to express donor-speci-
ficity. Also, recent reports showed that antigen specific TREG that are selectively
expanded from polyclonal populations are characterized by a superior suppres-
sive capacity10-12. These observations indicate that tolerance inducing strategies
in transplantation may particularly be successful when the proportion of TREG
with allospecificity can be expanded in vivo, allowing the TREG to dominate
over alloreactive TEFF13. However, the expansion of allospecific TREG is not so
obvious, in view of the predominant reactivity of naturally occurring TREG to
self antigen14-16.
To optimally exploit TREG in allograft tolerance we analyzed the expansion
of naturally occurring CD4+CD25+ T-cells with either immobilized anti-CD3
mAb (polyclonal stimulation) or allogeneic dendritic cells (allospecific stimula-
tion). We investigated how the suppressive capacity and phenotype of TREG
populations are modified by either type of stimulation. Finally, we studied to
what extent these cells participate as a regular component of unmodified allore-
sponse in vivo.
alloreactive treg in vivo
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Materials and methods
Cell purification
Mice were purchased from Charles River Lab (Charles River, Sulzfeld, Ger-
many). Mice were sacrificed and pooled peripheral lymph node and spleen cells
were depleted of erythrocytes by osmotic shock using a lysis buffer containing
0.15mM NH4Cl (Merck, Darmstadt, Germany), 10.0 mM KHCO3 (Merck)
and 0.1 mM Na2EDTA (Sigma-Aldrich, Steinheim, Germany). The cell sus-
pension was enriched for CD4+ T-cells by depletion of MHC class II positive
cells by incubation with aMHC class II mAb coated magnetic microbeads and
aCD8 mAb coated magnetic microbeads (Miltenyi, Bergisch Gladbach, Ger-
many), followed by passage through a LD microbead column (Miltenyi).
Purification of CD4+CD25+ T-cells was carried out by fluorescence activated
cell sorting (FACS; Coulter Epics Elite, Beckman Coulter, Miami, USA). To
this end, the T-cell enriched population was incubated with saturating amounts
of biotin-labeled aCD25 antibody (7D4; BD Biosciences, San Diego, USA) and
subsequently incubated with streptavidin-PE (BD Biosciences, San Diego,
USA). After the FACS procedure, the PE-positive fraction was >98%
CD4+CD25+. CD25+ T-cell depleted populations typically contained <1%
CD4+CD25+ T-cells.
Dendritic cell culture
Dendritic cells (DC) were cultured from bone marrow (BM) derived cells using
a protocol adapted from Lutz et al 17. Briefly, BM was flushed from femoral and
tibial bones of C57Bl/6 mice and subsequently cultured in six-well plates
(Nunc, Glostrup, Denmark) at a density of 1.0x106 cells/well in RPMI1640
(Invitrogen, Leek, The Netherlands), supplemented with 20 ng/mL of 
rGM-CSF (Pepro-Tech, London, United Kingdom) and 10% fetal calf serum
(Greiner, Frickenhofen, BRD). At day 7 of culture, dendritic cells were matured
by adding 50 ng/mL lipopolysaccharide (Sigma-Aldrich, Zwijndrecht, The
Netherlands) 16 hours before harvesting. Their maturation status was con-
firmed by FCM. Dendritic cells were characterized by flowcytometry (FAC-
Scan, BD Biosciences, San Jose, USA) using monoclonal antibodies specific for
CD11c (N418, IQP, Groningen, The Netherlands),MHCclass II (17/227,
ATCC, Manassas, USA), CD40 (3/23, BD), CD86 (HB253, ATCC), and iso-
typematched controls. Cell viability was assessed by annexin-V (Alexis, San
Diego, USA) and propidium iodide (Sigma-Aldrich) double staining.
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Expansion cultures
For plate-immobilized CD3 stimulation, anti-CD3e mAb (145-2C11; hamster
IgG; BD Pharmingen, San Diego, USA) 5 mg/ml was precoated on flat bottom
96-well plates by overnight incubation at 4ºC. Before use, the plates were
washed with sterile PBS. 1*106 BALB/c (H-2d) CD4+CD25+ T-cells were poly-
clonally activated by immobilized anti-CD3 mAb in the presence of 100 U/ml
rmIL-2 (BD Biosciences, San Diego, USA) in 24 well plates (Costar, Corning,
USA). Cells were harvested at day 3 of culture and further cultured in the 
presence of 100 U/ml rmIL-2 with a cell density of around 1.0*106 cells/ml
throughout culture. For DC stimulated expansion, 5*104 BALB/c CD4+CD25+
T-cells were pre-cultured with 5*104 C57BL/6 (H-2b) γ-irradiated (27.5 Gy) 
BM derived DC in the presence of 1000 U/ml rmIL-2. Cells were harvested at
day 6 of culture and allowed to proliferate 1 day in the presence of 1000 U/ml
rmIL-2.
Suppression assay
To test for suppressive capacity increasing numbers of freshly isolated or
expanded CD4+CD25+ T-cells were added to a primary MLR. BALB/c (H-2d)
CD4+CD25- responder cells were purified as described above. C57Bl/6 (H-2b),
C3H (H-2k), or BALB/c stimulator cells were obtained by culturing splenocytes
in 9 cm petridishes (Allegiance, Zutphen, The Netherlands) for two hours fol-
lowed by further overnight culture of the adherent cell fraction. After 18 to 24
hours, the non-adherent cells were obtained by harvesting the supernatant and
gently washing the petridish. Responder T-cells were cultured with γ-irradiated
(27.5 Gray) enriched splenocytes at a ratio of 1*105 responders to 2.5*104 stimu-
lator cells in flat bottom 96-well plates (Costar, Corning, USA) containing
RPMI 1640 (Gibco, Paisley, UK) with 10% FCS (Invitrogen, Leek, The Nether-
lands), 50 mM 2-ME (Biorad, Hercules, USA), 1 mM sodium pyruvate, gluta-
max and antibiotics (100 U/mL penicillin; 100 mg/mL streptomycin)(all from
Gibco) at 37º, 95% humidity and 5% CO2. CD4+CD25+ T-cells were added
from the start of culture. Cell proliferation was monitored by tritiated thymi-
dine incorporation. To this end the cells were pulsed with tritiated thymidine
(0.5 mCi) during the last 16-18 h of the culture. Tritiated thymidine incorpora-
tion was analyzed by a gas scintillation counter and is expressed as mean count
per 5 minutes and SD of at least triplicate measurements.
alloreactive treg in vivo
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Flow cytometry
T-cells were phenotypically analysed by three colour fluorescence. Cells were
washed twice with phosphate-buffered saline supplemented with 0.2% bovine
serum albumin (BSA) (Sigma). The following antibodies were used: PE-conju-
gated anti-CD4 (L3T4); anti-CD25 (7D4); anti CD62L (MEL-14) (all from BD
Biosciences, Erembodegem, Belgium). FoxP3 was determined by intracellular
analysis after fixation and permeabilization using a PE-conjugated anti-mouse
FoxP3 (FJK-16s) staining set (eBioscience, SanDiego, USA). All incubations
were conducted for 20 minutes at room temperature and thereafter the cells
were washed twice. The samples were run on a Coulter Epics XL, Beckman
Coulter and at least 20.000 live gate events were collected based on live lympho-
cyte gating, as indicated by 5 mg/mL propidium iodide staining. Data were ana-
lyzed using Coulter Epics Expo 32.
CFSE-analysis of cell division
For in vitro MLR cell division analysis, freshly isolated BALB/c CD4+CD25+
T-cells were labeled with 0.1 mM CFSE at 1*106 cells for 10 min. Carboxyfluo-
rescein Diacetate Succinimidyl Ester (CFDA-SE, Molecular Probe, Eugene,
OR). The cell division of alloreactive T-cells in vivo was studied by labelling
BALB/c responder CD4+CD25+ T cells or CD4+CD25- T cells with CFSE.
BALB/c CD4+ T-cells were infused in the tail vein of (BALB/cxC57Bl/6)F1
(CB6) recipients. Syngeneic CB6 CD4+ T cells were used as control.
CD4+CD25+ T cells were labeled with 0.1 mM CFSE at 1*106 cells for 10 min.
CD4+CD25- T cells were labeled with 4 mM CFSE at 2*107 cells for 10 min. An
equal volume of FCS was added, and cells were washed with medium. A total of
5*106 CD4+CD25+ T cells or 10*106 CD4+CD25- T cells was injected i.v. into
CB6 mice in a total volume of 0.25 ml sterile PBS. Recipients were sacrificed at
48 or 72 hours and the spleen was harvested. CFSE-intensity was measured by
flowcytometry. Live gate events, if possible 1*106, were analyzed using Coulter
Epics Expo 32.
Mouse skin transplantation
Experiments were performed with completely MHC-mismatched combina-
tions of BALB/c recipients (H-2d) and C57Bl/6 (H-2b) donors. Mice were used
at 8 to 12 weeks of age and housed in a specified pathogen free facility. Tail skin
grafts were sutured onto the flanks of BALB/c recipients and recipients were
sacrificed 40 days after skin transplantation.
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Figure 1. Stimulation with alloantigen drives cell division in a part of the CD4+CD25+ T-
cell population.
Freshly isolated BALB/c CD4+CD25+ T-cells were CFSE labeled and stimulated by C57BL/6
BM derived DC in the presence of high-dose IL-2. For polyclonal expansion, cells were 
stimulated by immobilized anti-CD3 mAb in the presence of high-dose IL-2. Histograms show
number of events (Y-axis) and CFSE intensity (X-axis) for cells gated on live lymphocytes
(day 7 of culture).The square indicates the population of undivided cells.
Statistics
Statistical analysis was performed using Graphpad Prism 3.0 and Microsoft
Excel 2000. For comparisons between groups, we used (non-parametric)
ANOVA or Student’s t test where appropriate, assuming unequal variances
because of small sample sizes.
Results
TREG expanded in the presence of allogeneic DC manifest potent 
suppression of alloreactivity
Stimulation of freshly isolated CD4+CD25+ BALB/c T-cells with allogeneic
(C57Bl/6) bone-marrow derived mature DC (allo-DC) was compared with
polyclonal stimulation. After sorting CD4+CD25high T-cells from spleen and
lymph nodes, these cells were cultured with either allo-DC or immobilized
anti-CD3 mAb, in both cases supplemented with high doses of exogenous IL-2.
During a 8 day culture, cells expanded two-fold when stimulated by allo-DC,
while the cell number had increased around 5-6 times in the case of polyclonal
alloreactive treg in vivo
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Figure 2. Allogeneic DC driven proliferation induces potent TREG with increased
antigen-specificity
Freshly isolated BALB/c CD4+CD25+ T-cells, polyclonally (anti-CD3) expanded CD4+CD25+
T-cells and C57Bl/6 DC expanded CD4+CD25+ T-cells were co-cultured in increasing num-
bers with 1*105 freshly isolated BALB/c CD25- responder T-cells and 2.5*104 C57Bl/6 (“cog-
nate antigen”) or 2.5*104 C3H (“3rd party antigen”) stimulator splenocytes to asses suppres-
sive capacity. Proliferation as measured by 3H-thymidine incorporation on day 6 is shown on
the Y-axis and expressed as percentage inhibition of the response of a control MLR to which
no CD4+CD25+ T-cells were added. A typical example out of four independent experiments is
shown. (*=p<0.05)
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stimulation. In additional cultures, the starting population of responder
CD4+CD25high T-cells was labeled with CFSE. Flowcytometry after 7 days of
culture revealed a substantial proportion of undivided (CFSEhigh) cells after
stimulation by allo-DC as compared to polyclonal stimulation (Fig. 1), in which
case, according to expectation, almost all cells had divided. This finding indi-
cates that allo-DC stimulation favours oligoclonal expansion. The regulatory
potential and antigen-specificity of both expanded TREG populations were 
then evaluated in suppression assays. CD25- effector T cells and expanded
CD4+CD25+ T cells (both of BALB/c origin) were co-cultured at different
ratios with a fixed number of C57BL/6 stimulator splenocytes. Polyclonal
expansion resulted in CD4+CD25+ T-cells that displayed slightly enhanced sup-
pressive capacity relative to the suppression mediated by freshly isolated
CD4+CD25+ T-cells (Fig. 2). However, when stimulated by their C57Bl/6 cog-
nate antigen, allo-DC expanded CD4+CD25+ T-cells were clearly more suppres-
sive than either anti-CD3 expanded CD4+CD25+ T-cells or freshly isolated
CD4+CD25+ T-cells. When stimulated by 3rd party C3H splenocytes, the level
of inhibition of CD25- effector T cells by allo-DC expanded CD4+CD25+ T-
cells was similar to the suppression mediated by anti-CD3 mAb expanded
CD4+CD25+ T-cells.
Concluding, allo-DC expanded CD4+CD25+ T-cells display potent sup-
pressive capacity, particularly when directed towards the alloantigens to which
these cells have previously been exposed.
Phenotype of allospecific and polyclonally expanded TREG
We then analyzed whether the difference in functional properties between the
allo-DC and anti-CD3 mAb expanded CD4+CD25+ T-cells was correlated with
a different expression of several phenotypic markers associated with Treg func-
tion. Next to the membrane expression of CD25 we measured the intracellular
expression of the transcription factor FoxP3, which crucially determines the
suppressive capacity of TREG. Furthermore, the expression of CD62L and
CD27 were measured since these markers allow the identification of a subset of
very potent TREG18-20. There was no clear difference in the expression of any of
these markers by anti-CD3 expanded versus allo-DC expanded CD4+CD25+
T-cells (Fig. 3).
TREG participate in the allo-immune response
The presentation of alloantigen in vivo induces the expansion of reactive effec-
tor T cells. We here analyzed whether alloantigens also have the potential to
alloreactive treg in vivo
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Figure 3. Phenotype of expanded CD4+CD25+ T-cells
BALB/c CD4+CD25+ T-cells were activated by immobilized anti-CD3 or by C57BL/6 DC in the
presence of high-dose IL-2. Flow cytometry histograms gated on live lymphocytes (day 7 of
culture) are shown for CD25, CD62L, CD27, and Foxp3 expression. A typical example out of
three independent experiments is shown.
Figure 4.TREG proliferate upon exposure to alloantigen in vivo.
CFSE labeled BALB/c CD4+CD25+ T cells, CD4+CD25- T cells or syngeneic CB6 cells 
were adoptively transferred into CB6 recipients. Flow cytometry dot-plots gated on live 
lymphocytes harvested from the recipient spleen at 48 hours after adoptive transfer are
shown.The numbers in the plot designate the percentage of cells that have divided.
(FS; Forward Scatter)
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activate and expand naturally occurring TREG in vivo. Freshly isolated naturally
occurring BALB/c CD4+CD25+ T-cells were CFSE labeled and infused into a
CB6 (C57Bl/6xBALB/c F1 hybrid) non-lymphopenic recipient. In parallel, the
BALB/c CD4+CD25- T-cell fraction was infused into a CB6 recipient as a posi-
tive control for alloreactive TEFF proliferation. After 48 hours at least three
rounds of cell division had occurred in both the TREG and the TEFF population
(Fig. 4). The divided cells made up 7.6% and 25.8% respectively of the different
populations of infused cells. No clear proliferation was detected when syngene-
ic CB6 CD4+ T-cells were transferred into CB6 mice, which demonstrates
minor background proliferation in this system (divided cells 1.4%). In conclu-
sion, naturally occurring TREG display cross-reactivity for alloantigen in vivo
and can thus be considered as typical participants of an allo-immune response.
Allogeneic priming in vivo results in enhanced TREG suppressive capacity
Based on the increased donor-specific suppressive capacity of allo-DC expand-
ed TREG in vitro and the observed proliferation of TREG upon allo-antigen
exposure in vivo, we reasoned that presentation of allo-antigens in vivo may
enhance the donor-reactive suppressive capacity of the TREG pool. To assess the
effects of allogeneic priming on CD4+CD25+ TREG in vivo, we measured the
suppressive capacity of the CD4+CD25+ T-cell population 40 days after trans-
plantation of allogeneic tail skin. Earlier, priming with donor DC was shown to
increase the number of alloreactive T-cells and skin grafts contain many DC
that promote a strong alloreactive immune response6;21. Others had demon-
strated that fully differentiated responses can be distinguished from ongoing
effector responses after skin transplantation by allowing a resting period of 40
days22.
When BALB/c recipients were grafted with C57Bl/6 tail-skin without any
immune suppression, the grafts were rejected in 10 ± 2 days (data not shown).
Forty days after skin grafting the CD4+CD25+ fraction was isolated from the
spleen of recipient mice and as a control cell population the CD4+CD25+
splenocytes of naive BALB/c mice were used. The CD4+CD25+ fractions isolat-
ed from grafted and naive mice did not show any difference with respect to phe-
notype or population size (data not shown). When stimulated by C57Bl/6 allo-
antigens in ex-vivo suppression assays, the CD4+CD25+ T-cell fraction of graft-
ed recipients displayed a higher suppressive capacity than the CD4+CD25+ T-
cell fraction of naïve mice (Fig. 5). Thus, even though the immune response to
alloantigens had resulted in rejection of the graft, the recipient TREG acquired
an enhanced capacity to regulate the donor-specific response of effector T cells.
alloreactive treg in vivo
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Figure 5. Priming with a skin graft results in enhanced capacity of TREG to suppress
the response against donor allo-antigens.
Non-parametric ANOVA indicated that primed CD4+CD25+ T-cells and freshly isolated
CD4+CD25+ T-cells display a significant difference in suppressive capacity (*=p<0.05).
BALB/c mice received tail-skin allografts from C57Bl/6 donors. At day 40 after transplanta-
tion, CD4+CD25+ T-cells were isolated by FACS sorting from spleens. For comparison,
CD4+CD25+ T-cells were isolated from the spleens of naïve mice. CD4+CD25- BALB/c T-cells
were co-cultured with C57Bl/6 stimulator splenocytes and increasing numbers of
CD4+CD25+ T-cells from grafted or naïve mice.The bars show the proliferation as measured
by 3H-thymidine incorporation (Y-axis) on day 5 of culture at a suppressor:effector ratio of
1:16 for four separate experiments.
Discussion
In order to harness TREG for the induction of transplantation tolerance, it is
important to obtain knowledge on how alloantigen-specific TREG can originate
from a diverse repertoire of polyclonal TREG. We found that DC of donor ori-
gin can potently stimulate the expansion of alloreactive regulatory CD4+CD25+
T-cells in vitro, which results in a substantial enhancement of the allospecific
suppressive capacity of the TREG population as a whole. In vivo, allo-reactive
naturally occurring TREG revealed a clear proliferative capacity. Moreover, allo-
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geneic skin grafting resulted in an enhanced capacity of CD4+CD25+ TREG to
suppress the ex-vivo response towards donor antigens. These findings indicate
that alloreactive TREG are regular participants of an allo-immune response.
It is estimated that about 10% of the effector T-cells are able to respond to
allo-antigens23. It can be imagined that if a similar cross-reactivity would hold
true for TREG, the capacity of a polyclonal TREG population to suppress the
response to a specific alloantigen may benefit from a rise in the proportion of
TREG that are cross-reactive to that particular allo-antigen. However, due to
selection processes in the thymus, a prominent feature of naturally occurring
TREG is their predominant self-reactivity15. Nevertheless, we found that TREG
can readily proliferate in response to allogeneic DC and exogenous IL-2. CFSE
analysis revealed that after stimulation with allo-antigen a part of the TREG pop-
ulation divided, which resulted in a TREG population with increased antigen-
specificity of its suppressive capacity. Furthermore, when TREG were infused
into an allogeneic non-lymphopenic host, their division rate paralleled that of
alloreactive effector T cells. Both populations had divided at least three times.
In correspondence with their predominant self-reactivity, the population of
dividing TREG was smaller than the population of dividing TEFF. Considering
the high purity obtained in the isolation of CD4+CD25+ T-cells it is not likely
that the observed division patterns reflect the division of CD4+CD25- TEFF.
The phenotype of allo-DC expanded TREG did not differ from that of poly-
clonally expanded TREG. We analyzed the expression of CD62L and CD27,
because these markers have been used to distinguish TREG subsets with different
potency18-20;24;25. Both types of expanded TREG expressed CD27 and CD62L in
a similar manner. Analysis of intracellular FoxP3 expression revealed that both
allo-DC and anti-CD3 based expansion sustained the expression of FoxP3 to a
similar extent. Considering the absence of any phenotypic difference between
both populations of cells and the observation that allo-DC induced prolifera-
tion of only a part of the TREG population, it is likely that the increased capacity
of allo-DC expanded TREG to suppress the response to the particular allo-
antigens rests on a skewing of the TCR repertoire of this population in favor of
allospecific TREG. In line with the higher suppressive potency of our allo-DC
stimulated TREG, various studies showed that small numbers of antigen-specific
TREG were able to block and reverse auto-immune diabetes mellitus, whereas a
higher number of polyclonal cells was inactive26;27. Additionally, in a mouse
model of graft-versus-host disease, allospecific TREG had a more pronounced
effect on the division, expansion and differentiation of donor TEFF, than poly-
clonally expanded TREG12. Whether our results and those of others can be fully
alloreactive treg in vivo
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explained by skewing of the TCR repertoire of the Treg population towards 
specific antigens, or if an enhancement of the suppressive capacity on a per cell
basis might play a role, requires further elucidation
In view of the demonstrated ability of alloreactive CD4+CD25+ T-cells to
proliferate in vivo, we analyzed whether the exposure to donor alloantigens in
the form of a skin graft results in enhancement of alloreactive CD4+CD25+
TREG function. Interestingly, we demonstrated that enhanced TREG function
can be found within the CD4+CD25+ T-cell population of BALB/c recipients
40 days after challenge with a skin graft that was rejected in the absence of
immunosuppressive therapy. Earlier, allo-specific CD4+CD25+ TREG have been
found both at the graft site and in lymphoid tissue after treatment with a toler-
ance-inducing regimen5;28;29. In correspondence with recent findings, the
encounter of alloantigen resulted in a potentiation of the suppressive capacity of
CD4+CD25+ TREG towards donor antigen despite the rejection of the allograft
itself. This observation supports the notion that TREG cross-reactive for
alloantigens are a regular component of an alloresponse30.
In summary, our data show that TREG display cross-reactivity to alloanti-
gens. Exposure of TREG to allo-antigens results in a potent suppressive capacity
with a rise in the proportion of TREG specific to the presented alloantigens. We
propose that selectively favoring the expansion of alloreactive TREG over non-
specific TREG is a key element in tolerance inducing strategies.
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Abstract
The immunosuppressive drugs rapamycin and cyclosporin A (CsA), are widely
used to prevent allograft rejection. Moreover, they were shown to be instrumen-
tal in experimental models of tolerance induction. However, it remains to be
elucidated whether these drugs have an effect on the CD4+CD25+ regulatory T-
cell (TREG) population, which plays an important role in allograft tolerance.
Recently, we reported that alloantigen driven expansion of human CD4+CD25+
TREG gives rise to a distinct highly suppressive CD27+TREG subset next to a 
moderately suppressive CD27-TREG subset. In the current study we found that
rapamycin and CsA do not interfere with the suppressive activity of human nat-
urally occurring CD4+CD25+ T cells. However, in contrast to CsA, rapamycin
preserved the dominance of the potent CD27+TREG subset over the CD27-TREG
subset after alloantigen driven expansion of CD4+CD25+ TREG in vitro.
Accordingly, CD4+CD25+ TREG cultured in the presence of rapamycin dis-
played much stronger suppressive capacity than CD4+CD25+ TREG cultured in
the presence of CsA. In addition, CD4+CD25+ TREG cultured in the presence of
rapamycin, but not CsA, were able to suppress ongoing alloimmune responses.
This differential effect of rapamycin and CsA on the CD27+TREG subset domi-
nance, may favor the use of rapamycin in tolerance-inducing strategies.
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Introduction
The development of an alloimmune response into rejection or stable allograft
tolerance is strongly determined by the balance between alloreactive effector
cells and CD4+CD25+ regulatory T cells (TREG)1,2. Currently used immuno-
suppressive drugs are efficient in preventing allograft rejection by reducing
effector T cell expansion. However, it remains to be elucidated whether these
drugs antagonize the induction of tolerance by affecting the naturally occurring
TREG population.
CD4+CD25+ TREG exert their immunosuppressive effect after activation by
T cell receptor (TCR) triggering3. Moreover, it has recently been demonstrated
that signaling through the interleukin-2 (IL-2) receptor is crucial for the func-
tional activity of TREG4,5. Cyclosporine (CsA) inhibits TCR-mediated activa-
tion and IL-2 production, whereas rapamycin blocks intracellular signaling in
response to T cell growth factors like IL-26,7. It can therefore be expected that
CsA and rapamycin have different effects on the function of CD4+CD25+
TREG. Indeed, calcineurin inhibition by CsA may impair the development and
function of TREG, whereas rapamycin was found to favor CD4+CD25+ T cell
dependent immunoregulation in vitro and in vivo8-12.
Recently, we reported that allogeneic expansion of human naturally occur-
ring CD4+CD25+ TREG leads to the emergence of a distinct highly suppressive
CD27+TREG subset next to a CD27-TREG subset13. These CD27+TREG and CD27-
TREG subsets displayed a 50% inhibition of in vitro responses at ratios of 1:500
and 1:50 respectively, and were further distinguished by distinct growth charac-
teristics and phenotype. The CD27+TREG subset was shown to suppress not only
naïve and antigen experienced memory T cells, but also ongoing T cell respons-
es. In line with our findings, CD4+CD25+CD27+ TREG were identified as a
potent regulatory subset in cord blood and in a large scale in vitro expansion sys-
tem14,15. In addition, the combined expression of CD25 and CD27 allowed the
differentiation of highly suppressive FoxP3+ regulatory T cells from activated
effector T cells in synovial fluid of juvenile idiopathic arthritis patients16. It can
be envisaged that the strong regulatory capacity of CD27+TREG may be of value
in promoting stable allograft tolerance.
Here we describe that both CsA and rapamycin permit the activation of 
the naturally occurring regulatory CD4+CD25+ TREG. However, rapamycin
fosters the dominance of CD27+TREG over CD27-TREG after expansion of the
CD4+CD25+ TREG pool upon allogeneic activation, whereas expansion in the
presence of CsA tips the balance in favor of CD27- TREG. The high CD27+TREG to
CD27-TREG subset ratio, as preserved by rapamycin, benefits the suppressive
rapamycin preserves cd4+cd25+cd27+ treg
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capacity of the CD4+CD25+ TREG pool as a whole. Moreover, while TREG cul-
tured in the presence of either CsA or rapamycin are able to suppress naïve T
cell responses, only TREG cultured in the presence of rapamycin can suppress
ongoing T cell responses. We thus propose that rapamycin promotes the induc-
tion of allograft tolerance by preserving a beneficial CD27+TREG to CD27-TREG
subset ratio.
Materials and methods
Isolation of cells
Peripheral blood mononuclear cells (PBMC) were isolated by density gradient
centrifugation (Lymphoprep, Nycomed Pharma AS, Oslo, Norway) of buffy-
coats obtained from normal healthy donors. CD4+ T cells were purified from
PBMC by negative selection using monoclonal antibodies (mAb) directed
against CD8 (RPA-T8), CD14 (M5E2), CD16 (3G8), CD19 (4G7), CD33
(P67.6), CD56 (B159) and CD235 (BD Biosciences, Erembodegem, Belgium)
combined with sheep anti-mouse IgG coated magnetic beads (Dynal Biotech,
Oslo, Norway). This resulted in a CD4+ T cell purity of >95 % and the absence
of CD8+ T cells. From purified CD4+ T cells, naturally occurring CD4+CD25+
T cells were isolated using the MACS CD25+ magnetic microbead method
(Miltenyi Biotec GmbH, Bergisch Gladbach, Germany), using half the amount
of beads recommended by the manufacturer. CD4+CD25+ T cells were immedi-
ately used after isolation, while all other cell types were used either fresh or upon
thawing of liquid nitrogen stored cell stocks. HLA typing was conducted
according to ASHI (American Society for Histocompatibility and Immuno-
genetics) standards and largely as described previously17.
Primary Mixed Lymphocyte Reaction
Primary Mixed Lymphocyte Reaction (MLR) cultures were performed by cul-
turing 5x104 isolated CD4+CD25+ T cells or control CD4+CD25- T cells with
0.5x105 fully HLA mismatched γ-irradiated (30 Gy) stimulator PBMC in 200
ml culture medium (RPMI-1640 with glutamax supplemented with (0.02mM)
pyruvate, 100 U/ml penicillin, 100 mg/ml streptomycin (all Gibco, Paisley,
UK), and 10% human pooled serum (HPS)) at 370C, 95% humidity and 5%
CO2 in 96 wells round bottom plates (Greiner, Frickenhausen, Germany).
Recombinant human IL-2 (12.5 U/ml, Proleukine, The Netherlands) and IL-15
(10 ng/ml, BioSource, Nivelles, Belgium) were added to the medium at the start
of culture. Proliferation was analyzed by 3H-thymidine incorporation using a
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Gas Scintillation Counter (Canberra Packard, Matrix 96 Beta-counter, Meri-
den, U.S.A.). To this end 0.037MBq (1mCi) 3H-thymidine (ICN Pharmaceuti-
cals, Irvine, CA, USA) was added to each well, cells were harvested after 8 hours
of culture, and 3H-thymidine incorporation was measured. The 3H-incorpora-
tion is expressed as mean ±SD counts per 5 minutes of at least triplicate mea-
surements.
CFSE labeling
T cells (0.5-2 x106) were labeled with 0.2-1 mM Carboxyfluorescein Diacetate
Succinimidyl Ester (CFDA-SE, Molecular Probes, Eugene, OR, USA) just
before stimulation. Intracellular esterases cleave the acetate groups leading to
the fluorescent carboxyfluorescein succinimidyl ester (CFSE). Cell division
accompanied by CFSE dilution was analyzed by flowcytometry.
Immunosuppressive drugs
Sandimmune Cyclosporine A (CsA) was obtained from Novartis Pharma B.V.
(Arnhem, The Netherlands). Rapamycin was kindly provided for research pur-
poses (Dr S.N. Sehgal, Wyeth-Ayerst, NJ, USA).
MLR co-culture assay to study T cell suppressor function
The suppressor capacity of T cells was studied in a MLR co-culture assay.
CD4+CD25+ or CD4+CD25- T cells were primed with (target) alloantigen in
the presence of recombinant human IL-2 and IL-15. Following expansion, the
cells were harvested, washed, allowed to rest for 3 days in medium containing 2-
5% HPS and 5 ng/ml IL-15. The cells of interest were added to a newly set-up
primary MLR, consisting of freshly thawed original responder PBMC and γ-
irradiated (30 Gy) stimulator PBMC
Flowcytometry
Cells were phenotypically analyzed by four or five color flowcytometry as
described previously17. The following conjugated mAb were used: CD3
(UCHT1) PE, CD4 (MT310) PE, CD8 (DK25) PE, CD27 (M-T271) PE, CD25
(M-A251) PE, (Beckman Coulter Corporation, Miami, Fl, USA), FoxP3
(PCH101) FITC (Ebioscience, San Diego, CA), CD4 (T4) ECD, CD4 (T4)
PC5, CD25 (B1.49.9) PC5 and CD62L (DREG54) ECD (Beckman Coulter).
Isotype matched antibodies were used to define marker settings. Intracellular
analysis of CTLA-4 and FoxP3 was performed after fixation and permeabiliza-
tion, using Fix and Perm reagent (Ebioscience, San Diego, CA).
rapamycin preserves cd4+cd25+cd27+ treg
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Statistical analysis
Statistical Analysis was performed using Graphpad Prism 3.0, Microsoft Excel
2000 and Statistical Product and Services Solutions (SPSS) package version
12.0. For comparisons between groups, we used where appropriate, the Wilcox-
on signed rank test or Student’s t test, assuming unequal variances because of
small sample size. To determine the pooled standard deviation (Fig. 6) we used
the following formula;
SDp=(((n1-1)(SD1)2)+((n2-1)(SD2 )2)/(n1+n2-2))1 ⁄2.
Results
CsA and rapamycin both permit the activation and suppressor function of
naturally occurring CD4+CD25+ TREG
TREG require activation in order to perform their immunoregulatory function.
To asses whether CsA or rapamycin interfere in the allogeneic activation of sup-
pressor function, we performed MLR co-culture assays in the presence or
absence of these drugs. Previous dose-response experiments indicated that CsA
concentrations between 40 ng/mL and 400 ng/mL, and rapamycin concentra-
tions between 10 nM and 1000 nM, are suboptimal for inhibition of the allore-
sponse of effector T cells18. Repetition of these experiments yielded the same
results (data not shown), Therefore, the use of these concentrations of drugs
would allow us to asses an additional inhibition of effector T cells by added
TREG. Using this set-up, we observed that the addition of CD4+CD25+ TREG to
both CsA and rapamycin treated cultures led to an enhanced inhibition of
CD4+CD25- effector T-cell proliferation (Fig. 1). Neither drug abrogated the
suppressive effect of the added CD4+CD25+ TREG. It can thus be concluded
that biologically active concentrations of both CsA and rapamycin allow the
activation and subsequent suppressor function of CD4+CD25+ TREG.
CsA and rapamycin inhibit the alloantigen driven expansion of
CD4+CD25+ TREG
It can be envisaged that upon activation of naturally occurring CD4+CD25+
TREG the induction of tolerance in vivo is further promoted by subsequent 
antigen-specific expansion of cells with regulatory capacity. Indeed, experi-
mental transplantation models have demonstrated that alloantigen-specific
CD4+CD25+ TREG contribute significantly to transplantation tolerance19,20.
Therefore, we analyzed the effects of CsA and rapamycin on allogeneic expan-
sion of freshly isolated human naturally occurring CD4+CD25+ TREG. To this
104
chapter 5
Coenen_prfsch_def  20-03-2007  20:58  Pagina 104
020
40
60
80
100
CsA (ng/ml) Rapamycin (nM)
40 400 100 1000
No TREG added
CsA (ng/ml) Rapamycin (nM)
40 400 100 1000No Drug No Drug
With TREG added
3 H
-in
co
rp
or
at
io
n
(x
10
-3
)
*
*
*
Figure 1. CsA and rapamycin both allow the activation and regulatory action of
CD4+CD25+ T cells.
Primary MLR was set up with 1*105 responder CD4+CD25- T cells and 5*104 γ-irradiated (30
Gy) fully HLA mismatched stimulator PBMC. In co-culture assays (right-hand side of the fig-
ure), CD4+CD25+ T cells were added in a suppressor:effector ratio of 1:4. CsA and
rapamycin were added at the start of primary MLR at indicated concentrations (X-axis). Pro-
liferation at day 5 of culture as measured by 3H-thymidine incorporation is shown on the Y-
axis. One representative experiment is shown (n=5). *P<0.05 for difference between groups.
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end, freshly isolated CD4+CD25+ T cells were labeled with CFSE and stimulat-
ed with alloantigen and additional IL-2 and IL-15. These cytokines are known
to drive cell division in activated CD4+CD25+ regulatory T-cells13. At day 6 of
culture in the absence or presence of various doses of CsA or rapamycin, we ana-
lyzed the level of cell division by calculating the percentage of non-dividing T
cells (Fig. 2). As anticipated, in the drug-free condition CD4+CD25+ TREG pro-
liferated strongly upon fully allogeneic stimulation in the presence of IL-2 and
IL-15, and only 36% of CD4+CD25+ TREG was left in the non-dividing popula-
tion. In contrast, both CsA and rapamycin induced a pronounced inhibition of
cell division. In case of the highest concentrations of the drugs tested we
observed a non-dividing cell population of 62% for CsA and 64% for
rapamycin preserves cd4+cd25+cd27+ treg
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Figure 2. CsA and rapamycin inhibit the allogeneic expansion of CD4+CD25+ T cells.
Freshly isolated CD4+CD25+ T cells (2.5*104) were labeled with CFSE and stimulated 
with γ-irradiated (30 Gy) HLA mismatched stimulator PBMC (1*105) in the presence of IL-2
and IL-15. CsA and rapamycin were added at the start of the cultures at indicated concen-
trations. Cell division represented by the dilution of CFSE was analyzed by flowcytometry at
day 6 of culture. Histograms show CFSE intensity (X-axis) and the number of events (Y-axis).
One representative experiment is shown (n=4)
rapamycin. Taken together, both CsA and rapamycin are able to inhibit the
expansion of CD4+CD25+ TREG upon allogeneic activation in the presence of
the T-cell growth factors IL-2 and IL-15.
In contrast to CsA, rapamycin fully preserves the regulatory capacity of
expanded CD4+CD25+ TREG
Since antigen driven expansion of CD4+CD25+ TREG has been demonstrated to
increase the suppressive capacity of the resultant population13,21, a compromis-
ing effect of CsA or rapamycin on proliferation may weaken the regulatory
function of the expanded population. To examine this, CD4+CD25+ TREG were
106
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stimulated with alloantigen and additional IL-2 and IL-15 in the absence or
presence of CsA (400 ng/ml) or rapamycin (100 nM). Subsequently, the cells
were washed, rested for two days, and tested for suppressive capacity in co-cul-
ture MLR (as depicted in Fig. 3A). Strikingly, CD4+CD25+ TREG cultured in
the presence of rapamycin displayed potent dose-dependent suppressive capaci-
ty similar to control cells, whereas suppression by CD4+CD25+ TREG cultured
in the presence of CsA was markedly reduced (Fig. 3B). A 50 % inhibition by
TREG cultured in the presence of rapamycin was reached already at a suppressor:
effector ratio of 1:256, whereas TREG cultured in the presence of CsA reached a
50% inhibition at a suppressor:effector ratio of 1:16. In other words,
CD4+CD25+ TREG cultured in the presence of rapamycin were 16-fold more
potent in suppressor capacity as compared to Treg cultured in the presence of
CsA. This difference was observed irrespective of the concentrations that were
used, as shown in Figure 3C for a single TREG to TEFFECTOR cell ratio. Thus, in
contrast to CsA, rapamycin preserves suppressive capacity of TREG over a broad
range of concentrations.
In contrast to CsA, rapamycin favors potent suppression by allowing 
a beneficial CD27+TREG to CD27-TREG subset ratio
Previously, we demonstrated that after allogeneic expansion the CD4+CD25+
TREG pool is composed of subsets of CD27-TREG and extremely potent
CD27+TREG. Based upon this observation and literature data14-16 it is conceivable
that the proportion of the highly potent CD27+TREG subset relative to the CD27-
TREG subset will determine the overall suppressive capacity of the expanded
TREG pool. Therefore, we analyzed the proportions of CD27+TREG and CD27-
TREG present in CD4+CD25+ TREG after allogeneic expansion in the presence
of CsA or rapamycin. CD4+CD25+ TREG were cultured for 7 days in the pres-
ence of various concentrations of CsA or rapamycin. After two days of rest, i.e.
prior to putative addition to co-culture MLR, cells were analyzed for the expres-
sion of CD25 and CD27. Interestingly, the TREG pool cultured in the presence
of rapamycin was, similar to control cells, dominated by the CD27+TREG subset,
whereas the TREG pool cultured in the presence of CsA contained a relatively
large proportion of CD27-TREG (Fig. 4A).
In six independent experiments, the CD27+TREG to CD27-TREG subset ratios
within the CD25+ pool were determined after TREG expansion in the absence or
presence of immunosuppressive agents. It was found that TREG expansion in
the presence of CsA consistently resulted in a significant decrease of the
CD27+TREG to CD27-TREG subset ratio relative to TREG cultured in the presence
rapamycin preserves cd4+cd25+cd27+ treg
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 Figure 3. Rapamycin fosters regulatory function of expanded CD4+CD25+ T cells
A. Schematic representation of CD4+CD25+ T-cell expansion culture.
B. 2.5*104 freshly isolated CD4+CD25+ T-cells were stimulated with 1*105 γ-irradiated (30 Gy)
HLA mismatched stimulator PBMC and additional IL-2 and IL-15, in the absence or presence
of CsA and rapamycin. CsA and rapamycin were added at the start of the cultures at indicat-
ed concentrations. Cells were harvested at day 7, washed 3 times and rested. At day 10 the
cells were examined for suppressor function in co-culture assays. ExpTREG derived from con-
trol (untreated), CsA-treated, and rapamycin-treated cultures were co-cultured at the indicat-
ed suppressor:effector ratio’s (X-axis) using 5*104 responder CD4+CD25- effector T cells and
5*104 γ-irradiated (30 Gy) stimulator PBMC. Proliferation at day 5 of culture as measured by
3H-thymidine incorporation is shown on the Y-axis. One representative experiment is shown
(n=6). *P<0.05 for difference between groups.
C. CD4+CD25+ T cells were cultured as described above. CsA and rapamycin were added at
the start of primary MLR at indicated concentrations (X-axis). Cells were harvested at day 7,
washed, rested and co-cultured at a suppressor:effector ratio of 1:128 with 5*104 responder
CD4+CD25- T cells and 5*104 γ-irradiated (30 Gy) stimulator PBMC (grey bars). Control cul-
tures were performed without the addition of suppressor cells (black bars). Proliferation at day
5 of culture as measured by 3H-thymidine incorporation is shown on the Y-axis. One repre-
sentative experiment of 3 independent experiments is shown. Because off small sample
sizes the conditions in which treated cells were used were grouped together resulting in three
groups; untreated cells, CsA treated cells and rapamycin treated cells. *P<0.01 for difference
between groups.
of rapamycin or in the absence of either drug (Fig. 4B, p<0.05). Thus, expan-
sion in the presence of rapamycin, and not CsA, preserves the highly potent
CD27+TREG subset.
Previously, the CD4+CD25+CD27+ TREG was characterized by a high FoxP3
expression level16. Corresponding to the higher content of CD27+TREG,
CD4+CD25+ TREG cultured in the presence of rapamycin or in the absence of
drugs displayed higher FoxP3 expression than cells cultured in the presence of
CsA (Fig. 4C).
Subsequently, we analyzed the relationship between the CD27+TREG to CD27-
TREG subset ratio and the suppressive capacity for CD4+CD25+ TREG popula-
tions cultured in the presence of CsA or rapamycin. In five out of six experi-
ments the low CD27+TREG to CD27-TREG subset ratio of TREG cultured in the
presence of CsA corresponded to reduced suppressor potency. Conversely,
when TREG were cultured in the presence of rapamycin or in the absence of
drugs, a high CD27+TREG to CD27-TREG subset ratio was related to a stronger
suppressive activity (Fig. 5).
rapamycin preserves cd4+cd25+cd27+ treg
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 Figure 4. Rapamycin preserves a high CD27+TREG : CD27-TREG ratio.
A. The expression of CD25 and CD27 on CD4+CD25+ TREG expanded in the absence or
presence of CsA or rapamycin was measured by flowcytometry. 2.5*104 freshly isolated
CD4+CD25+ T cells were stimulated with 1*105 γ-irradiated (30 Gy) allogeneic PBMC and
additional IL-2 and IL-15. CsA and rapamycin were added at the start of primary MLR at indi-
cated concentrations. Cells were harvested at day 7, washed, rested and analyzed for CD25
and CD27 expression at day 10 of culture. Dot plots show CD25 and CD27 expression of live-
gated cells. One representative experiment out of 3 independent experiments is shown.
B. CD27+TREG to CD27-TREG subset ratios (Y-axis) within the CD25+ fraction were calculated for
the ExpTREG pool, the ExpTREG CsA pool (cultured with 400 ng/mL CsA), and the ExpTREG
rapamycin pool (cultured with 100 nM rapamycin).The results of six independent experi-
ments are shown. *P<0.05 for difference between groups.
C. The intracellular expression profile of FoxP3 in the ExpTREG pool, the ExpTREG CsA pool
(cultured with 400 ng/mL CsA) and the ExpTREG rapamycin pool (cultured with 100 nM
rapamycin) was determined by flowcytometry. Histograms show intracellular FoxP3 expres-
sion of live-gated cells. (Dotted line; CD4+CD25- cells. Solid line; CD4+CD25+ cells).
In summary, the CD27+TREG to CD27-TREG subset ratio crucially determines
the suppressive capacity of the expanded TREG pool as a whole. In contrast to
CsA, rapamycin favors potent suppression by allowing a beneficial CD27+TREG
to CD27-TREG subset ratio.
Only CD4+CD25+ TREG cultured in the presence of rapamycin inhibit
ongoing T-cell responses
In transplant patients that have been primed with alloantigens, or in patients
presenting with T cell mediated autoimmune diseases, it is crucial to restrain T
cell responses that are already in progress. As described previously, a crucial dif-
ference between CD27+TREG and CD27-TREG is the ability of CD27+TREG to
inhibit ongoing T cell responses. Since rapamycin, but not CsA, preserves the
CD27+TREG pool it can be hypothesized that TREG cultured in the presence of
either drug differ with respect to their ability to inhibit ongoing T cell respons-
es. Therefore, we analyzed the potential of TREG cultured in the presence of
immunosuppressive drugs to inhibit effector T cell proliferation at an advanced
state of a MLR. Notably, TREG cultured in the presence of CsA lost the ability
to prevent ongoing T-cell responses of 2 days after the start of MLR, whereas
TREG cultured in the presence of rapamycin were still able to suppress this
response (Fig. 6).
rapamycin preserves cd4+cd25+cd27+ treg
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Figure 5. A high CD27+TREG :CD27-TREG ratio corresponds to potent suppression
The relative suppression (Y-axis) at a suppressor:effector ratio of 1:128 was plotted against
the corresponding CD27+TREG to CD27-TREG subset ratio (X-axis) for the ExpTREG pool, the
ExpTREG CsA pool (cultured with 400 ng/mL CsA) and ExpTREG rapamycin pool (cultured 
with 100 nM rapamycin).The results of six independent experiments are shown.
Discussion
In several experimental transplantation models it has been observed that CsA
can antagonize the induction of tolerance, while rapamycin does not22-25. One
mechanism that may account for these observations is that in contrast to CsA,
rapamycin easily permits apoptosis of alloreactive T cells8. Another possibility is
that both drugs have different effects on TREG since these cells have been
demonstrated to play an important role in many models of tolerance induc-
tion9. Indeed, it was reported that CsA, and not rapamycin, blocks the genera-
tion of TREG after pretransplant donor-specific blood transfusion in rats12. Fur-
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Figure 6. CD4+CD25+ T cells cultured in the presence of rapamycin, but not CsA, are
able to inhibit ongoing T-cell responses.
2.5*104 freshly isolated CD4+CD25+ T cells were stimulated with 1*105 γ-irradiated (30 Gy) 
HLA mismatched stimulator PBMC and additional IL-2 and IL-15 in the absence or presence
of CsA (400 ng/mL) and rapamycin (100 nM). Cells were harvested at day 7, washed 3 times
and rested. At day 10 the cells were examined for suppressor function in suppression 
co-culture assays. ExpTREG derived from control (untreated), CsA-treated and rapamycin-
treated cultures (X-axis) were co-cultured from day 0 (T=0) or day 2 (T=2) of MLR at a 
suppressor:effector ratio of 1:16 using 5*104 responder CD4+CD25- effector T-cells and 
5*104 γ-irradiated (30 Gy) stimulator PBMC. Proliferation at day 5 of culture was measured 
by 3H-thymidine incorporation, and is depicted as percentage of inhibition on the Y-axis.
A representative experiment is shown. *P<0.05 for difference between groups.
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thermore, a relative increase of CD4+CD25+ T cells in peripheral lymphoid
organs was observed in rats treated with rapamycin. Recently, Battaglia et al.11
described that exposure to rapamycin results in a selective expansion of murine
CD4+CD25+ TREG in vitro.
We here present a novel explanation for the favorable immunomodulatory
effects of rapamycin. First of all, we confirm that both rapamycin and CsA allow
the activation and suppressor function of human TREG. As a new finding, we
demonstrate that after allogeneic stimulation of human naturally occurring
CD4+CD25+ TREG, rapamycin treatment fosters a high CD27+TREG to CD27-
rapamycin preserves cd4+cd25+cd27+ treg
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TREG subset ratio. Recently, we described the characteristics of these two TREG
subsets induced upon allogeneic expansion of human CD4+CD25+ TREG13. A
major difference between these subsets is their suppressive capacity, the
CD27+TREG subset being highly suppressive, while the CD27-TREG subset has
modest suppressive potency13. The strong regulatory capacity of the CD27+TREG
subset has also been shown in other studies14-16. After expansion of CD4+CD25+
TREG, we typically find that the majority of cells is CD27+. In this study we
show that rapamycin and CsA act differently with regard to the preservation of
the high CD27+TREG to CD27-TREG ratio. In contrast to CsA, rapamycin pre-
served the dominance of CD27+TREG over CD27-TREG upon allogeneic stimula-
tion, resulting in strong suppressive capacity of the expanded CD4+CD25+
TREG pool as a whole. It can thus be envisaged that a predominance of
CD27+TREG, which is supported by treatment with rapamycin, can add to the
development of stable tolerance and prevention of rejection in solid organ
transplantation. Also in stem cell transplantation, patients may benefit from the
use of rapamycin as immunosuppressant for it becomes increasingly clear that
the presence of potent CD4+CD25+ regulatory T-cells favors immune reconsti-
tution and may control graft-versus-host disease while allowing graft-versus-
tumor activity26,27.
Next to the beneficial effect of CD27+Treg, the relevance of the CD27-TREG as
such should not be discarded. It can be expected that after transplantation
CD4+CD25+ TREG will expand in an antigen-specific manner in the draining
lymph nodes or in the graft28,29. Of note, CD27+TREG and CD27-TREG differ with
respect to the pattern of migratory receptors and adhesion molecules.
CD27+TREG were found to express CD62L, whereas CD27-TREG were devoid of
CD62L13. It can thus be argued that CD27+TREG are committed to local suppres-
sor function in the draining lymph node, whereas CD27-TREG are destined to
enter the periphery. Moreover, CD27-TREG are characterized by rapid expansion,
which may be of importance in outnumbering aggressive T-cells in the periph-
ery13. So, CD27-TREG may have a specific role and in vivo it may well be that the
induction of transplantation tolerance benefits from the use of CsA in specific
cases. In fact, CsA has been implicated in the induction of transplantation toler-
ance by sparing of CD4+ suppressor cells and when used in combination with
costimulation blocking agents12,30-34. Further research on the in vivo role of
CD27+TREG and CD27-TREG may elucidate how the effect of rapamycin and CsA
on the skewing of TREG subsets may differentially affect the induction of allo-
graft tolerance.
The frequency of the CD27+TREG is clearly affected by CsA. Cross-linking of
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CD27 has been shown to induce proliferation following the mobilization of
intracellular free Ca2+35,36. Since CsA specifically targets Ca2+ dependent activa-
tion pathways, CsA may thus selectively inhibit CD27+TREG proliferation. How-
ever, we have preliminary data that do not support an inhibition of proliferation
(data not shown), rather it appears that CD27 expression levels are affected
upon stimulation in the presence of CsA. This is in agreement with the previous
finding that elevation of intracellular Ca2+ levels is important in the up-regula-
tion of CD27 expression36.
It has been proposed that signaling by the growth factor IL-2 is crucial for
the functional activity of TREG4,5. CsA inhibits TCR-induced activation and IL-
2 production, whereas rapamycin blocks signaling in response to T cell growth
factors6,7. In theory, both drugs could therefore interfere with the function of
TREG function. Interestingly, we observed that in the presence of CsA or
rapamycin freshly isolated CD4+CD25+ TREG were able to suppress
CD4+CD25- T cells, indicating that CsA and rapamycin did not significantly
interfere in the activation or suppressor function of these cells. In line with these
findings, basiliximab, a chimeric monoclonal antibody directed against the IL-2
receptor, also did not interfere in the suppressive capacity of human
CD4+CD25+ T cells37. This may indicate that inhibition of the IL-2 pathways is
not as detrimental to the function of human CD4+CD25+ TREG as could be
expected from in vivo findings on CD4+CD25+ TREG in a mouse model38.
In summary, our data show that CsA and rapamycin do not interfere with
the activation or suppressor function of freshly isolated human CD4+CD25+
TREG. However, CsA and rapamycin differentially affect TREG subset hetero-
geneity upon expansion after allogeneic activation. Expansion of CD4+CD25+
TREG in the presence of rapamycin favors CD27+TREG subset dominance, which
is beneficial for the suppressive capacity of the CD4+CD25+ T cell pool as a
whole and allows the suppression of ongoing T cell responses. During expan-
sion of TREG in the presence of CsA, the dominance of the CD27+TREG subset is
lost and this is accompanied by a decrease of suppressive activity of the resulting
population. These findings provide a novel contribution to explain the favor-
able effects of rapamycin in strategies of tolerance induction.
rapamycin preserves cd4+cd25+cd27+ treg
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Abstract
Reducing effector T-cells while preserving the function of regulatory T-cells
(TREG) is of major importance in transplantation medicine. Cyclosporine A
(CsA) and rapamycin reduce the expansion of effector T-cells by blocking inter-
leukin (IL)-2 production and signaling, but signaling by IL-2 is pivotal for TREG
homeostasis. There is concern about the impact of interfering with IL-2 signal-
ing by immunosuppressive agents on the preservation of TREG, and conse-
quently, on the induction of tolerance.
Mice were treated with high and low doses of CsA or rapamycin and
analysed for the presence of TREG in different immune compartments. Admin-
istration of the anti-CD25 monoclonal antibody PC61 was applied to analyze
TREG homeostasis in the presence of CsA or rapamycin. Treatment with CsA, in
contrast to rapamycin resulted in a strong reduction of CD25+FoxP3+ T-cells in
spleen, lymph nodes and peripheral blood. During prolonged treatment, CsA
and rapamycin differentially affected the generation of CD4+ single positive T-
cells in the thymus. Rapamycin treatment allowed thymic generation of
CD4+FoxP3+ T-cells, whereas CsA led to a reduced generation of these cells.
In comparison with CsA, rapamycin is more permissive of FoxP3+ T-cell
preservation. These findings may have implications for the management of
immune-mediated diseases if one aims to exploit TREG for the achievement of
tolerance to self or allo-antigens.
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Introduction
Organ transplantation has become a successful therapeutic modality for end-
stage renal, cardiac, hepatic and pulmonary disease. Progress in transplantation
medicine has been realized in great part by the advent of potent immunosup-
pression during the 1980’s. The immune-inhibitory effect of several of these
agents rests on the interference in IL-2 signaling, thereby reducing the expan-
sion of detrimental effector T-cells1.
Recently, it has become clear that signaling by IL-2 is not only stimulatory
for effector T-cell proliferation but is also pivotal for immune regulation at sev-
eral stages2-4. In the thymus, signaling through the common γ-chain of cytokine
receptors is essential for the development of naturally occurring CD4+CD25+
regulatory T-cells (TREG). The induction of the forkhead family transcription
factor FoxP3 in thymocytes designates their fate as TREG5,6. Being part of the
normal peripheral T-cell repertoire, these cells have the capacity to suppress
immune responses to autoantigens7. The importance of these cells in maintain-
ing immune homeostasis is e.g. illustrated by the observation that day 3 thymec-
tomy in neonatal mice led to the development of severe autoimmune patholo-
gy8. Next to their role in self-tolerance, TREG have been shown to control effec-
tor T-cell responses to alloantigens in both solid organ and bone-marrow trans-
plantation9,10. In the periphery, IL-2 signaling is required for sustaining the
TREG population at a size necessary to maintain immune homeostasis2,3. This
raises considerable concern about the impact of blocking IL-2 production or 
IL-2 signaling or by different immunosuppressive agents on CD4+CD25+ TREG
homeostasis.
Cyclosporine A (CsA) inhibits the activity of calcineurin, which leads to a
decreased dephosphorylation of the nuclear factor of activated T cells (NFAT).
As a consequence, the translocation of this regulatory factor from the cytoplasm
to the nucleus is impaired, resulting in a reduced expression of several cytokine
genes, including that of IL-211. Rapamycin binds to a protein kinase, called the
mammalian target of rapamycin, and blocks cell growth and proliferation in
response to growth factors like IL-212-14. According to their mechanism of
action (blocking the production of IL-2 and interfering with the downstream
effects of IL-2 respectively), either drug may compromise the TREG population.
Earlier, CsA has been implicated in the generation of auto-immune like phe-
nomena and the impairment of tolerance induction in transplantation15-19. In a
previous study we have demonstrated that, in contrast to CsA, rapamycin pre-
serves the highly potent human CD4+CD25+CD27+TREG in vitro20. Moreover,
a beneficial effect of rapamycin on CD4+CD25+ T-cells in vivo has also been
csa compromises treg homeostasis
121
Coenen_prfsch_def  20-03-2007  20:59  Pagina 121
shown21-23. Recently, rapamycin rather than CsA was found to preserve the
function of TREG in a GVHD model24.
Here we analyzed the effects of CsA and rapamycin on the ontogeny and
maintenance of TREG. The frequency of TREG was determined in thymus,
peripheral blood and secondary lymphoid organs during treatment with either
CsA or rapamycin in naive mice. To further analyze the effects of CsA and
rapamycin on TREG homeostasis, mice were depleted for TREG by CD25-deplet-
ing monoclonal antibody (mAb) prior to the initiation of drug treatment. 
We here demonstrate that CsA compromises the thymic generation of
CD4+CD25+FoxP3+ T-cells and their homeostasis in peripheral immune com-
partments. These data may have implications for the choice of immunosuppres-
sive drugs if a regimen that optimally allows the contribution of TREG to toler-
ance induction is pursued.
Materials and methods
Mice
C3H (H-2k), C57BL6 (H-2b) and BALB/c (H-2d) mice were purchased from
Charles River Lab (Charles River, Sulzfeld, Germany). Mice were used at 8 to 12
weeks of age and housed in a specified pathogen free facility. All experiments
were performed according to the guidelines of the Animal Ethics Committee of
the Radboud University Nijmegen.
Drug treatment
Cyclosporin A (Novartis, Basel, Switzerland) was delivered subcutaneously by a
14- or 28- day osmotic pump (Alzet, Palo Alto, CA). Rapamycin (Wyeth
Europe, Berkshire, UK ) was diluted in vehicle containing sodium car-
boxymethylcellulose (C-5013 high viscosity; Sigma-Aldrich, St. Louis, MO) and
polysorbate 80 (P-8074; Sigma-Aldrich) and administered by intraperitoneal
(i.p.) injection on days 0, 1, and 2, and subsequently every other day. PC61 anti-
body (Bioceros BV, Utrecht, The Netherlands) was administered i.p. in a single
dose of 150 mg in 300 mL phosphate-buffered saline.
Cardiac allograft transplantation
Cardiac allografts were placed in an intra-abdominal location using the tech-
nique described by Corry et al 25. Graft function was assessed every two days by
palpation. The day of rejection was defined as the day of cessation of palpable
heartbeat.
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Flow cytometry
After the mice were sacrificed, thymus, spleen, lymph nodes, and peripheral
blood were collected. Cell suspensions of different immune compartments or
peripheral blood were depleted of erythrocytes by osmotic shock using a lysis
buffer containing 0.15mM NH4Cl (Merck, Darmstadt, Germany), 10.0 mM
KHCO3 (Merck) and 0.1 mM Na2EDTA (Sigma-Aldrich, Steinheim, Ger-
many). Subsequently, cells were phenotypically analysed by three- or four-
colour fluorescence. Cells were washed twice with phosphate-buffered saline
supplemented with 0.2% bovine serum albumin (Sigma). The following anti-
bodies were used: FITC-, PE-, or PE-Cy7-conjugated anti-CD4 (L3T4), FITC-
or PE-conjugated anti-CD8 (53-6.7), and biotin-conjugated anti-CD25 (7D4)
(all from BD Biosciences, Erembodegem, Belgium). All incubations were con-
ducted for 20 minutes at room temperature and thereafter the cells were washed
twice. For secondary staining of biotin-conjugated antibodies, streptavidin-PE
(BD Biosciences, Erembodegem, Belgium) or Streptavidin-Cy5 (Beckman
Coulter, Miami, USA) was used. FoxP3 was determined by intracellular analysis
after fixation and permeabilization using a PE-conjugated anti-mouse FoxP3
(FJK-16s) staining set (eBioscience, SanDiego, USA). The samples were run on
a Coulter Epics XL, Beckman Coulter (Miami, USA) and at least 100.000-
150.000 events were collected based on live lymphocyte gating, as indicated by 5
mg/mL propidium iodide staining. Isotype matched antibodies were used to
define marker settings.
Cell purification for proliferation assays
A cell suspension of BALB/c spleen and lymph nodes was enriched for CD4
T-cells by incubation with aMHC class II mAb coated magnetic microbeads
and aCD8 mAb coated magnetic microbeads (Miltenyi, Bergisch Gladbach,
Germany), followed by passage through a LD microbead column (Miltenyi).
Purification of CD4+CD25+ T-cells was carried out by fluorescence activated
cell sorting (FACS) (Coulter Epics Elite, Beckman Coulter, Miami, USA). To
this end, the CD4 T-cell enriched population was incubated with saturating
amounts of biotin-labeled aCD25 antibody (7D4; BD Biosciences, San Diego,
USA) and subsequently incubated with streptavidin-PE (BD Biosciences, San
Diego, USA). After the FACS procedure, the PE-positive fraction was >98%
CD4+CD25+. CD25+ T-cell depleted populations typically contained <1%
CD4+CD25+ T-cells. C57BL/6 stimulator cells were enriched by culturing
splenocytes in 9 cm petridishes (Allegiance, Zutphen, The Netherlands) for two
hours followed by further overnight culture of the adherent cell fraction. After
csa compromises treg homeostasis
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18 to 24 hours the non-adherent cells were obtained by harvesting the super-
natant and gently washing the petridish. For plate-immobilized anti-CD3 stim-
ulation, anti-CD3e mAb (145-2C11; hamster IgG; BD Pharmingen, San Diego,
USA) 2.5 mg/ml was precoated on flat bottom 96-well plates by overnight incu-
bation at 4∞C. Before these anti-CD3 coated plates were used they were washed
with sterile PBS. CD25+ T-cell depleted T-cells were plated in anti-CD3 mAb
coated plates at 5*104 cells per well.
Suppression assay
To test for suppressive capacity, increasing numbers of CD4+CD25+ T-cells were
added to a primary MLR. In primary MLR, BALB/c CD25- responder T-cells
were cultured with γ-irradiated (27.5 Gray) enriched C57BL/6 splenocytes at a
ratio of 1*105 responders to 2.5*104 stimulator cells in flat bottom 96-well plates
(Costar, Corning, USA) containing RPMI 1640 (Gibco, Paisley, UK) with 10%
FCS (Invitrogen, Leek, The Netherlands), 50 mM 2-ME (Biorad, Hercules,
USA), 1 mM sodium pyruvate, glutamax and antibiotics (100 U/mL penicillin;
100 mg/mL streptomycin)(all from Gibco) at 37º, 95% humidity and 5% CO2.
Cell proliferation was monitored by tritiated thymidine incorporation. To this
end the cells were pulsed with tritiated thymidine (0.5 mCi) during the last 16-
18 h of the culture. 3H-thymidine incorporation was analyzed by a gas scintilla-
tion counter and is expressed as mean count per 5 minutes and SD of at least
triplicate measurements.
Statistics
Statistical analysis was performed using Graphpad Prism 3.0 and Microsoft
Excel 2000. For comparisons between groups, we used ANOVA or Student’s t
test where appropriate, assuming unequal variances because of small sample
sizes.
Results
Determination of effective dose of CsA and rapamycin and TREG depletion
by PC61
To determine the effects of CsA and rapamycin on CD4+CD25+ regulatory 
T-cells, we first established that the drug dosages used are biologically active in
vivo. BALB/c recipients were transplanted with C3H cardiac allografts and
monitored for rejection in the absence or presence of treatment with CsA (20
mg/kg/day) or rapamycin (0.2 mg/kg on alternating days). We confirmed that
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at these dosages CsA and rapamycin were therapeutic since cardiac allograft sur-
vival was successfully extended (Fig. 1A).
We next established that the CD4+CD25+ T-cell population as identified by
our technique harbors regulatory capacity. BALB/c CD4+CD25+ T-cells were
FACS sorted and added in increasing numbers in a suppression assay. As antici-
pated, the CD4+CD25+ T-cell fraction displayed dose-dependent suppressive
capacity of an allogeneic effector response in MLR (Fig. 1B).
To ensure proper analysis of the reemergence of CD4+CD25+ TREG after
depletion, we first examined the percentage of CD25+FoxP3+ T-cells in the dif-
ferent immune compartments after administration of the anti-CD25 mAb
PC61. Administration of PC61 resulted in a more than 75% reduction of the
CD4+CD25+FoxP3+T-cell population in the different immune compartments
(Fig 1.C).
Taken together, we concluded that the use of PC61 and the concentrations
chosen for CsA and rapamycin should be suitable for analysis of the immuno-
suppressive drugs on the CD4+CD25+ regulatory T-cell population.
CsA results in CD25+FoxP3+ T-cell depletion in peripheral immune 
compartments
The expression of the IL-2 receptor α chain (CD25) converts the intermediate
affinity IL-2 receptor (consisting of a βand γ chain only) to a high affinity IL-2
receptor, which is required for the normal immune function of T cells26 and
specifically for the maintenance of TREG in the peripheral T cell pool2. Because
the expression of CD25 is regulated by IL-227, it can be imagined that blocking
IL-2 production or signaling can interfere with CD25 expression and subse-
quently with TREG physiology. We therefore analyzed the proportion of
CD4+CD25+ T-cells, with special focus on the CD25high population, in spleen,
lymph nodes and peripheral blood after mice were treated for 7 days with CsA
or rapamycin. Overall, we observed that in the various peripheral immune com-
partments the proportion of CD25high T-cells within the CD4+ subset was sig-
nificantly reduced by CsA in a dose-dependent manner, whereas rapamycin
treated and non-treated animals contained similar proportions of these cells
(Fig. 2A and 2B). The administration of PBS in osmotic pumps did not
decrease the proportion of CD4+CD25high T-cells. Moreover, two weeks after
cessation of CsA treatment, the CD4+CD25high T-cell population was restored
to normal levels (Fig. 2C).
IL-2 signaling is also required for the maintenance of FoxP3 expression,
which is considered the best marker of TREG and is pivotal for their function2.
csa compromises treg homeostasis
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 Figure 1. Determination of effective dose of CsA and rapamycin and TREG depletion
by PC61 .
A. BALB/c recipients of C3H cardiac allografts were treated with 20 mg/kg/day CsA (continu-
ous s.c. infusion during 14 days) or with 0.2 mg/kg rapamycin i.p. on days 0, 1, 2, 4, 6, 8, 10,
12 and 14 after transplantation, or untreated, and monitored for allograft rejection.
* : P<0.05 for differences between treated and control groups.
B. BALB/c CD4+CD25+ T-cells were isolated by FACS and co-cultured in increasing numbers
with syngeneic 1*105 CD25- T-cells and 2.5*104 C57BL/6 γ-irradiated (27.5 Gy) splenocytes
to asses their suppressive capacity. Proliferation as measured by 3H-thymidine incorporation
on day 6 of culture is shown on the Y-axis as mean cpm ± SD. A typical example out of three
independent experiments is shown. * : P<0.05.
C. A single dose of the anti-CD25 antibody PC61 (150 mg) was administered i.p. to BALB/c
mice. After 7 days, lymphocytes from the spleen, lymph nodes, and peripheral blood were
analyzed for CD4, CD25 and intracellular FoxP3 expression. Flow cytometry dot plots gated
on live CD4 T cells are shown for CD25 and FoxP3 expression. A typical example out of 2
independent experiments is shown.
To analyze whether interference in IL-2 signaling by immunosuppressive drugs
results in reduction of the number of TREG, and not merely their CD25 expres-
sion, intracellular FoxP3 expression was analyzed in combination with CD25
expression. To exclude that a putative effect on TREG was left unnoticed during
a relatively short period of treatment (i.e. one week), we treated the mice for 28
days. CsA treatment resulted in a strong reduction of the proportion of
CD4+FoxP3+ T-cells in the various immune compartments (Fig. 3), which par-
alleled the observed decrease in CD4+CD25high T-cells.
Rapamycin, not CsA, preserves the homeostasis of CD4+CD25high T-cells 
in the periphery
To analyze how CsA and rapamycin may interfere in the homeostasis of
CD4+CD25high T-cells, we depleted the CD4+CD25high T-cells in mice by anti-
CD25 mAb (PC61) treatment and analyzed if and when the population of
CD4+CD25high T-cells re-emerged in the absence or presence of either drug. We
found a sharp reduction of CD4+CD25high T-cells in the spleen at day 7 after
anti-CD25 injection (Fig. 4A). At 3 to 4 weeks after anti-CD25 injection, the
proportion of CD4+CD25high T-cells in the spleen was restored to normal levels,
which is indicative of the presence of CD4+CD25high T-cell homeostasis (Fig.
4A). Interestingly, in the presence of CsA this homeostasis of CD4+CD25high T-
cells was compromised, whereas treatment with rapamycin allowed a similar
recovery of the CD4+CD25high T-cell population as seen in the control animals
csa compromises treg homeostasis
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 Figure 2. CsA dose-dependently reduces the peripheral regulatory CD4+CD25+ T-cell
population.
A. Mice were treated with CsA (10 or 20 mg/kg/day), rapamycin (0.2 or 0.4 mg/kg on 
days 0, 1, 2, and subsequently on alternating days) or PBS. After 7 days, the frequency 
of CD4+CD25high T-cells was analyzed in suspensions of spleen and lymph nodes and in
peripheral blood. Flow cytometry dot plots gated on live CD4+ T-cells are shown for CD4 and
CD25 expression. A typical example out of 5 independent experiments with equal numbers 
of events analyzed is shown.
B. Percentages of CD4+CD25high T-cells in spleen, lymph nodes and peripheral blood after 
7 days of treatment with different doses of CsA or rapamycin. Each data point represents 
an average of 3-5 mice. * : P<0.05.
C. Percentages of CD4+CD25high T-cells in the spleen 14 days after the end of 7 day 
treatment with CsA or rapamycin. Each data point represents an average of 3-5 mice.
(Fig. 4A and B). In the lymph nodes and peripheral blood similar observations
were made (data not shown).
CsA compromises thymic ontogeny of FoxP3+ T-cells
The intracellular processes that are affected by CsA and rapamycin in activated
T cells, are also involved in maturation and selection of thymocytes28. Since
thymic TREG substantially contribute to the peripheral TREG population29, CsA
and rapamycin may interfere in the homeostatic control of TREG by affecting
TREG genesis in the thymus.
In the thymus, CD4+ T-cell maturation typically involves successive stages
of precursor CD4-CD8- double negative (DN) thymocytes, CD4+CD8+ double
positive (DP) thymocytes, and end-stage CD4+CD8- single positive (SP) thy-
mocytes30. We analyzed the effect of CsA and rapamycin at 7 and 28 days of
administration on the different stages of thymic development of CD4+ T-cells.
After 7 days of administration, neither CsA nor rapamycin clearly affected the
thymic subset composition (Fig. 5A). However, long-term treatment with either
CsA or rapamycin resulted in considerable changes in the proportions of the
different subsets within the thymus (Fig. 5B). Treatment with CsA led to a
reduction of the CD4+ SP T-cell compartment. In contrast, rapamycin resulted
in a reduction of CD4+CD8+ DP thymocytes, with a concomitant relative
increase of CD4-CD8- DN and CD4+CD8- SP thymocytes.
We subsequently evaluated the effect of CsA and rapamycin treatment on
the thymic emergence of regulatory T-cells. During thymic ontogeny,
CD4+CD25+ expression is not the most accurate marker of TREG, since the
expression of CD25 can precede the induction of FoxP3, while the latter deter-
csa compromises treg homeostasis
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Figure 3. CsA and rapamycin differentially affect the peripheral CD4+CD25+FoxP3+
T-cell population during prolonged treatment.
Mice were treated with CsA (20 mg/kg/day via continuous s.c. infusion) or rapamycin (0.4
mg/kg i.p. on days 0, 1, 2, and subsequently on alternating days). After 28 days of treatment,
lymphocytes from the spleen, lymph nodes, and peripheral blood were analyzed for CD4,
CD25 and intracellular FoxP3 expression. Flow cytometry dot plots gated on live CD4+ T-
cells are shown for CD25 and FoxP3 expression. A typical example out of 3 experiments with
equal numbers of events analyzed is shown.
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mines the TREG fate. The induction of FoxP3 occurs predominantly in the
CD4+ SP stage or during the transition to this stage from the CD4+CD8+ DP
stage5. We observed that the proportion of Foxp3 expressing thymocytes within
the total CD4+ compartment was significantly lower in CsA treated animals as
compared to untreated and rapamycin treated animals (Fig. 5C).
Thus, rapamycin allows for CD4+ SP thymocyte maturation and induction
of FoxP3, whereas CsA compromises CD4+ SP thymocyte maturation and gen-
eration of FoxP3+ T-cells during prolonged treatment.
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Figure 4. CsA compromises peripheral CD4+CD25high T-cell homeostasis.
A. A single dose of the anti-CD25 antibody PC61 (150 mg) was administered i.p. to BALB/c
mice in the presence or absence of treatment with CsA (20 mg/kg/day via continuous s.c.
infusion) or rapamycin (0.4 mg/kg i.p. on days 0, 1, 2, and subsequently on alternating days)
during 28 days. After 7, 21, and 28 days, lymphocytes from the spleen, lymph nodes, and
peripheral blood were analyzed for CD4 and CD25 expression (gated on live CD4+ T-cells).
A typical example out of 3 independent experiments with equal numbers of events analyzed
is shown.
B. Summary of the effects of treatment with PC61 with or without concomitant treatment with
CsA or rapamycin. Each data point represents an average of 3 mice. * : P<0.05 for compari-
son between CsA and control groups within time points.
0
5
10
15
Day 0 Day 7 Day 21 Day 28
%
 C
D
4+
C
D
25
h
ig
h
ce
lls
*
PC61
PC61 + CsA 
PC61 + Rapamycin 
*
A
B
csa compromises treg homeostasis
131
Coenen_prfsch_def  20-03-2007  21:00  Pagina 131
CsA RapamycinUntreated
0
1.0
2.0
%
 C
D
4+
F
o
xP
3+
T
-c
el
ls
* *
*
Figure 5. CsA and rapamycin differentially affect thymic composition and generation
of FoxP3+ T-cells during prolonged treatment.
A. Mice were treated with CsA (20 mg/kg/day via continuous s.c. infusion) or rapamycin 
(0.4 mg/kg i.p. on days 0, 1, 2, and subsequently on alternating days). After 7 days of 
treatment, the thymus was isolated and analyzed for CD4 and CD8 expression with equal
numbers of events analyzed.
B. CD4 and CD8 expression in the thymus after 28 days of treatment with CsA or rapamycin.
C. Intracellular expression of FoxP3 within the total thymic CD4 compartment after 28 days 
of treatment with CsA or rapamycin* : P<0.05, ** : P<0.01.
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Discussion
During the last decade, TREG have emerged as an intrinsic part of the immune
system, pivotal for the maintenance of tolerance to self-antigens31. An impor-
tant clinical goal is to harness these tolerance inducing elements, and to facili-
tate that these TREG will control the organ destructive potential of self-reactive
cells in auto-immune disease and of allo-reactive cells in transplantation. There-
fore, a more thorough understanding of naturally occurring TREG ontogeny
and survival in the presence of currently used immunosuppressive drugs is
essential. Here we demonstrate that CsA and rapamycin differentially affect
CD4+FoxP3+ TREG homeostasis in vivo.
After short term treatment, CsA reduced the peripheral TREG population,
but did not alter thymic subset composition. In agreement with our data, it has
been shown that TCR triggering and IL-2 are both essential for the mainte-
nance of the TREG population in the periphery2,32, whereas IL-2 was found to
be dispensable for the development of TREG in the thymus2-4. Setoguchi et al.
demonstrated that neutralization of IL-2 in vivo results in a decrease of TREG
numbers with similar kinetics as we observed during treatment with CsA. In
that study it was concluded that peripheral TREG depend on IL-2 produced by
CD25low T-cells4. It thus appears that the interference of CsA with TCR signal-
ing and IL-2 production affects TREG homeostasis at least in part by impairing
the maintenance of the TREG population in the periphery.
After depletion of TREG, we observed a compromised recovery of the regula-
tory T-cell population in the presence of CsA. In addition, we found a reduced
generation of CD4+FoxP3+ SP cells in the thymus after prolonged treatment
with CsA. This is in agreement with earlier observations that CsA inhibits the
development of CD4+ SP thymocytes from their CD4+CD8+ DP precursors33.
The commitment to the CD4+ T-cell lineage is controlled by TCR-signals of
sufficient strength or duration30,34. There is also a direct link between TCR trig-
gering and FoxP3 induction35, which occurs predominantly in the CD4+ SP
thymocyte stage or during the transition from CD4+CD8+ DP cells to this
stage6,36. CsA can inhibit this thymic generation of CD4+FoxP3+ TREG by
impairment of TCR signaling, and more specifically by reducing the NFAT
dependent FoxP3 promotor activity37. Rapamycin inhibits biochemical path-
ways required for the cell cycle progression from the G1 to S phase, but allows
the intitial signal transduction upon TCR triggering13. We found that
rapamycin does not affect the thymic CD4+FoxP3+ T-cell generation. This is
supported by a previous study in which it was demonstrated that rapamycin
inhibits the proliferation of CD4+CD8+DP thymocytes, but in contrast to CsA,
csa compromises treg homeostasis
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allows the maturation of CD4+SP thymocytes38. Regarding the essential role for
IL-2 in the peripheral survival of CD4+CD25+ T-cells, it is interesting that these
cells differ from primed CD4+ T-cells in their IL-2 receptor signaling pathway.
In CD4+CD25+ T-cells, the effects of Il-2 are mediated by activation of the
Janus kinase/STAT pathway, while rapamycin-sensitive downstream targets of
phosphatidylinositol 3-kinase (like p70s6kinase) are not activated39. It is thus con-
ceivable that rapamycin does not affect the IL-2 dependent peripheral survival
of CD4+CD25+ TREG.
Taken together, our data indicate that CsA inhibits the development of
CD4+ SP T-cells from CD4+CD8+ DP T-cells, and concomitantly compromises
the selection and induction of CD4+FoxP3+ TREG in the thymus. In contrast,
rapamycin allows for the CD4+CD8+ DP to CD4+ SP transition and the induc-
tion of CD4+FoxP3+ TREG. In the peripheral immune compartments,
rapamycin is permissive of the survival of CD4+CD25+FoxP3+ T-cells, whereas
CsA treatment compromises the homeostasis of this TREG population. So far,
the functional differences between CsA and rapamycin with respect to tolerance
induction in experimental models were mostly attributed to differences in facil-
itation of activation induced cell death of effector cells and to different cell-sur-
face expression of particular costimulatory molecules16,17,19. We think that the
contrasting effects of CsA and rapamycin on the generation and homeostasis of
CD4+FoxP3+ TREG that we here describe, may offer an additional explanation
for the dissimilar influence of these drugs on tolerance induction. In agreement
with our findings, CsA treatment of newborn mice was found to cause autoim-
mune diseases similar to those observed following neonatal thymectomy. The
latter are ascribed to a detrimental effect of neonatal thymectomy on TREG
homeostasis40. Furthermore, our data fit with the observations that CsA
decreases the expansion of adoptively transferred FoxP3+ T-cells24,41, while
rapamycin treatment spares TREG in vivo10,24.
In conclusion, CsA and rapamycin differentially affect the generation and
homeostasis of CD4+FoxP3+ TREG in vivo. This may influence the choice of
drugs if the treatment of immune-mediated diseases is aimed at the achieve-
ment of tolerance to self- or alloantigens.
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Summary and Discussion
7.1. General
Organ transplantation has become a successful therapeutic modality for end-
stage organ disease since the advent of potent immunosuppression during the
1980’s. However, long-term administration of immunosuppressive drugs can
also result in a range of unwanted side effects which can in the end have detri-
mental effects to both the organ and the patient1. T-cells play a crucial role in
the rejection of allografts and response of these alloreactive T-cells determines
the succes of transplantation. In the expansion of the alloreactive effector T-cell
pool, costimulation is required for optimal survival, cytokine production and
proliferation of T-cells. Conversely, blockade or absence of costimulatory path-
ways has been shown to result in the prevention of allograft rejection and the
induction of tolerance2-6. Therefore, a promising experimental immunosup-
pressive strategy is therefore the specific targeting of activating costimulatory
signals. Currently, clinical trials with several blocking antibodies are being per-
formed and in December 2005 CTLA4-Ig was approved as the first costimula-
tory blocking agent for clinical application7-9.
During the last decade, regulatory T-cells (TREG) have emerged as an intrin-
sic part of the immune system pivotal for the maintenance of tolerance to self-
antigen. TREG are hypothesized to have a predominant autoreactive TCR-reper-
toire, however evidence builds up that next to the activation of effector cells, the
activation of alloreactive TREG is also part of the alloreactive immune
response10-12. An important goal is to harness these tolerance inducing elements
and to facilitate that they will dominate organ destructive allo-reactive cells,
thereby allowing minimization of the use of the immunosuppressive drugs13,14.
To this end a thorough understanding of the survival, expansion of naturally
occurring TREG as well as their response in partnership with currently used and
experimental immunosuppressive drugs is essential.
In this thesis, the interplay of TREG with costimulatory blocking antibodies
in dominating the alloreactive effector pool is analyzed in chapter 2 and chapter
3. Subsequently, the extent to which allospecific TREG may contribute to trans-
plantation tolerance is analyzed in chapter 4. Bearing in mind ultimate use of
TREG in a clinical setting, the compatibility of these cells with conventionally
used immunosuppressive agents, like CsA and rapamycin, is assessed in chapter
5 and chapter 6.
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7.2. Functional dominance of TREG in transplantation
In chapter 2 we reasoned that a regimen that blocks pro-mitotic signaling but
ensures antigen driven T-cell activation, like co-stimulation blockade, may
facilitate a functional dominance of regulatory T-cells by the synergizing effects
of selective reduction of alloreactive effector pool and activation of alloantigen
specific regulatory T-cells. Our data indicated that the absence of pro-mitotic
signals due to impaired CD28:CD86 and CD40:CD40L signalling selectively
reduced the alloreactive effector T-cell pool size, while regulatory T-cell func-
tion was allowed by intact TCR engagement. Consequently, combined anti-
CD86 and anti-CD40L mAb treatment tipped the balance between effectors
and regulators, favoring dominance of immunoregulatory mechanisms exerted
by a relatively small number of activated CD4+CD25+ T-cells. This implicates
that anti-CD40L plus anti-CD86 mAb treatment does not compromise the
suppressive capacity of CD4+CD25+ regulatory T-cells, despite their dependen-
cy on costimulation for thymic generation and homeostasis15. Also in vivo, we
observed that costimulation blockade resulted in a shift of balance between
alloreactive effectors and regulatory CD4+CD25+ T-cells.
An important regulatory mechanism in T-cell responses is the engagement
of the CD28 homologue cytotoxic T lymphocyte antigen-4 (CTLA-4)16,17.
CTLA-4 is upregulated upon T-cell activation, and subsequent binding of this
molecule to the B7 molecules CD80 or CD86 results in down regulation of the
T-cell response. CTLA-4 signalling has been implicated in the acquirement of
transplantation tolerance, but exactly how CTLA-4 exerts its effect in this
process remains a matter of debate18,19. CTLA-4 is constitutively expressed on
regulatory CD4+CD25+ TREG and various studies suggest an association
between the engagement of CTLA-4 and TREG function20-23, but this could not
be confirmed in other studies24-26. In chapter 3, we sought to characterize to
what extent CTLA-4 engagement may contribute to the development of trans-
plantation tolerance under the cover of CD40/CD40L and CD28/CD86
blockade, either by activation of regulatory T-cells, by containment of the
alloreactive effector pool size, or a combination of both. The effects of costimu-
lation blockade were markedly impaired if CTLA-4 engagement was abrogated
or if CD4+CD25+ regulatory T-cells were depleted. CTLA-4 engagement was
not required for CD4+CD25+ regulatory T-cell action, while in the absence of
CD4+CD25+ regulatory T-cells, blockade of CTLA-4 signaling resulted in
enhanced effector cell proliferation, predominantly by compromised inhibition
of CD8+ T-cell expansion. Combining, during CD40/CD40L and
CD28/CD86 blockade CTLA-4 engagement by CD80 limits the expansion of
142
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•Blockade of costimulatory signalling
Figure 1.The balance of effector T-cells and regulatory T-cells in transplantation 
tolerance.
Containment of the alloreactive T-cell pool size (TEFF) can facilitate functional dominance of
regulatory T-cells (TREG) in transplantation.
deleterious alloreactive T-cells, which facilitates the ability of CD4+CD25+ T-
cells to maintain the balance between regulatory versus effector cells. Like in
chapter 2, we demonstrated that the efficacy of costimulation blockade in the
prevention of allograft rejection relies on mechanisms that are integral in main-
taining normal immune homeostasis (Fig.1)
In a recent study, using anti-CD40L mAb and donor-specific transfusion to
induce graft tolerance, it was demonstrated that the aborted expansion of
alloreactive effector cells allows CD4+CD25+ regulatory T-cells to chronically
suppress effector cell responses27. This underscores that application of costimu-
lation blockade can contribute to the dominance of TREG function. However, it
can not be discarded that anti-CD40L mAb can also contribute to prolongation
of graft survival by Fc dependent selective depletion of activated effector cells28.
Whether the costimulatory pathways implicated play a role in the exertion of
suppressive effects by TREG remains enigmatic. Co-stimulation did not appear
to be required for the suppression by CD4+CD25+ TREG in vitro and in vivo,
and blockade of CD40L on TREG was suggested to enhance regulatory func-
tion29,30. Nevertheless, costimulatory signalling by CD80 and CD86 has been
implicated in the homeostasis and development of both thymic and peripheral
summary and discussion
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CD4+CD25+ regulatory T-cells31-33. Of interest, CTLA-4 has been implicated in
TGF-β mediated generation of peripheral TREG and TREG cell cycle progres-
sion34,35. How interference in costimulatory pathways may interfere in TREG
homeostasis and function thus warrants further investigation.
7.3. Allospecificity of TREG
The hallmark of peripheral allograft tolerance is the emergence of active T-cell
immunoregulation. Activation of naturally occuring TREG is pivotal for the
establishment of an immune regulatory network that creates peripheral allo-
graft tolerance14,18,36. In the thymus, TREG are generated as a safeguard for toler-
ance to self-antigen37,38. When activated by auto-antigen, the TREG limit
autoreactivity by downregulating the responses of T cells with receptors that
recognize other auto-antigens in the same tissue. In order to facilitate the domi-
nance of naturally occuring TREG over alloreactive effector cells it is crucial to
identify whether self-reactive TREG can respond to allogeneic stimulation.
Indeed, several models indicated that antigen-specific TREG will exhibit a par-
ticularly strong suppressive capacity11,39,40. Alternatively, TREG may contribute
to transplantation tolerance through non-specific bystander suppression of
alloreactive effector cells upon recognition of self antigen. In chapter 4 we
demonstrated that allo-antigen specific TREG activation is a normal part of the
allo-immune response. DC of donor origin were found to potently stimulate
alloreactive TREG in vitro, resulting in a substantial enhancement of the sup-
pressive capacity of the TREG population as a whole. In vivo analysis of infused
naturally occurring allogeneic TREG in wild type hosts revealed a robust prolif-
erative capacity for TREG upon stimulation. Moreover, allogeneic skin trans-
plantation apparently primed alloreactive Treg and resulted in enhanced sup-
pressive capacity by these cells compared to unprimed TREG. This indicates that
the activation of TREG is an intricate part of the regular alloimmune response
and that this feature can be exploited for therapeutic purposes.
Combining, allospecific TREG populations displayed potent suppressive
capacity upon allogeneic stimulation. Hence, exploitation of the allospecific
CD4+CD25+ TREG fraction may successfully add to the induction of transplan-
tation tolerance.
7.4. Effects of conventional immunosuppression on TREG
TREG do not form a homologous cell population and certain subsets of cells
contained in the TREG population have more potent suppressive capacity than
others41-43. Expansion of human naturally occurring TREG leads to the emer-
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gence of a distinct highly suppressive TREG subset characterized by the expres-
sion of CD27, next to a TREG subset that does not express CD27. It can be
envisaged that the strong regulatory capacity of CD27+TREG may be of value in
promoting stable tolerance to transplanted organs and it is therefore important
to elucidate the conditions best preserving this subset in vivo. Also, clinical
application of regulatory T-cell infusion therapy, will be aided by the availability
of compatible immunosuppression. Cyclosporin A (CsA) and rapamycin are
widely used as conventional immunosuppression to reduce the expansion of
organ destructive effector cells. In chapter 5 we demonstrate that CsA and
rapamycin both permit the activation of the naturally occurring human TREG
and the exertion of their suppressive capacity. However, rapamycin fosters the
dominance of CD27+TREG over CD27-TREG after expansion of the TREG pool
upon activation, whereas expansion in the presence of CsA tips the balance in
favor of CD27- TREG. The high CD27+TREG to CD27-TREG subset ratio, as pre-
served by rapamycin, benefits the suppressive capacity of the TREG pool as a
whole. We thus propose that rapamycin may be of benefit to tolerance to trans-
planted organs by preserving a beneficial CD27+TREG to CD27-TREG subset ratio.
It has become clear that signaling by IL-2 is important in several developmental
stages of TREG44-46. In the thymus, signaling through the common γ-chain -
part of the IL-2 receptor- is essential for naturally occurring TREG development.
In the periphery, IL-2 signaling is required for sustaining the TREG population
at a size necessary to maintain immune homeostasis44,45. This raises concern
about the impact of blocking IL-2 signaling by different immunosuppressive
agents on CD4+CD25+ TREG homeostasis and the maintenance of tolerance to
self antigen or the induction of tolerance to alloantigen. Despite their different
modes of action, CsA and rapamycin both block IL-2 signaling and may there-
fore compromise the TREG population and the induction and maintenance of
tolerance. In chapter 6 we analyzed the effects of CsA and rapamycin on the
ontogeny and maintenance of TREG in different immune compartments in
vivo. We demonstrated that, in contrast to CsA, rapamycin allows for the
thymic generation and the presence of CD4+CD25+FoxP3+ T-cells in peripheral
immune compartments of mice. The findings presented in chapter 5 and chap-
ter 6 corroborate earlier findings of differential effects of CsA and rapamycin
with respect to immune tolerance. CsA has been implicated in the generation of
auto-immune like phenomena and the impairment of tolerance induction in
transplantation47-52, whereas rapamycin was found to favour CD4+CD25+
TREG function in vitro and to benefit CD4+CD25+ T-cells in vivo36,53,54. Hence,
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Figure 2.The effects of cyclosporine and rapamycin on TREG.
The balance between alloreactive T-cells (TEFF) and regulatory T-cells (TREG) determines the
outcome of an alloresponse. Both cyclosporine and rapamycin are able to reduce the allore-
active effector T cell pool. However, in contrast to cyclosporine, rapamycin favours a high ratio
between the CD27+TREG and CD27-TREG subsets. Dominance of CD27+TREG over CD27-TREG will
more easily allow potent containment of residual alloreactive T-cells.
the use of CsA or rapamycin may have important implications for treatment of
immune-mediated diseases if the achievement of durable tolerance to self- or
alloantigens is desired.
7.5. Synthesis; from bench to bedside
It is generally accepted that the induction of allograft tolerance is governed by a
balance between immune effector vs. regulatory mechanisms. In this thesis it is
shown that selective targeting of activating costimulatory signals in effector T-
cell-APC interactions can contribute to the facilitation of TREG function and
containment of effector T-cells mediating graft rejection. These TREG were
found to be activated and maintained by donor antigen in vivo. Moreover, it
was found that the right choice of immunosuppressive regimen may contribute
to the exploitation of potent donorspecific TREG function in transplantation.
Although several studies indicate a relative ease of tolerizing inbred laborato-
ry animals by costimulation blockade, it appears difficult to tolerize outbred
humans exposed to a vast array of foreign antigens. Heterologous sensitization
by infectious agents generates effector/memory T-cells that are particularly
resistant to costimulation blockade55. A preferential deletion of memory T-cells
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may thus be an important component of future tolerance induction protocols.
However, depletion of memory T-cells will increase the susceptibility to infec-
tions, and will also induce the “spontaneous” proliferation of T-cells in response
to self-MHC peptide complexes. The cells formed by this mysterious process of
homeostatic proliferation are characterized by a memory T-cell phenotype.
Costimulatory blockade neither significantly suppresses homeostatic prolifera-
tion nor prevents allograft rejection56. Although, costimulatory molecules have
been implicated in memory T-cell formation. Of note, TREG have been shown
to be able to suppress memory T-cells42,57-59. Therefore, further strategies
should ideally be active against activated memory T-cells and simultaneously
spare regulatory T-cells60.
The most obvious clinical application of TREG involves successful facilita-
tion of the function of naturally occurring TREG. In addition, the ex vivo gener-
ation of large amounts of antigen-specific TREG seem an attractive form of
immunotherapy. In either situation it is essential to know how currently used
immunosuppressive drugs can affect TREG function, for it is not likely that such
a therapy will be introduced into the clinic without a cover of conventional
immunosuppressive drugs. With regard to shifting the regulatory to effector T-
cell balance, conventional immunosuppressive drugs have different effect on
TREG, but also on the deletion of alloreactive T cells through activation induced
cell death (AICD). Rapamycin has been observed to contribute to tolerance
induction by allowing apoptosis of alloreactive T-cells, whereas CsA can com-
promise apoptosis and the induction of tolerance49. Consequently, rapamycin
may thus create a more beneficial regulatory to effector T-cell balance by a more
thorough reduction of effector cells in addition to the sparing of TREG, thereby
promoting tolerance at different levels of regulation36,61. However, one must
bear in mind that in the clinic the choice of immunosuppression is mainly guid-
ed by finding the strongest immunosuppression with the lowest amount of
adverse events. This does not necessarily equal the immunosuppressive regimen
that appears preferable for the induction and maintenance of tolerance. The
optimal immunosuppressive therapy must therefore respect several criteria and
can best be designed when the knowledge and experience of various disciplines
is combined.
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Samenvatting
Orgaantransplantatie en het immuunsysteem
Transplantatie van een donororgaan is vaak de beste mogelijkheid om ernstige
aandoeningen door een falend orgaan te genezen. Tegenwoordig worden
donororganen met veel succes getransplanteerd. Dit is te danken aan de ontwik-
keling van immunosuppressieve medicijnen die de afstoting van het donoror-
gaan door ons immuunsysteem kunnen remmen. Een groot nadeel van deze
medicijnen is echter is dat ze niet specifiek werken en daardoor ook de respons
tegen virussen, bacteriën en tumorcellen remmen. Daarnaast heeft het noodza-
kelijke continue gebruik van deze medicijnen nog andere bijwerkingen zoals het
ontstaan van nierschade en bloeddrukproblemen. Het is dus van groot belang
om de huidige immunosuppresieve medicijnen sterk te reduceren en een vorm
van immunosuppressie te ontwikkelen die donor-specifiek is.
Ons immuunsysteem is een complexe organisatie van weefsels, cellen en
eiwitten die ons beschermt tegen verschillende ziekten als gevolg van bacteriën
of virussen. Het immuunsysteem kan worden ingedeeld in natuurlijke en speci-
fieke immuniteit. Natuurlijke immuniteit is het deel van het immuunsysteem
dat reeds bij de geboorte aanwezig is en gebruik maakt van niet specifieke verde-
digingsmechanismen. Het specifieke of verworven deel van het immuunsys-
teem heeft de capaciteit om bij herhaalde infecties een versterkte immuunre-
spons te genereren. De specifieke immuniteit wordt bepaald door zogenaamde
T- en B- cellen, die geactiveerd worden door antigen presenterende cellen
(APC’s). Deze APC’s presenteren eiwitfragmenten van aanwezige infectieuze
pathogenen aan T- en B- cellen. Sommige T-cellen kunnen geinfecteerde cellen
vernietigen, andere T-cellen kunnen B-cellen en bepaalde T-cellen stimuleren.
B-cellen maken, na activatie, antilichamen die aan pathogenen zoals bacteriën
en virussen hechten en het niet-specieke immuunsysteem helpen de pathoge-
nen te vernietigen. De activiteit van het immuunsysteem dient echter strak
gereguleerd te worden omdat het anders schade toebrengt aan gezond weefsel.
Wanneer het immuunsysteem zich toch richt tegen gezond weefsel ontstaan er
zogenaamde auto-immuun ziekten. Bekende voorbeelden hiervan zijn reuma-
toïde artritis, multiple sclerose en type I diabetes mellitus. Om immuunreacties
te balanceren beschikt het lichaam over de zogenaamde regulatoire T-cellen, die
de capaciteit hebben om de groei en functie van agressieve T-cellen te remmen.
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Een ander voorbeeld waarin een excessieve immuunrespons negatieve gevol-
gen heeft is de situatie die ontstaat na orgaantransplantatie. Na een transplanta-
tie kan het immuunsysteem het getransplanteerde orgaan als “lichaamsvreemd”
herkennen en een immuunrespons initiëren, hetgeen kan leiden tot afstoting.
B- en T-cellen van de ontvanger worden in dit geval geactiveerd door weefsel
antigenen die aanwezig zijn op het donororgaan. Voor het in dit proefschrift
beschreven onderzoek hebben we ons gericht op de immuunrespons van de 
T-cellen. Het weefsel antigen zorgt voor het op scherp zetten van de T-cel (sig-
naal 1). Na deze herkenning volgt er een tweede signaal, de zogenaamde costi-
mulatie (signaal 2). Wanneer ook het tweede signaal aanwezig is, deelt de T-cel
zich en wordt deze agressief voor donorweefsel. T-cellen die reageren op donor-
weefsel worden ook wel allo-reactief genoemd.
Transplantatie tolerantie
Transplantatie tolerantie is de situatie waarin een donororgaan in de afwezig-
heid van immunosuppressieve medicijnen niet afgestoten wordt door het
immuunsysteem. Tolerantie wordt sterk bepaald door de balans tussen agressie-
ve T-cellen en regulatoire T-cellen. Naast agressieve T-cellen kunnen regulatoire
T-cellen ook specifiek allo-reactief zijn. Teveel agressieve allo-reactieve T-cellen
leiden tot afstoting, terwijl meer allo-reactieve regulatoire T-cellen leiden tot
een betere balans en een verhoogde kans op transplantatie tolerantie. Nieuwe
immunosuppressieve technieken zijn gericht op het faciliteren van de functie
van deze allo-reactieve regulatoire T-cellen, met als hoogste doel donor-specifie-
ke transplantatie tolerantie. De balans kan op verschillende manieren in het
voordeel van de regulatoire T-cellen beslecht worden:
a. Specifieke remming van de activatie en groei van agressieve allo-reactieve 
T-cellen.
b. Toename van allo-reactieve regulatoire T-cellen.
c. Combinatie van a en b.
In dit proefschrift hebben we onderzocht of agressieve allo-reactieve T-cellen
selectief geremd kunnen worden terwijl regulatoire T-cellen gespaard blijven, en
of dit bijdraagt aan transplantatie tolerantie. Hiernaast hebben we onderzocht
of de momenteel gebruikte immunosuppressieve medicijnen de regulatoire T-
cellen ten goede of ten kwade beïnvloeden. Een mogelijke toekomstige strategie
is het in grote hoeveelheden kweken van regulatoire T-cellen en deze bij de ont-
vanger in te spuiten bij een orgaantransplantatie. Ook in dit geval is het belang-
rijk te weten welke medicijnen er direct na transplantatie als een beschermende
“paraplu” gebruikt kunnen worden zonder dat de regulatoire T-cellen aange-
daan worden.
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Immunosuppressie en regulatoire T-cellen
In hoofdstuk 1 wordt een algemene inleiding gegeven over transplantatie
immunologie en regulatoire T-cellen. Hoofdstuk 2 beschrijft hoe een veelbelo-
vende nieuwe therapie bij kan dragen aan transplantatie tolerantie. In deze the-
rapie worden anti-lichamen gebruikt die signaal 2 (de costimulatie) blokkeren.
Met deze anti-lichamen, gericht tegen de moleculen CD40L en CD86, wordt
voorkomen dat T-cellen die een vreemd eiwit herkennen tot volle activatie
komen. Dit leidt er toe dat de balans tussen agressieve allo-reactieve T-cellen en
regulatoire T-cellen verschuift in het voordeel van de regulatoire T-cellen. In
hoofdstuk 3 laten we zien dat het in deze therapie van belang is niet teveel ver-
schillende soorten signaal 2 moleculen te blokkeren. Een bepaald signaal 2
molecuul, CD80, bindt ook aan een molecuul met een sterk remmend effect op
de agressieve allo-reactieve T-cellen, het CTLA-4 molecuul. Een complicerende
factor is dat dit niet alleen tot expressie komt op agressieve allo-reactieve T-cel-
len, maar ook op allo-reactieve regulatoire T-cellen. In dit hoofdstuk laten we
zien dat CTLA-4 geen rol speelt in de functie van de regulatoire T-cel. Het
ongemoeid laten van het CTLA-4 signaal draagt wel bij aan een vermindering
van agressieve allo-reactieve effector cellen, waardoor de balans in het voordeel
van de regulatoire T-cel blijft. Co-stimulatie blokkade kan op deze manier bij-
dragen aan transplantatie tolerantie.
De resultaten uit hoofdstuk 2 en 3 laten zien dat het belangrijk is een balans
te houden tussen agressieve allo-reactieve T-cellen en regulatoire T-cellen. Ech-
ter, regulatoire T-cellen zijn vanuit een evolutionair oogpunt ontwikkeld om
excessieve immuunresponsen tegen lichaamseigen weefsel te remmen. Regula-
toire T-celllen worden dan ook voornamelijk geactiveerd door herkenning van
lichaamseigen weefselantigenen. Daarom hebben we in hoofdstuk 4 bestudeerd
in welke mate er allo-reactieve regulatoire T-cellen kunnen ontstaan uit de oor-
spronkelijke populatie regulatoire T-cellen. Hieruit komt naar voren dat regula-
toire T-cellen net als agressieve T-cellen sterk geactiveerd kunnen worden door
de weefsel antigenen op het getransplanteerde orgaan. Deze activatie leidt bin-
nen de oorspronkelijke populatie tot een relatieve verrijking van regulatoire T-
cellen die specifiek en met zeer potente suppressieve capaciteit reageren op de
herkenning van transplantatie weefselantigenen.
Met het oog op de balans tussen agressieve en allo-reactieve T-cellen geeft
hoofdstuk 4 aan dat het belangrijk kan zijn de populatie regulatoire T-cellen te
sparen in een patiënt die een orgaantransplantatie ondergaat. Van de regulatoire
T-cellen is bij de mens bekend dat er sub-groepen zijn te onderscheiden door
het meten van de aan- of afwezigheid van het molecuul CD27 aan hun opper-
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vlak. De regulatoire T-cellen die CD27 tot expressie brengen zijn cellen met een
extra krachtige suppressieve capaciteit. Regulatoire T-cellen waarbij CD27 niet
aanwezig is laten een sterkere groeicapaciteit zien. De immuno-suppressiva die
tegenwoordig in de kliniek gebruikt worden hebben een remmend effect op 
T-cel activatie en T-cel deling in het algemeen. In hoofdstuk 5 hebben we daar-
om onderzocht of deze medicijnen ook de activatie en deling van de regulatoire
T-cellen negatief beïnvloeden. Cyclosporine en rapamycine zijn twee van deze
medicijnen en werden met elkaar vergeleken vanwege hun verschillende wer-
kingsmechanismen. Uit onze bevindingen komt naar voren dat het gebruik van
cyclosporine of rapamycine de werking van regulatoire T-cellen niet verstoort.
Het blijkt wel dat het gebruik van rapamycine de aanwezigheid van regulatoire
T-cellen met CD27 toelaat, terwijl het gebruik van cyclosporine resulteert in
een relatieve vermindering van deze cellen. Dit kan consequenties hebben voor
het ontstaan van transplantatie tolerantie. De signalen die door rapamycine en
cyclosporine geblokkeerd worden in de T-cellen zijn ook van belang in de ont-
wikkeling van T-cellen in de thymus. Bovendien zorgen dezelfde signalen ook
voor het gehandhaafd blijven van de populatie regulatoire T-cellen in bloed en
in de perifere lymfoïde organen zoals milt en lymfknopen. In hoofdstuk 6 heb-
ben we onderzocht hoe door het op verschillende manieren blokkeren van deze
signalen door cyclosporine en rapamycine het onstaan van regulatoire T-cellen
in de thymus en de handhaving van deze cellen in de perifere lymfoïde organen
verstoord wordt. Rapamycine laat het ontstaan van deze regulatoire T-cellen in
de thymus toe en zorgt voor een betere handhaving van deze cellen in de perif-
ere lymfoïde organen. Cyclosporine blokkeert de ontwikkeling van regulatoire
T-cellen in de thymus en vermindert de aanwezigheid van regulatoire T-cellen
in bloed, milt en lymfknopen. Verschillende immunosuppressiva kunnen dus
op uiteenlopende wijze de regulatoire T-cel populatie beinvloeden. In hoofd-
stuk 7 wordt tot slot een beschouwing van de in dit proefschrift behandelde
onderwerpen gegeven.
Het verschuiven van de balans tussen agressieve alloreactieve T-cellen en
regulatoire T-cellen ten gunste van regulatoire T-cellen draagt bij aan het indu-
ceren van transplantatie tolerantie. Regulatoire T-cellen kunnen geactiveerd
worden door transplantie antigenen en kunnen bij toepassing van de juiste
immuunsuppressie gespaard blijven. Hopelijk draagt het aanwenden van dit
lichaamseigen beschermingsmechanisme in de toekomst bij aan de vermijding
van afstoting van getransplanteerde organen en daarmee aan een betere kwali-
teit van leven van de ontvangers.
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Curriculum Vitae
Jeroen Coenen, de auteur van dit proefschrift is geboren in 1976 te Nijmegen,
als de zoon van Margriet Knoop en Antoon (Toon) Coenen. Het VWO diplo-
ma werd behaald in 1994 waarna hij begon met de studie Medische Biologie aan
de Universiteit van Amsterdam. Na een overstap naar de KU Nijmegen in 1996
werd het doctoraal Medische Biologie in 2000 behaald met als specialisaties
haematologie onder begeleiding van Jules Meijerink en cellulaire dierfysiologie
onder begeleiding van Niels Cornelisse. Aansluitend begon hij als junior onder-
zoeker op de Afdeling Bloedtransfusie en Transplantatie Immunologie (ABTI)
in samenwerking met de afdeling Nefrologie van het Radboud Universiteit 
Nijmegen Medisch Centrum (RUNMC) onder supervisie van Dr. Irma Joosten
en Dr. Luuk Hilbrands. Op deze afdeling werd onderzoek gedaan naar regula-
toire T-cellen in de context van orgaantransplantatie, zoals beschreven in dit
proefschrift. Na een korte periode in een project van de afdeling Medische
Microbiologie van het RUNMC werkt hij momenteel als Scientific Editor op
de afdeling vaccinontwikkeling van Intervet BV.
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Stellingen
behorende bij het proefschrift
Facilitation of CD4+CD25+ regulatory T-cell function 
in transplantation
1. Gerichte blokkade van costimulatoire signalen draagt bij aan een gunstige
balans tussen effector T-cellen en regulatoire T-cellen.
Dit proefschrift
2. Activatie van regulatoire T-cellen is een intrinsiek deel van de cellulaire
respons tegen transplantatie-antigenen. 
Dit proefschrift
3. De keuze van de juiste immunosuppressie kan een belangrijke bijdrage
leveren aan het ontwikkelen van transplantatie tolerantie.
Dit proefschrift
4. Het manipuleren van de regulatoire T-cel functie zal een essentieel element
gaan uitmaken van een breed spectrum aan immunotherapieën.
5. “Nothing in biology makes sense except in the light of evolution.”
Theodosius Dobzhansky (1900-1973)
6. “What we observe is not nature itself, but nature exposed to our method of 
questioning.”
Werner Heisenberg (1901-1976)
7. In een kenniseconomie dient men spaarzaam met het wetenschappelijke
kapitaal om te gaan.
8. Voor de gemiddelde Nederlander is de kans om een orgaantransplantatie te
moeten ondergaan nog altijd vele malen groter dan de kans om slachtoffer te
worden van een terreuraanslag.
9. Op de fiets naar je werk kunnen gaan is een luxe.
10. Ook vroeger was vroeger alles beter.
Jeroen JA Coenen, mei 2007
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